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ABSTRACT 
Despite the high rates of mortality and morbidity associated with malaria very few new 
antimalarial drugs are being developed. Hence there is much to be gained by optimising 
currently available antimalarials. 
Using pharmacokinetic and pharmacodynamic data from field trials where mefloquine was 
administered either alone or in combination with artesunate important information 
regarding optimal dosing for the clinician has been obtained. The pharmacokinetics of 
mefloquine were influenced relatively little, or not at all, by factors such as age, sex, or 
measures of acute malaria severity. Splitting the 25 mglkg dose of mefloquine 
monotherapy was associated with a 50% increase in oral bioavailability, and bioavailability 
increased by 20% for the split dose on the combination treatment. Oral bioavailability was 
also observed to be associated with more rapid parasite clearance, a surrogate outcome 
measure for cure. 
A mechanistic mathematical model was developed that describes the change in total 
parasite burden with time in vivo, in the presence of mefloquine. Estimates for the 
pharmacokinetic and pharmacodynamic parameters were obtained from population 
modelling of pharmacokinetic and in vitro pharmacodynamic data, both derived from the 
same region. Model simulations confirmed that, early in the evolution of resistance, 
conventional assessments of the therapeutic response 28 days after treatment underestimate 
considerably the level of resistance. Longer follow-up is required. The model also indicates 
that initial deployment of a lower (l5-mglkg) dose of mefloquine provides a greater 
opportunity for the selection of resistant mutants and would be expected to lead more 
rapidly to resistance than de novo use of the higher (25-mglkg) dose. 
From the modelling of malaria therapy data it was observed that even in the absence of 
drugs the patient parasitaemia versus time profiles varied greatly between both patients and 
parasites. Parasite multiplication rate every 48 hours was estimated to be approximately 8 
fold. 
xxiv 
1. INTRODUCTION 
Each year approximately 270 million people suffer from malaria with an annual mortality 
of somewhere between I and 2.5 million deaths (World Health Organisation 1998). The 
development of new medicines for treating malaria is essential since malaria parasites have 
acquired resistance to nearly all established antimalarial drugs (Winstanley, 2000). Despite 
the urgent need for new therapeutic agents there is little financial gain for drug companies 
to produce drugs that are mainly needed for developing countries where malaria is 
predominate. Of the 1223 new molecular entities sold worldwide during 1975-96, less than 
I % were destined for tropical diseases (Trouiller and Olliaro, 1999). With very few new 
drugs for malaria there is much to be gained by optimising currently available drug 
therapies. 
Malaria is a disease caused by the invasion of the red blood cells by the Plasmodium 
parasites. Plasmodium jalciparum, one of the four species of human malaria, is the most 
dangerous species causing almost all severe disease and deaths. Despite attempts to 
eradicate malaria the disease is still endemic in many parts of the world. One of the major 
contributing factors to its continued presence is the emergence of malaria parasites which 
are resistant to one or more of the antimalarial drugs. Drug resistance is defined as the 
'ability of a parasite to multiply or to survive in the presence of concentrations of a drug 
that would normally destroy parasites of the same species or prevent their multiplication' 
(World Health Organisation 1973). Drug resistance arises as a result of genetic mutations 
that reduce the parasite susceptibility to antimalarial drugs. 
Studies monitoring the therapeutic efficacy of drugs in vivo and the minimum inhibitory 
concentrations (MIC) of the drug in vitro need to be reported regularly in order to detect 
emerging drug resistance as soon as possible. Pharmacokinetic studies investigate the 
changes in drug concentration over time and the association between the pharmacokinetic 
parameters (e.g. absorption rate of the drug) and the dynamics of the disease. These studies 
may aid the doctor in detennining the most beneficial way to give the drug. 
The pharmacokinetic properties of antimalarial drugs have been studied extensively using 
the conventional approach of multiple sampling in relatively few healthy volunteers or 
patients. However there is an increasing interest in the design of population based studies 
using a much larger number of subjects with fewer samples (often 2-4) collected at random 
times. These studies may provide infonnation that is more representative of, and thus 
relevant to, the patient population of interest since they allow characterisation of the 
different sources of variation in the pharmacokinetic parameters. Population modelling 
approaches seek to: relate dose to effect, explain some of the inter-patient variability with 
covariate analysis, and characterise unexplained inter-individual variability. Some 
examples of population modelling of studies where only sparse data has been used to 
generate population models of pharmacokinetics and pharmacodynamics are theophylline 
used in the treatment of asthma (Driscoll et al. 1989) and anti-HIV treatment with 
zidovudine (Gittennan et al. 1990). 
In some areas mefloquine is the treatment of choice for uncomplicated multi-drug resistant 
falciparum malaria. Little work has been done using the popUlation approach to investigate 
how mefloquine concentrations relate to the therapeutic effect. Large inter-individual 
variability has been reported for mefloquine indicating that population pharmacokinetic-
pharmacodynamic modelling is needed to provide a framework for optimisation of 
mefloquine dosing regimens. 
2 
On the Thai-Bunnese border pharmacokinetic data were collected prospectively from 
patients receiving mefloquine as part of trials conducted between 1990 and 1995. Prior to 
1994 mefloquine was given alone and thereafter in combination with artesunate. Using 
these data the population pharmacokinetic parameters for mefloquine were estimated. In 
order to derive clinically useful dosing guidelines pharmacokinetic models must be 
combined with pharmacodynamic models. Population pharmacodynamic models of in vivo 
mefloquine actions were developed using a combination of in vitro pharmacodynamic data, 
population parasitaemia time series in untreated patients (available historical data) and 
from the data mentioned above. After the above models were defined the relationship 
between these models of kinetics and dynamics were determined using sequential 
pharmacokinetic-pharmacodynamic modelling (Davidian and Giltinan, 1995). 
Ultimately the population modelling approaches that were applied to mefloquine in this 
thesis will highlight the factors influencing inter-patient variability in the dose-response 
relationship, and provide the clinician with optimal dosing strategies. The new approach 
rationalising the use of pharmacokinetic analysis in relation to the efficacy of mefloquine 
presented here may also be used as a guideline for optimisation of other antimalarial drugs. 
1.1 Malaria 
Malaria is a disease caused by the invasion of the red blood cells by the Plasmodium 
parasite. Transmission of malaria to humans results from the bite of an infected female 
Anopheles mosquito. There are four species of Plasmodium infecting humans,Jalciparum. 
vivax. ovale and malariae. Plasmodium Jalciparum is the most dangerous species causing 
almost all severe disease and deaths of human malaria. 
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The life cycle of Plasmodium Jalciparum is described below and illustrated in Figure 1.1:-
a} The P. Jalciparum parasite is injected into the blood stream of the human host 
usually by the infected female Anopheles mosquito in the form of sporozoites. 
b} The sporozoites invade the liver after a few minutes. 
c} In the liver the sporozoite multiplies over a period of 5-7 days, the pre-erythrocytic 
incubation period. 
d} After development in the liver the hepatic schizonts rupture to release merozoites 
into the bloodstream. The merozoites enter the red blood cells where they feed on 
the contents of the cells. This begins the intra-erythrocytic asexual cycle that causes 
the disease malaria. The parasite first develops as a tiny, then small, and then large 
ring. The parasite begins to digest haemoglobin to produce haemazoin pigment, 
which is deposited within the food vacuole. At this stage the parasite is called a 
mature trophozoite. 
e} After 18-26 hours (approximately when pigment is first visible microscopically), 
the trophozoites cause the red blood cells to adhere to the endothelium of the small 
blood vessels. In this period (26-48 hours), these older stages of the parasite 
sequester in the vasculature of deep tissues and are not readily seen in the 
peripheral blood film. 
f) The trophozoite divides into daughter merozoites to become a schizont which then 
ruptures releasing 16-32 merozoites into the blood ready to infect other red blood 
cells. This whole process takes approximately 48 hours. 
g} Merozoites that invade the red blood cells can take one of two development routes: 
either develop into an asexual schizont and multiply further or become a 
gametocyte (the sexual stage of the parasite). The gametocyte develops over several 
days. When another anopheline mosquito bites the human host, the mature 
gametocyte can be ingested in the blood meal and infect the mosquito, where 
sexual reproduction (meiosis) occurs and the cycle begins again. 
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Pharmacokinetics K is the study of the relationship between the dose of a drug and the 
manner in which it concentr tions in the body change over time. A PK model provides a 
mathematical r pr ntation f th processes by which the drug enters the body 
(absorption mo arOlLl1d the ody (distribution) and leaves the body (elimination). The 
body is consid r d to consi t f n or more "compartments". In a one compartment 
modeJ, the drug nt r th ompartm nt either instantan ous1y (intra enous bolus 
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injection) or gradually (e.g. infusion, intramuscular or oral administration). The drug then 
distributes evenly to fill an "apparent" volume of distribution, and is cleared from this 
compartment. The apparent volume of distribution (V) is a theoretical value based on the 
ratio of the total dose in the body to the blood concentration before elimination. Since 
drugs tend to bind to tissue components the volume of distribution can be much larger than 
the true volume of the body. The total body clearance (eL) of a drug is defined as the 
volume of plasma or blood cleared of drug per unit of time. 
Pharmacodynamics (PD) is the term used to describe the time course and relationship to 
concentration of the pharmacological effect of the drug (i.e. the therapeutic response and 
any other important beneficial or harmful biological effects). 
The PK properties of most drugs, not just those used to treat tropical diseases, are generally 
studied using the conventional approach of multiple sampling in relatively few healthy 
volunteers or patients. These labour intensive studies tend to involve few subjects who are 
not necessarily representative of the patients likely to receive the drug. Larger studies 
carried out on the target population therefore have major advantages (Aarons, 1992). 
Patient characteristics (e.g. gender, ethnicity, weight, disease severity, hepatic or renal 
impairment) that might modify the PK behaviour of the drug can be explored and 
dissected. However intensive blood sampling of a large sample of the target population is 
not always feasible. It might be medically hazardous for some patients to be sampled 
repeatedly (e.g. very ill patients, small infants and elderly) or logistically impossible. There 
are also cost implications particularly for field trials in the developing world, where the 
main burden of tropical diseases resides. 
An alternative to conventional PK studies is now available. This uses PK data derived from 
only a few blood samples or as little as one per subject, and can be analysed using 
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population methods (Aarons, 1993). The population approach is based on relatively recent 
statistical methodology (Vozeh et al. 1996). It seeks to estimate the mean PK parameters 
(e.g. clearance, half-life) and to identify the patient or disease characteristics (i.e. 
physiological, pathological, environmental or genetic factors) that explain as much as 
possible of the inter-patient variability of the PK parameters. 
1.2.1 Pharmacokinetics 
1.2.1.1 Traditional pharmacokinetic methods 
A drug development program usually consists of three phases. Phase I is a clinical trial to 
determine the PK behaviour of the drug within a small group of healthy volunteers. Phase 
II determines the PK behaviour in a small group of patients with the condition intended to 
be treated. Phase III trials are usually large-scale clinical trials to evaluate safety and 
efficacy. Data collected during Phase I and II trials have historically been used to 
determine the PK profiles of a drug. The data consists of frequent sampling from a handful 
of subjects, not always representative ofthe patients likely to receive the drug. 
The data are traditionally analysed using the standard two-stage approach. The first stage is 
to estimate the PK parameters for each individual separately. The second stage is to 
calculate the appropriate centre of the distribution (i.e. mean, median or geometric mean) 
and variation of the individual PK parameter estimates to obtain estimates of the overall 
population PK parameters. The obvious advantage of this approach is the simplicity in 
calculation of the PK parameters. 
The disadvantages however are:-
• Numerous blood samples per subject are required. 
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This may be difficult for studies conducted on the young, elderly or seriously ill 
or those with poor venous access. For example the majority of the African 
population with severe malaria are young anaemic children. 
This restriction means that subjects with poor compliance will need to be 
excluded from analysis, thus reducing numbers and possibly introducing bias. 
Laboratory errors or samples that have been misplaced or stored incorrectly will 
lead to exclusion of a subject and thus reduce numbers. In many situations in 
the tropics drug analysis is performed by overseas collaborators (Winstanley 
and Watkins, 1992); and consequently frozen samples may be lost or ruined 
during transportation. 
The difficulties and discomfort involved in serial sampling and the cost of 
analysis tends to limit the total number of subjects examined that may lead to an 
unrepresentative sample of the population being studied. 
• This approach systematically overestimates the inter-individual variability and 
therefore is biased (Steimer et al. 1984). Each individual PK parameter is estimated 
from the original drug concentration-time data with some error. This error adds 
variability to the PK parameter estimates thus increasing the estimate of the inter-
individual variability. 
• All data from each individual must be described by the same PK model. If fifty percent 
of the subjects are fitted with a two-compartment model and the remaining subjects are 
fitted with a one-compartment model then it is not possible to combine the four 
parameters from the two-compartment model with the two parameters from the one-
compartment model. 
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1.2.1.2 Population pharmacokinetic methods 
In contrast to traditional PK methods, the population approach to analyse PK data requires 
only a few blood samples collected from each patient. As fewer samples are required per 
patient in a population study, it is feasible to study a greater number of patients and also to 
study patients where it may not be ethical or logistically possible to perform intensive 
serial blood sampling. For example, a population PK study could be incorporated into a 
Phase III clinical trial. The patient population in Phase III clinical trials, is more 
representative of the overall popUlation for which the drug will be finally used (Sheiner 
and Benet, 1985). 
The advantages of the population approach are:-
• All patients are included in the analysis. Patients where a blood sample was misplaced 
or not recorded are not excluded. 
• Samples do not need to be collected from subjects at the same times. In fact variation 
in the time of collection is often desirable. 
• For the same cost more subjects can be studied since fewer samples per subject are 
required. 
• Accurate estimates of the inter-individual, intra-individual, and inter-occasion 
variability are feasible. 
• Sub-groups of patients that are different from the general population can be identified 
and consequently information on dosing requirements obtained. 
• The association between the therapeutic response and PK of a drug can be explored to 
determine risk:benefit relationships. 
• Posterior individual PK parameter estimates can be obtained from the population 
analysis. 
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The disadvantages ofthe population approach are:-
• Certain preliminary PK information should be known before any population PK study 
is undertaken. 
• Logistically it is more complicated compared with traditional PK methods. 
• It requires statistical expertise. 
• It is a computer-intensive technique. 
• Occasionally the sparse data collected during a population PK study may not provide 
adequate information for the characterisation of a reasonable PK model. 
The popUlation approach for analysis of PK data is termed hierarchical nonlinear mixed 
effects modelling. The term hierarchical is used to describe the data structure. Generally 
there are two levels in PK data: the measured concentration at the fh time (level 1) of the ith 
individual (level 2) (see Figure 1.2 below). 
Level 2 
Individual 
Levell 1 2 ....... nl 
Concentration measured 
at time point j. 
D 
1 2 ....... nz 1 2 ....... Dj 
Figure 1.2:- Pharmacokinetic data structure for the two-level hierarchical model. 
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The nonlinear mixed effects model can be described by the following equation:-
c. = f(x .. ,f3.) + 8 .. 
Y Y' Y 
• Cy represents the /h concentration of the ith individual. 
• f(xy ,f3i ) denotes a nonlinear function of some independent variables, Xi} (e.g. time, 
dose, etc .. ) and some PK parameters, Pi (e.g. clearance for the ith individual). 
• By represents the residual error (also known as intra-individual error), that is the 
difference between the predicted and observed values, and is assumed to have zero 
mean and an unknown variance (ri e). 
The f(xy, Pi) comprises of two parts: a structural model (this is usually a conventional 
PK model, e.g. a one-compartment model, which may also involve covariates such as 
weight), and a variance model. The variance model describes the difference between the 
drug concentration of an individual and that predicted by the structural model. The 
parameters, Pi (e.g. absorption rate), vary across individuals and can be modelled using 
the following equation:-
where P is a vector of fixed effects (the mean population PK parameters and may also 
include individual covariates) and bi is a vector of random effects. The bi are assumed 
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to arise from a population distribution with zero mean and a covariance matrix, D, 
which quantifies the random inter-individual variation. 
The data for all individuals are analysed simultaneously, with the mixed effects model 
taking into account both the fixed and random effects (described below). 
• Fixed effects parameters. 
These may be the mean values of the PK parameters or a number of parameters that 
relate the PK parameters to demographic and pathophysiological variables, such as 
age, body weight, blood pressure, etc. 
• Random effects parameters. 
There are two types. The vanances of the PK parameters (inter-individual 
variability within the population) and the residual intra-individual variability due to 
random fluctuations in an individual's parameter values, measurement error and all 
other sources of error not accounted for by the other parameters. These two sources 
of variability are contrasted in Figure 1.3. 
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Figure 1.3:- Sources of population PK variability. The black solid line represents the 
population mean profile. The grey solid lines represent the individual profiles for subject i1 
(data 0) and subject i2 (data X). The difference between an individual profile and the 
population mean profile is due to inter-individual variability while the difference between 
the observed data and the individual profile is due to intra-individual variability. 
The computer programmes that are capable of analysing data using hierarchical modelling 
are not simple to use and the user needs to be fairly familiar with the philosophy and 
theory of population PK. For a detailed review of the programmes available see Aarons 
(1999) and Davidian and Gilitinan (1995). Maximum likelihood is the main estimation 
method used for hierarchical modelling. Maximum likelihood methods are implemented by 
NONMEM (a procedure developed in 1979 (Beal and Sheiner, 1980» and the NLME 
procedure (Lindstrom and Bates, 1990) of the statistical computing package, S-PLUS 
(StatSci, Mathsoft Inc. Seattle, Washington). Other methods available for the analysis of 
population PK data include nonparametric methods (Mallet, 1986; Steimer et al. 1984) 
and Bayesian methods (Best et al. 1995; Spiegelhalter et al. 1997). 
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1.2.1.3 Design of population phannacokinetic studies 
The design of population PK studies is a relatively new area of research and precise 
methodology has yet to be defined. Population PK studies can form part of large clinical 
trials (usually Phase III trials) where a few blood samples are taken from each patient or 
from a randomly selected sub-group of patients. This extra data collection should not alter 
greatly the original protocol or cause ethical problems (Aarons et al. 1996). 
To determine the timing of blood samples computer simulation and optimal design 
methods (D'Argenio, 1981; Mentre et al. 1997; Retout et al. 2001) can be used. These 
methods ensure that data are collected at informative times for estimation of PK 
parameters. The study investigator is given a sampling window (that is, a range of times 
rather than a particular time) when a blood sample must be collected. Patients should be 
sampled throughout the duration of the study to allow for changes over time in the PK 
parameters (known as inter-occasion variability). 
The protocol for population PK studies should not be overly complicated, and the times of 
blood sampling should be convenient both to patients and to clinical staff. The 
investigators and patients should understand the necessity of blood sampling and the 
importance of accurate recording of the time the blood sample was taken. Sun et al. (1999) 
provide more detailed recommendations regarding the design of popUlation PK studies. 
Population PK studies allow a great deal of freedom concerning the inclusion criteria and 
the blood sample collection. The studies require fewer design criteria than other methods 
and are adaptable to the clinical setting. However there are still practical issues to consider, 
such as integration of the population PK study within the existing clinical trial protocol, 
quality control of the data, and the extra time, cost and expertise required for laboratory 
and statistical analyses. 
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1.2.2 Phannacodynamics 
The principles discussed above are also applicable to PD data. A common modelling 
approach is to relate a single measure of drug exposure (e.g. area under the concentration-
time curve) to a single measure of drug effect (e.g. time to maximum effect). More difficult 
approaches relate the entire time course of drug concentration to the time course of drug 
effect. Additional factors that may have to be modelled are disease progression and drug 
interactions. 
In vivo the PD properties of antimalarial drugs are assessed by clinical outcome (mortality, 
speed of recovery from coma and fever clearance) and parasitological outcome (White and 
Krishna, 1989). Parasitological recovery from malaria is measured by the clearance of 
parasites from peripheral blood smears. The measures currently used are parasite clearance 
time (pCT; which is the time from initiation of treatment to the first of at least two 
negative smears), PC50 (time until parasitaemia has been reduced by 50%), PC90 (time until 
parasitaemia has been reduced by 90%) and P~8 (parasite reduction ratio at 48 hours) 
(White, 1997). Unfortunately the parameters above do not describe the time course of the 
effect and therefore might not be adequate for describing the efficacy of the drug in the 
host since the amount of drug available changes over time. Additionally there are 
methodological and scientific limitations associated with measuring the parasite burden 
from peripheral blood smears. The limit of detection for microscopy is around 50 parasites 
IIlI, therefore adult patients with less than 2.5* 1 08 parasites in the blood stream will be 
classified as aparasitaemic. Furthermore the relationship between the number of parasites 
detected by the microscope and disease severity is not straightforward. A patient may be in 
a deep coma yet have only a few parasites visible by microscopy whereas a child may be 
able to walk and eat when they have much higher parasite burdens. The explanation for 
these phenomena is that for P. Jalciparum malaria only the first half of the 48 hour life 
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cycle of the parasite is visible to the microscopist (explained in more detail in section 1.1). 
Thus more representative measures of the PD properties of antimalarial drugs in vivo are 
needed to assess accurately and predict the therapeutic response of the antimalarial drugs. 
1.2.3 Pharmacokinetic-Pharmacodynamic modelling 
In the past the relationship between drug dosage and therapeutic response was investigated 
by randomising patients to one of several dose groups and comparing the response profiles. 
The problem with this method is that the dose response profile may be blurred by 
substantial inter-patient variation in drug kinetics. This can now be overcome by 
mathematical modelling of the kinetics and dynamics together. There are two approaches 
to this type of modelling, that is, sequential or simultaneous modelling. 
1.2.3.1 Sequential modelling 
Firstly the PK model is fitted to the concentration-time data. The individual specific PK 
parameter estimates obtained are then used to predict concentrations corresponding to the 
times at which PD measurements were taken. 
For example:- the Emax model, 
( Emax; - Eo;) Y ·· = Eo. + +e .. Y I EC IJ l+(~) 
Cij 
eij - within subject error 
Cj - drug concentration at fh measurement for the ith subject 
The models can include inter-individual error on the dynamic parameters Eoi, Emaxi & 
EC50i. 
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1.2.3.2 Simultaneous modelling 
Fitting both the PK and PD models together. This allows simultaneous assessment of the 
PK and PD variability. 
ni - total number ofPK and PD measurements on subject i. 
Vector Yi [size-ni*l] - denotes stacked PK and PD measurements taken on subject i. 
Cp( tij) - PK model (e. g. one or two compartment models) 
The models can include inter-individual variation on both the PK and PD parameters. 
1.2.3.3 Problems associated with pharmacokinetic-pharmacodynamic modelling 
a) To model successfully the response a reasonable range of concentrations across 
subjects is required. 
b) It is important to choose the appropriate response for the PD model. In other words 
the clinical relevance, ease of measurement, variability in the response and overall 
sensitivity to changes in drug concentration need to be considered. 
c) For some effect measures there is a possible lag time between the plasma 
concentration and PD effect. This occurs when the PK measurements are not taken 
directly at the effect site. To investigate this plot both the effect and plasma 
concentrations versus time. This plot is called a hysteresis curve. The distance 
between curves at different times reflects the degree of hysteresis. There are two 
ways to deal with varying degrees of hysteresis: only use plasma concentrations at 
steady state where the plasma concentration and effect levels are a constant ratio or 
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extend the PK model to include a hypothetical 'effect' compartment. In the case of 
antimalarial efficacy the "effect compartment" is the intra-erythrocytic parasite. 
d) If the measurement error of drug concentrations is ignored then a possible bias 
could affect the PD parameters. 
There is a lack of consensus in the literature about whether it is more informative to 
perform a sequential or simultaneous PK-PD analysis, however it is well established that 
the presence of PK data improves the precision of the estimates of the PD parameter values 
(Hashimoto and Sheiner, 1991). 
1.3 Mefloquine 
Mefloquine was introduced in Thailand at the end of 1984 as the first line treatment for 
falciparum malaria. It was developed in the 1960s as part of a programme by the Walter 
Reed Army Institute of Research, Washington, USA, to identify and develop antimalarial 
drugs effective against resistant strains of P. falciparum. Mefloquine is effective for all 
species of malaria parasites infecting humans, including multidrug-resistant P. falciparum. 
It is given both as a prophylactic and therapeutic agent (Palmer et al. 1993). 
In some areas mefloquine, in combination with an artemisinin derivative, is the only 
efficacious treatment left for uncomplicated highly multi-drug resistant P. falciparum 
malaria. 
1.3.1 Structure and activity 
Mefloquine is a quinoline-methanol antimalarial, structurally related to quinine (Figure 
1.4). 
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Figure 1.4 Structural formula of mefloquine 
Mefloquine has two enantiomers: the (+) RS-enantiomer and (-) SR-enantiomer. An 
enantiomer is a compound derived from a molecule that exhibits optical-isomerism 
because of the presence of one or more optically active chemical centres. 
This agent is active against the asexual stages of parasite development (see section 1.1 
above), but has no activity against mature gametocytes or against the sporozoites. During 
the asexual stage, mefloquine has greater inhibitory activity against the more mature 
trophozoite and schizont forms than against the younger ring stages (Geary et al. 1989). 
Despite knowledge of when mefloquine inhibitory activity occurs the precise mode of 
action of mefloquine remains obscure. Three primary mechanisms of antimalarial activity 
have been postulated: 
1) Drugs that are active against the mature stages of the parasite are proposed to 
accumulate within the food vacuole of the parasite. Haem (ferriprotoporphyrin IX) 
produced from the parasite digestion of the host cells' haemaglobin is also found 
within the food vacuole. Haem can either bind with the drug or with protein to form 
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haemozoin (a malaria pigment not hannful for the parasite). Unlike haemozoin, the 
drug-haem complex is toxic to malaria parasites (Fitch, 1983; Warhurst, 1987). 
2} Mefloquine adheres to the DNA ofthe parasite and thus affects transcription. 
3} The parasite is unable to digest host cell haemaglobin because mefloquine reduces 
the acidity of the parasite food vacuole (known as vacuolar alkalinization). This 
hypothesis is weak since Ginsburg et al. (1989) found no correlation between the 
antimalarial activity of the drugs and pH levels within the parasite food vacuole. 
Of the above three mechanisms it is believed that mechanism one, the inhibition of binding 
between haem and protein, is the most plausible. However it should be noted that this 
mechanism, which has been shown for chloroquine (Slater and Cerami, 1992), is still 
unproven for mefloquine. 
1.3.2 Formulations 
Mefloquine is an antimalarial drug administered orally. There is no intravenous 
formulation as parenteral administration is associated with local irritation (Goldsmith, 
1989). Thus determination of the absolute oral bioavailability of mefloquine is not 
possible. 
1.3.3 Pharmacokinetic properties 
Several assay methodologies have been developed to measure mefloquine concentration 
levels. High performance liquid chromatography is the most frequently used (Edstein et al. 
1991; Green et al. 1999). The concentration levels of the (+) RS- and (-) SR- enantiomers 
of mefloquine can also be measured by high performance liquid chromatography 
(Bergqvist et al. 1994). 
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After oral administration mefloquine is absorbed, and then extensively distributed in the 
tissues before being cleared slowly from the body. The PK profile of mefloquine is usually 
modelled using a two-compartment model, sometimes even a three-compartment model. 
Studies have shown the half life of the drug to be between 14 and 28 days; apparent 
volume of distribution (V IF) to range between 13 and 41 l/kg; and apparent oral clearance 
(CLIF) to lie within 0.02 up to 0.07 l/kglh (Karbwang and White, 1990). 
Considerable inter-individual variation in the PK parameters of mefloquine has been 
reported (Karbwang and White, 1990) yet few factors have been shown to alter the 
pharmacokinetics. Higher blood drug concentrations (approximately double) have been 
reported in adult male Thai patients with acute falciparum malaria compared to healthy 
adult male Causcasian volunteers (Looareesuwan et al. 1987), these could be due to either 
genetic or disease related factors. Other studies comparing malaria patients and healthy 
volunteers within the same ethnic group have conflicting findings (Karbwang et al. 1988; 
Juma and Ogeto, 1989; Boudreau et al. 1990). Karbwang et al. (1988) found reduced 
elimination half-life and mean residence time in Thai patients compared to healthy Thai 
volunteers. In contrast, Juma and Ogeto (1989) found a longer elimination half-life 
together with reduced total clearance and volume of distribution for severe falciparum 
malaria in Kenyan patients compared to healthy volunteers. Boudreau et al. (1990) 
demonstrated a higher plasma Cmax and prolonged tmax in Thai patients compared with 
healthy Thai volunteers. Food has been observed to alter the absorption kinetics of 
mefloquine (Crevoisier et al. 1997). Peak plasma concentrations of mefloquine were 
achieved earlier and were higher in the non-fasting state. These changes in absorption 
resulted in an increased bioavailability of mefloquine of 40% and thus suggesting 
mefloquine should be administered at meal times. Mefloquine bioavailability was also 
found to increase for patients receiving mefloquine (as part of the combination therapy: 
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artesunate plus mefloquine) during convalescence as opposed to the acute stage of disease 
(Price et al. 1999a). 
There is good agreement between mefloquine levels measured in the whole blood of the 
capillary and the vein (ter Kuile et al. 1994). Venous levels ofmefloquine are 1.15 (95% 
CI: 1.03 - 1.29) times greater than levels measured in the plasma (ter Kuile et al. 1994). 
However, Daniel Todd et al. (1997) found mefloquine levels measured in the serum to be 
1.28 (95% CI: 1.24 - 1.32) times larger than the levels measured in the whole blood. 
The plasma protein binding for mefloquine has been reported to be approximately 98% 
(White, 1992c). However it should be noted that it is difficult to determine the plasma 
protein binding accurately since mefloquine in vitro sticks avidly to plastics. 
1.3.4 Pharmacodynamic properties 
Mefloquine appears to have relatively little effect on asexual malaria parasites in the first 
half (24 hrs) of the life cycle (White, 1997) and exhibits its greatest inhibitory activity 
against the more mature trophozoite and schizont forms (Geary et al. 1989). As a result 
most circulating P. falciparum parasites continue to mature in the host and sequester. 
Following treatment with mefloquine, the average parasitaemia-time profile is that of a lag 
phase, during which the population mean parasitaemia remains unchanged before 
beginning to decline. Mefloquine has antimalarial activity comparable to other quinolines, 
reducing the number of parasites in the body by 100 to 1000 fold per parasite life cycle 
(White, 1997). The long half-life of mefloquine allows therapeutic concentrations to 
remain until all the parasites in drug-sensitive infections have been removed. 
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1.3.5 History of therapeutic efficacy 
Mefloquine was first introduced in Thailand in 1984, originally in combination with 
sulphadoxine-pyrimethamine in a single tablet form (MSP, Fansimef®: Roche 
Pharmaceuticals) in the hope this would preserve its antimalarial activity. However P. 
falciparum in Thailand was already highly resistant to sulphadoxine and pyrimethamine 
and by 1990 efficacy of this combination tablet had fallen from an initial cure rate of >99% 
to a cure rate of71 % (Nosten et al. 1991b). Since the combination regimen was no longer 
superior to mefloquine alone, mefloquine monotherapy was adopted, first at 15 mglkg and 
then at 25 mglkg. This increased dose improved cure rates to 91 % (ter Kuile et al. 1992) 
initially, but by 1994 resistance had worsened further and the cure rate for the 25 mglkg 
dose had dropped to 60% (Price et al. 1995). Mefloquine monotherapy for uncomplicated 
falciparum malaria was discontinued and replaced by a combination of mefloquine (25 
mglkg) and 3 days of artesunate administration (4 mglkg/day) (Nosten et al. 1994). 
1.3.6 Present function of mefloguine 
Mefloquine is currently prescribed as prophylaxis for malaria for people travelling to 
endemic areas with chloroquine resistant malaria. With regards to the treatment, 
mefloquine is only used for the treatment of uncomplicated malarial infections. Mefloquine 
is not a suitable drug for the treatment of severe malaria since it can only be given orally 
and is associated with a high rate of vomiting. In areas where the level of drug resistance is 
high, such as in Southeast Asia, mefloquine is now given as part of a combination therapy 
(mefloquine plus an artemisinin derivative) for the treatment of uncomplicated P. 
falciparum infections (Nosten et al. 2000; Price, 2000; Nosten et al. 1994). Mefloquine is 
too expensive for general use throughout tropical Africa (Winstanley, 2000). 
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2. AIMS AND OBJECTIVES OF THESIS 
2.1 Aims 
a) To apply population modelling approaches to mefloquine PK data to characterise the 
factors influencing inter-patient variability in the dose-response relationship, and 
provide the clinician with optimal dosing strategies. 
b) To develop a mechanistic PK-PD model for mefloquine in vivo that can be used to 
simulate the PD response in vivo with different dosing regimes or in areas of varying 
levels of mefloquine resistance. 
c) To determine the population dynamics of the Plasmodium falciparum parasite within 
the human host in the absence of antimalarial drugs, in order to understand and 
characterise any subsequent drug effects. 
d) To determine the population in vivo PD parameters for mefloquine using sequential 
PK-PD modelling. 
2.2 Objectives 
Aim I (Chapter 3) 
a) To estimate the population PK parameters and their inter-individual variability for 
different mefloquine dosing regimes:-
Mefloquine monotherapy - single dosing (25 mglkg) 
Mefloquine monotherapy - split dosing (15 mglkg initially, 10 mg/kg 24 hours later) 
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Mefloquine in combination with artesunate - single dosing of mefloquine (25 mglkg) 
Mefloquine in combination with artesunate - split dosing of mefloquine 
(15 mglkg initially, 10 mglkg 24 hours later) 
b) To explore the demographic characteristics and disease related factors that influence 
the PK parameters. 
c) To investigate the relationship between the individual PK parameters and therapeutic 
response where therapeutic response was measured by parasite and fever clearance and 
treatment failure. 
Aim 2 (Chapter 4) 
a) To develop a mechanistic mathematical equation that describes the change in total 
parasite burden over time in vivo in the presence of the antimalarial, mefloquine. 
b) To estimate the population PD parameters (slope of the concentration-effect curve and 
the mefloquine concentration that is 90% effective) and their inter-strain variability 
from in vitro concentration-effect data. 
c) To simulate total parasite burden-time profiles for the following scenarios; different 
dosages of mefloquine, different slopes of concentration-effect curves, differing levels 
of mefloquine resistance, and different proportions of free drug available in vivo. 
d) To predict the time to recrudescence for an infection that is classified as type RI 
resistance for different killing actions of mefloquine and differing levels of mefloquine 
resistance. 
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Aim 3 (Chapter 5) 
a) To estimate the parasite multiplication rate (PMR) and periodicity of the parasite cycle 
in the first week of patent parasitaemia using three different statistical methods:-
standard two-stage method 
global two-stage method 
nonlinear mixed effects modelling 
b) To investigate the effect of different P. falciparum strains and sporozoite and blood 
induced infections on the parameters, PMR and periodicity. 
Aim 4 (Chapter 6) 
a) To estimate the population in vivo PD parameters of mefloquine using sequential PK-
PD modelling of parasite count and mefloquine concentration data. 
b) To explore the demographic and disease related factors that influence the PD 
parameters. 
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3. POPULATION PHARMACOKINETICS OF MEFLOQUINE 
3.1 Introduction 
In this chapter a population pharmacokinetic (PK) analysis is described which was 
performed on a large number of patient measurements to provide information on optimum 
dosage both when mefloquine is used alone and in combination with an artemisinin 
derivative. The effect of patient covariates on the PK of mefloquine was also investigated. 
3.2 Methods 
3.2.1 Study population 
PK data were collected prospectively from patients receiving mefloquine as part of trials 
conducted between 1990 and 1995. Before 1994 mefloquine was given alone, and after 
1994 it was given in combination with artesunate (12 mg/kg over 3 days). 
The patients were from the Karen ethnic minority and lived in camps for displaced persons 
situated along the western border of Thailand in an area of low and seasonal malaria 
transmission (Luxemburger et al. 1996). Health care in these camps is provided by 
Medecins Sans Frontieres (MSF). 
Patients presenting to the clinics were enrolled into prospective studies of antimalarial 
treatment if they were symptomatic, with a microscopically confirmed infection with 
asexual stages of P. Jalciparum in the peripheral blood. Before 1994 the exclusion criteria 
for these studies were the following; weight less than 8kg, quinine administration within 
the previous 7 days, or mefloquine or sulfadoxine-pyrimethamine within the previous 14 
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days, pregnancy, signs of severity or concomitant disease requiring hospital admission 
(World Health Organisation, 1990). After 1994, on the basis of completed studies, these 
exclusion criteria were modified. Patients were excluded if any antimalarial medication 
had been given in the preceding 63 days, the parasitaemia at presentation was greater than 
4%, their weight was less than 5kgs, or there were signs of severity or concomitant disease 
requiring hospital admission. 
Informed consent was obtained from the patients, their parents or guardians. All studies 
were approved by the Ethical Committee of the Faculty of Tropical Medicine, Mahidol 
University, Bangkok, Thailand, and by the Karen Refugee Committee, Mae Sod, Thailand. 
3.2.2 Mefloguine dosing 
All patients received one of the following two mefloquine (Lariam® 250 mg base tablets, 
Roche Pharmaceuticals, Basel, Switzerland) dosing regimens; 25 mg/kg (single dose) or 25 
mg/kg (split dose - 15 mg/kg on day 0 followed by 10 mg/kg 24 hours later). Mefloquine 
was given to adults and older children to the nearest quarter tablet according to the 
calculated dose per kg of bodyweight. Younger children received mefloquine orally by 
syringe as crushed tablets, suspended in sugar water. For patients recruited prior to 1994 
mefloquine was given alone and after 1994 mefloquine was combined with artesunate, 4 
mg/kglday for three days (50 mg tablets: Guilin No 1 factory, People's Republic of China). 
3.2.3 Study procedures 
On admission a questionnaire was completed recording details of symptoms and their 
duration, and the history of previous antimalarial medication. Since health structures in the 
camp are the only source of antimalarial drugs in this area, the history is generally a 
reliable guide to pre-treatment (Price et al. 1997). A full clinical examination was made 
and blood was taken for blood film, haematocrit, and white cell count. Malaria parasite 
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counts were determined on Giemsa-stained thick films as the number of parasites per 500 
white blood cells. Patients were examined daily thereafter until they became 
aparasitaemic, and were then seen weekly for at least four weeks. At each clinic 
appointment a full physical examination was performed, the symptom questionnaire was 
completed, and, at the weekly visits, blood was taken for haematocrit and parasite count. 
Fever was defined as an axillary temperature greater than 37°C or an oral temperature 
greater than 37.SoC. 
For those patients who received mefloquine monotherapy heparinised whole blood was 
collected either by fingerprick (100-200 III of capillary blood) or venepuncture (500 III of 
venous blood) on various days (ranging from day 0 to day 28) after the onset of treatment. 
For those patients who received combined therapy, where artesunate was administered on 
admission and mefloquine administered 2 days later, whole capillary blood samples (400 
I.d) were collected on days 0, 3, 5, 7,9, 14 and 28. This corresponded to days 0, 1,3, 5, 7, 
12 and 26 following mefloquine administration. However for 27 of the subjects mefloquine 
and artesunate were both administered on admission and for these the blood samples were 
collected on days 0, 1,3,5, 7, 9, 14 and 28 following drug administration. 
3.2.4 Mefloguine assay 
All blood samples were stored at -70°C until analysed. Whole blood mefloquine 
concentration measurements were performed by high performance liquid chromatography 
(HPLC) with ultraviolet detection as described previously (Edstein et al. 1991). 
Quantitation of mefloquine was performed by reversed-phase chromatography with 
isocratic elution. WR184,806 (±2.8 bis (trifluoromethyl) 4-[I-hydroxy-3-(N-
tertbutylamino) propyl] quinoline phosphate) was used as an internal standard. Mefloquine 
was extracted by liquid-liquid extraction into dichloromethane layer, which was separated 
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from aqueous phase, evaporated to dryness and reconstituted in mobile phase before 
injection to HPLC (Edstein et al. 1991). Before 1994 whole blood was collected by either 
venepuncture (500 .... 1) or by fingerprick (100-200 .... 1). After 1994 all whole blood samples 
were collected by fingerprick (100-200 .... 1). Whole blood samples were diluted two-fold 
with distilled water and then sonicated for 30 seconds before assay. The assay was linear 
over 0.05 to 4 .... g/ml. For the levels measured before 1994 (i.e. when mefloquine was given 
as a monotherapy) and split dosing, the inter-assay coefficients of variation (CV%) for the 
whole blood assays (200 .... 1, n=19) were 6.1% and 3.6% at 100 and 1000 ng/ml 
respectively. For single dosing before 1994 the inter-assay coefficients of variation for the 
whole blood assays (200 .... 1, n=15) were 6.3% and 5.7% at 100 and 1000 ng/ml 
respectively. For the levels recorded during 1994 and 1995 the inter-assay coefficients of 
variation for the capillary whole blood assays (n=44) were 8.3% and 5.7% at 100 and 1000 
ng/ml respectively. The limit of detection of whole blood mefloquine was 50 ng/ml. At this 
study site capillary blood samples have been shown to give equivalent results to larger 
venous blood samples (ter Kuile et al. 1994). 
3.2.5 Pharmacokinetic model 
For the development of the popUlation PK model, patients with detectable whole blood 
concentrations of mefloquine on the day of admission to study were excluded. 
The data could only support, for orally administered mefloquine, a one-compartment 
model (Gibaldi and Perrier, 1982) with first-order absorption and first-order elimination. 
The equation for plasma concentration as a function of time after oral administration is bi-
exponential. 
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C [
ka.dOSe.F] [-(C:Jr -k .1] 
= * e -e a 
V.ka- CL 
where C - mefloquine concentration (nglml) 
ka - first order absorption rate constant (/day) 
dose - dosage of drug given (f-lglkg) 
F - fraction of drug absorbed 
V - total apparent volume of distribution (l/kg) 
CL - clearance (l/kglday) 
t - time (days) 
The data in this part of the analysis came originally from standard PK studies where serial 
samples were taken at the same times for each subject and a standard two-stage PK 
analysis performed (ter Kuile et al. 1993b; Price et al. 1999a). The first mefloquine level 
measured was taken on average 24 hours (range 20-31 hours) after drug intake so there 
was minimal information regarding the absorption phase. As absolute bioavailability 
cannot be determined the fundamental PK parameters used to characterise the above one-
compartment model were apparent clearance (CLlF) and apparent volume of distribution 
(V/F). The absorption rate constant was set to a constant value of 7.0 /day derived from a 
PK study (Nosten et al. 1991a) of malaria patients from the same population as the present 
study. 
3.2.6 Statistical model 
The residual intra-individual error was modelled using an additive error model. That is the 
departure of an individual concentration from the predicted population value is 
independent of the actual concentration. 
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Cij is the fh observed concentration for the ilh individual and Cpij is the fh predicted 
concentration for the ilh individual. Eij is the residual intra-subject error tenn and is assumed 
to be randomly Nonnally distributed with zero mean and variance (i. 
Inter-individual variability in apparent clearance (CLlF) and volume of distribution (V IF) 
were modelled with log nonnal error models. A log-nonnal error model differs from an 
additive error model because the model assumes departure of the individual PK parameter 
(either CLlFi or V lFi) from the population mean PK parameter (either CLIF or V IF) is 
dependent on the value of the PK parameter, not constant across all individuals. Log 
nonnal error models also ensure the individual PK parameters, (CLIF)i and (VIF)i, must be 
greater than zero. 
(CLI F)j = (CLI F).exp(TJicLlF ) 
(V I F)i = (V I F).exp(TJ/IF) 
(3.1) 
(3.2) 
CLlFi and V lFi are the PK parameters for the individual and CLiF and V IF are the 
population means. The llicUF and lliv/F are random effects with zero mean and variances 
cr2CUF and cr2V/F' respectively, which represent the inter-individual variability for each of 
the parameters. The inter-individual variability of CLIP and VIF were expressed as 
asymmetric 90% prediction intervals: for example for apparent clearance, exp [lo&(CLlF) 
± 1.645*crcuF]. 
3.2.7 Data analysis 
The NLME procedure (Lindstrom and Bates, 1990) of the SPLUS data programme 
(SPLUS 4.5 for Windows, Mathsoft, Inc.) was used to calculate estimates of the population 
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PK parameters (CL/F, V/F) and their respective inter-individual variances (r{UF, 11 V/F). 
The programme also provides estimates of the residual random intra-individual error (E) 
and the variances of the inter-individual error terms (cr2CUF' cr2V/F). Convergence was 
achieved when, between iterations, the objective value did not differ by more than some 
pre-specified difference (eg 0.0001) and the programme returned the final estimates of the 
population PK parameters. The objective function (minus twice the log-likelihood of the 
data) was used to determine the model that best fitted the data. A significant drop in the 
objective function (using the Chi-squared distribution with degrees of freedom equal to 
number of parameters which are set equal to a fixed value in the restricted model) from the 
general model to the restricted model was used to determine the final PK model. The 
goodness of fit of each model was also detennined by the precision of the parameter 
estimates and examination of the scatter plot of residuals versus predicted mefloquine 
levels. The individual PK parameters were calculated using the posterior estimates. 
Covariates were used to attempt to explain some of the inter-individual variability. 
Multiple linear regression was used to investigate the relationship between the fixed effects 
(i.e. demographic, laboratory and clinical data) and the random effects (i.e. the PK 
parameters). The PK parameters were the dependent variables and the fixed effects were 
entered into the regression model as the independent variables using stepwise methods. 
The statistical computations were perfonned using the statistical programme SPSS Version 
7.5 for Windows (SPSS Inc., Chicago, IL.). 
Covariates that were found to be significant in the above multiple linear regression 
analyses were introduced into the one compartment model by being incorporated into 
equations (3.1) and (3.2) as the following:-
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(eLI F)j = [(eLI F) + fJ1.(HF)].exp(1]/LIF) 
(V I F)j = [(V I F)+fJ2 .(TI)].exp(1]/IF) 
HF - history of fever = 1 if history of fever ~ 2 days; 
= 0 if history of fever < 2 days; 
TI - type of infection = I if mixed infection; 
= 0 if pure P. Ja/ciparum infection. 
0) represents the change in CLIF due to a prolonged history of fever 
and 02 represents the change in V IF due to a mixed infection. 
Covariates which were continuous variables were centred around their mean values so that 
the population estimates would represent those of an average patient. 
For example:- (eLI F)j = [(eLI F) + fJ3"(HCT -mean(HCT»)].exp(1]jCLI F) 
where HCT = haematocrit 
03 represents the change in CLIF due to haematocrit from the 
population mean value of CLIF for patients with a 
haematocrit equal to the mean value. 
A statistically significant improvement in the objective function, improvement in the 
precision of the parameter estimate (SE), and reduction in inter-patient and residual 
variability were used to determine the importance of the covariates as significant 
predictors. 
3.2.8 Efficacy modelling 
The variables chosen prospectively to represent therapeutic response were clearance of 
parasites and fever within 24 and 48 hours, and recrudescence of the infection (treatment 
failure) during 28 days of follow up. Multiple logistic regression was performed to model 
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these binary outcomes. The independent variables included in the analysis were admission 
parasitaemia (log transformed), admission temperature, age, type of dosage (split versus 
single), and individual estimates of AUCo-a) and VIF. 
3.3 Results 
Overall 1020 whole blood mefloquine concentrations (excluding 0 hr samples) taken from 
257 patients with acute fa1ciparum malaria between 1990 and 1995 were available for 
analysis. Of these, 513 mefloquine concentrations were from 159 subjects who were given 
a split dose: 15 mg/kg initially followed by 10 mg/kg 24 hours later. The remaining 507 
mefloquine concentrations were from subjects to whom a single dose of 25 mg/kg was 
administered. The demographic characteristics of the patients are given in Table 3.1. The 
majority of patients (83%) were followed weekly for at least four weeks. 
3.3.1 Population pharmacokinetic model 
The model that gave the best fit to the data was a one compartment model with first order 
absorption and with CLIF and V IF fitted as random effects. That is, equations (3.1) and 
(3.2) were fitted by the NLME procedure. To avoid convergence problems with the 
optimisation algorithm used in NLME due to the sparsity of the mefloquine concentrations 
in the data the random effects of CLIF and V IF were assumed to be independent. 
Appendices I and II give the SPLUS programmes used for fitting the one compartment 
model to split and single dosing respectively. 
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Table 3.1. Admission characteristics for all patients. 
Mefloquine alone Mefloquine + Artesunate 
Split dose (Group A) Single dose (Group B) Split dose (Group C) Single dose (Group D) 
No. of Subjects Enrolled 128 24 31 74 
Year of Study 1990- N=63 1990- N=O 1994- N=27 1994-N=28 
1991 - N=65 1991- N=24 1995 -N=4 1995 - N=46 
Males N (%) 76 (59) 13 (54) 19 (61) 41 (55) 
Age (years)" 14.8 (12.7-16.8) [1.2-54] 17.9 (12.8-23) [0.8-51] 9.1 (8.1-10) [5-14] 9.3 (8.6-9.9) [4-15] 
<5 N(%) 15 (12) 3 (13) 0 3 (4) 
5-14 N(%) 67 (52) 7 (29) 31 (100) 69 (93) 
>14 N(%) 46 (36) 14 (58) 0 2 (3) 
Weight (kg)' 31.0 (28.3-33.7) [8-61] 35.9 (29.2-42.7) [9-59] 24.0 (21.0-27.1) [14-42] 25.6 (23.8-27.5) [13-43] 
Primary Infection N(%) 90 (70) 23 (96) 31 (100) 74 (100) 
Fever on admission N(%) 91 (71) 16 (67) 18 (58) 48 (65) 
Prolonged history off ever N (%) 80 (74)" 18 (75) 16 (52) 35 (47) 
Pure P falciparum infection N (%) 110 (91)" 20 (83) 20 (65) 47 (64) 
Haematocrit (%) a,- 34.8 (33.5-36.2) [15-55] 34.2 (31.8-36.5) [21-44] 35.7 (34.1-37.2) [22.8-41.4] 35.7 (34.6-36.8) [22.8-44.9] 
Haematocrit < 30% N(%) 14 (18) 1 (5) 2 (7) 6 (9) 
Parasite count per III blood b 3486 (2516-4832) 3409 (1614-7200) 7204 (3719-13,954) 7730 (4727-12641) 
[64-146,080] [50-114,660] [55-105,152] [25-176,832] 
>10,00011l1 N(%) 39(31) 8 (33) 14 (45) 32 (43) 
a - mean (95% CI) [range], b - geometric mean (95% CI) [range], 
* - missing data for some patients (for haernatocrit: Group A n=79; Group B n=19; Group C n=29; Group D n=67) 
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The one compartment model was fitted separately to the following four datasets, 
monotherapy & split dosing (group A), 
monotherapy & single dosing (group B), 
combined therapy & split dosing (group C), 
combined therapy & single dosing (group D), 
since they exhibited very different PK profiles and had variability in the magnitude of their 
residual error. 
All mefloquine levels were assayed using capillary blood for datasets C and D. However, 
for datasets A and B, 53% (186/350) and 65% (53/82) of the mefloquine levels 
respectively were assayed from venous blood with the remainder analysed from capillary 
blood. There were no significant differences between mefloquine levels from venous and 
capillary blood for each of the sampling times (day 3, 7, 14, 21 and 28) or for the same 
patient on anyone day (ter Kuile et al. 1994). However, the magnitude of the residual 
variability was greater for concentrations measured from capillary blood as opposed to the 
venous blood. To adjust for this a covariate was attached to the residual error. This had 
little effect on the estimates of CLIP and V/F, but did improve the objective function 
significantly. 
Figures 3.1a, 3.1 b, 3.lc and 3.1d show scatter plots of the observed values and resulting 
population PK profiles versus time for the four different datasets. As shown in Figure 3.2 
the concentration-time profiles for the four datasets were very different. The patient 
specific profiles were characterised adequately (Figure 3.3) and the residual plots indicated 
no bias in estimation (Figures 3.4a, 3.4b, 3.4c, 3.4d). The mean population PK parameters 
of all four base models are presented in Table 3.2. Inter-individual variability, defined as 
90% prediction intervals of the population estimates, varied greatly for both CLiF and VIP. 
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Table 3.2. Population pharmacokinetic parameters for the base model. 
Mefloquine monotherapy Combined therapy 
Estimate (SE) 90% Estimate (SE) 90% 
Prediction Prediction 
Intervals. Intervals. 
Split dosing Group A GroupC 
CLIF (l/kg/day) 0.490 (0.023) 0.254, 0.946 1.027 (0.083) 0.600, 1.759 
VIP (l/kg) 8.14 (0.43) 3.66, 14.43 13.99 (0.70) 9.81, 19.95 
ke (elimination rate) 0.060/day 0.073/day 
t1l2 (elimination 11.6 days 9.5 days 
half life) 
AUCo_oo 51020 ng/ml*day 24343 ng/ml*day 
(area under curve) 
0"6 (ng/ml) 697.4 (for capillary) 262.5 (for capillary) 
219.5 (for venous) 
Single dosing GroupB Group D 
CLIF (l/kg/day) 0.733 (0.051) 0.572, 0.939 1.232 (0.082) 0.490,3.101 
VIF (l/kg) 20.37 (2.53) 8.09,51.32 14.95 (0.66) 8.64,25.86 
ke (elimination rate) 0.036/day 0.082/day 
t1l2 (elimination 19.3 days 8.5 days 
half life) 
AUCo_oo 34106 ng/ml*day 20292 ng/m1*day 
(area under curve) 
0"& (ng/ml) 180.4 (for capillary) 294.7 (for capillary) 
167.6 (for venous) 
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Figures 3.1a & 3.th. Whole blood mefloquine concentrations in acute falciparum malaria. The 
solid line shows the fit of the data and represents the predicted concentration-time profile for the 
population mean. 
A: mefloquine monotherapy: split dosing B: mefloquine monotherapy: single dosing 
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Figures 3.te & 3.td. Whole blood mefloquine concentrations in acute falciparum malaria. 
The solid line shows the fit of the data and represents the predicted concentration-time profile 
for the population mean. 
C: mefloquine & artesunate: split dosing D: mefloquine & artesunate: single dosing 
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Figure 3.2. Predicted population pharmacokinetic profiles for datasets, 
A: mefloquine monotherapy: split dosing; 
B: mefloquine monotherapy: single dose 
C: mefloquine & artesunate: split dosing; 
D: mefloquine & artesunate: single dosing 
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3.3.2 Split versus single dosing 
The area under the concentration time curve (AUCo-oo) was calculated from the popUlation 
estimate of CUP for groups A, B, C and D. Splitting the dose of mefloquine increased the 
AUCo-oo by 50% (95% CI: 36 to 65%) compared to a single dose for monotherapy and by 
20% (95% CI: 3 to 40%) for the combined therapy. 
Estimated VIF was significantly smaller for subjects receiving split dosing compared to 
those receiving single dosing (estimate (95% CI): 8.14 (7.49,8.86) vs 20.37 (16.26, 25.51) 
lIkg, p<O.OOI respectively) when mefloquine was given as a monotherapy. However, when 
mefloquine was given as combined therapy no significant differences in V IF were 
observed between those subjects receiving split dosing and those receiving a single dose 
(estimate (95% CI): 13.99 (9.16, 21.36) vs 14.95 (7.78,28.71) lIkg, p= 0.305 respectively). 
To check the above findings all four datasets were combined and formal hypothesis testing 
was performed to investigate the effects of the covariates: monotherapy versus combined 
therapy and split versus single dose. The results obtained confirmed the above findings. 
3.3.3 Relationship between pharmacokinetic parameters and covariates 
The covariates deemed important prospectively were age, weight, sex, temperature, 
haematocrit, admission parasitaemia, type of infection (pure P. falciparum, or mixed P. 
falciparum and P. vivax), vomiting or diarrhoea on admission; prolonged history of fever 
(fever for two or more days before admission); and history of vomiting and fever. 
However, only three subjects had diarrhoea on admission, so this variable was excluded 
from all analyses. For group D the covariate termed 'day of mefloquine administration' 
was included in the analysis to see ifthere was any change in the PK ofmefloquine when a 
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single dose of mefloquine was given on day 0 compared to day 2. Of the 74 subjects 27 
(36.S%) were given mefloquine on day O. 
No association between the body-weight normalised PK parameters and age or weight was 
observed for any of the four groups. Univariate associations between the PK parameters 
and the following independent variables; temperature, haematocrit, parasitaemia, vomiting 
and type of infection on admission, and a long history of fever were observed. For group D 
there was a significant association between apparent clearance and day of mefloquine 
administration. 
Thus stepwise multiple linear regression was performed to investigate the relationship 
between CLIF and V IF and the various covariates. 
Dependent variables-
Independent variables-
CLIF, VIF 
age, admission temperature, admission haematocrit, 
admission parasitaemia, long history of fever, pure P. 
Jalciparum infection on admission, vomiting on admission, 
day ofmefloquine administration (only for group D). 
Table 3.3 summarises the covariates that were independent predictors of both CLIF and 
VIF for each of the four groups. Figures 3.Sa, 3.Sb, 3.Sc, 3.5d, 3.Se, 3.5fand 3.Sg are either 
scatter plots or error bar plots where appropriate of the posterior PK parameters against the 
independent predictors summarised in Table 3.3. For group A none of the above variables 
were found independently to be significant predictors ofCUF. For group B no independent 
associations between both CLIF and V IF and any of the variables were found. 
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Table 3.3. Final regression models for CLIF and V IF from multiple "near stepwise regression. 
Group Regression model R2 
A 
C 
D 
Footnote: 
V IF = 48.75 - 1.060*temperature 
CLIF = 0.068 + 0.028*haematocrit 
VIF = 3.47 + 0.30*haematocrit 
CLIF = 1.376 + 0.217*(long history offever) - 0.125*(day of 
administration) 
VIF = 13.36 + 2.28*(long history offever) + 3.21 * (infection type) 
6.5% 
24% 
31% 
12.5% 
13.5% 
R2 - percentage of the total variation in the dependent variable (i.e. V IF or CLfF) 
explained by the regression model 
long history of fever = I if history off ever ~ 2 days 
= 0 ifhistory off ever < 2 days 
day of administration = 0 if mefloquine given on day of admission 
= I if mefloquine given 2 days after admission 
infection type = I if mixed infection 
= 0 if pure P. ja/ciparum malaria 
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Figure 3.Sd. Relationship between posterior estimates ofCLIF (l/kg/day) and 
prolonged history of fever in patients from group D (mefloquine & artesunate: 
single dosing). 
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3.3.4 Final model estimates 
From the multiple linear regression analysis the covariates found to be independently 
associated significantly with the individual estimates of CLiF and V IF were now added 
univariately to the PK model. Table 3.4 summarises the effects of each covariate on the PK 
model for groups A, C and D. 
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Table 3.4. Summary of results with incorporation of covariates into the base model. 
Parameter 95%CI Change in p-value 
estimate objective 
function 
Group A 
Effect of temperature on V IF -1.392 -2.23, -0.55 8.38 <0.01 
GroupC 
Effect ofhaernatocrit on CLIF, 0.012 -0.001,0.025 2.74 >0.05 
Effect ofhaernatocrit on VIF. 0.085 -0.017,0.188 2.49 >0.05 
GroupD 
Effect of prolonged history of 0.310 -0.019,0.639 3.17 >0.05 
fever on CUF, 
Effect of day of mefloquine -0.174 -0.346, -0.002 4.09 0.01 <p<0.05 
administration on CUF, 
Effect of prolonged history of 2.06 -0.55,4.67 2.60 >0.05 
fever on VIF, 
Effect of mixed infection on VIF. 3.82 1.00,6.64 7.38 <0.01 
It can be seen that the covariates had minimal effect on the fit of the PK model. For group 
A, the minimum, mean and maximum admission temperatures observed were 36,37.7 and 
40.3°C respectively. At these temperatures the respective population estimates of V IF 
would be 10.6, 8.21 and 4.59 l/kg. Thus in the most extreme scenario (i.e. a patient with a 
subnormal temperature of 36°C) there would be an approximate 29% increase in V IF from 
the population mean. For group D the inclusion of the covariate 'day of mefloquine 
administration' improved the objective function of the PK model marginally. 
Administering mefloquine on day 2 (i.e. during recovery) decreased the CLIF by 0.174 
l/kglday (95% CI: 0.002, 0.346). For group D a mixed infection was shown to increase the 
VIF by 3.82 l/kg (95% CI: 1.00, 6.64). Table 3.5 presents the final population parameter 
estimates and the inter-individual and residual variability for groups A and D where the 
addition of covariates improved the objective function significantly. 
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Table 3.5. Population pharmacokinetic parameters for the final models in the two groups 
where adjusting for covariates gave improved fits. 
CLIF (l/kg/day) 
Factor for day of 
drug administration 
during 
convalescence on 
CLIF 
VIF(l/kg) 
Change in V IF (l/kg) 
Mefloquine monotherapy 
& split dosing. 
Combined therapy & 
single dosing. 
Estimate (SE) 90% Estimate (SE) 90% 
Prediction Prediction 
Intervals. Intervals. 
Group Am Group DR 
0.487 (0.023) 0.253, 0.936 1.278 (0.089) 0.602,2.714 
-0.18 (0.09) 
8.21 (0.43) 3.83,17.61 13.71 (0.72) 8.25,22.79 
due to drop in 1°C of 1.39 (0.43) 
admission 
temperature 
Factor for mixed 
infection on V IF 
.......... .. _ .. __ ..... _ .. _ ...... _ ... __ ._. . .... '-'- .. 
ke (elimination rate) 
tl/2 (elimination 
half life) 
AVC 
(area under curve) 
(JE (ng/ml) 
........... _._ .. 
0.060/day 
11.6 days 
51335 ng/ml*day 
696.0 (for capillary) 
219.3 (for venous) 
3.88 (1.43) 
0.082/day 
8.5 days 
19562 nglml*day 
294.8 (for capillary) 
m - Incorporates the effects of admission temperature on V IF. 
n - Incorporates the effects of both day of drug administration on CLIF and type of infection on 
VIF. 
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3.3.5 Weight adjusted dose 
For the studies conducted post 1994 (Groups C & D) the actual dose of mefloquine given 
was recorded. Using the actual dose (mg) in the model as opposed to the weight adjusted 
dose (i.e. a single dose of 25 mg/kg or a split dose of 15mg/kg on day 0 followed by 10 
mg/kg 24 hours later), the relationship between the PK parameters (CUF and VIF) and 
body weight was investigated. 
Mefloquine combined therapy: split dose (Group C) 
The posterior patient specific estimates for CUF and V IF were significantly positively 
correlated with body weight (Figures 3.6a & 3.6b). The incorporation of body weight in 
the model as a covariate for both CLIF and V IF resulted in a reduction in the inter-patient 
variability from 48 to 37% for CLIF and from 39 to 26% for VIF. The minimum, mean and 
maximum admission body weights were 14, 24 and 42 kg respectively. At these body 
weights the respective population estimates of CLIF would be 15.27, 23.77 and 39.07 
l/day, and for V/F would be 211.53, 330.63 and 545.01 1. The final model parameter 
estimates are given in Table 3.6. These results confirm that the dose recommendation for 
split dose mefloquine should be adjusted for body weight. 
Mefloquine combined therapy: single dose (group D) 
The posterior patient specific estimates for CLIF and V IF were significantly positively 
correlated with body weight (Figures 3.6c & 3.6d). Incorporating body weight as a 
covariate for both CLIF and V IF in the model reduced the inter-patient variability from 66 
to 49% for CUF and from 50 to 34% for VIF. At the minimum (13 kg), mean (25.6 kg) 
and maximum (43 kg) body weights the respective popUlation estimates of CLIF would be 
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13.34, 33.0 and 60.14 l/day, and for VIF would be 192.34, 383.86 and 648.34 1. The final 
model parameter estimates are given in Table 3.6. These results confirm that the dose 
recommendation for single dose mefloquine should be adjusted for body weight. 
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Table 3.6. Mefloquine population pharmacokinetic parameters after adjusting for body 
weight. 
CLIF (l/day) * 
Change in CLIF (l/day) 
Combined therapy & 
split dosing. 
Estimate (SE) 90% 
Group C 
23.77 (2.16) 
Prediction 
Intervals. 
12.87,43.90 
due to an increase of 1 kg 0.85 (0.29) 
in body weight 
Combined therapy & 
single dosing. 
Estimate (SE) 90% 
GroupD 
33.00 (2.40) 
1.56 (0.26) 
Prediction 
Intervals. 
14.86, 73.28 
VIF (1) * 330.63 (19.19) 217.35,502.94 383.86 (18.27) 220.50,668.24 
Change in VIF (1) due to 
an increase of 1 kg in 
body weight 
lee 
(elimination rate lday)* 
11.91 (2.65) 
0.072 Iday 
-.. -----.. --- .. -... _ .. --"-" ... _._--- _ ... _- .-_ .. ", ... 
--11-/2 (elimination half life - 9.63 days 
days) * 
(JE (ng/ml) 259.2 
15.20 (2.10) 
0.086/day 
8.06 days 
295.6 
* _ For a person having a mean body weight (i.e. 24.0 kgs for Group C and 25.6 kgs for Group D) 
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3.3.6 Relationship between pharmacokinetic parameters and therapeutic response 
All but one of the patients treated with mefloquine combined with artesunate cleared their 
parasitaemias within the first 48 hours. Patients treated with the combination also had a 
very low failure rate; 2% (defined as a recrudescent infection within 28 days). This 
contrasts with patients treated with mefloquine alone; only 37% had cleared their 
parasitaemia within the first 48 hours, and the 28 day failure rate was 24% (Table 3.7). The 
addition of artesunate therefore improved cure rates considerably, and thus obscured the 
relationship between mefloquine blood concentration profiles and the therapeutic response. 
Therefore to investigate the association between PK parameters and therapeutic response, 
only patients who received mefloquine monotherapy (groups A & B, n=152) were included 
in this analysis. 
Table 3.7. Comparison of therapeutic response between mefloquine monotherapy and 
combined treatment with artesunate. 
Mefloquine alone Mefloquine + Artesunate P-value* 
Parasites cleared within 24 hrs 14.8% (18/122) 77.4% (72/93) <0.001 
Parasites cleared within 48 hrs 36.8% (43/117) 99.0% (95/96) <0.001 
Fever cleared within 24 hrs 65.6% (61/93) 50.0% (20/40) 0.091 
Fever cleared within 48 hrs 84.3% (75/89) 100% (20/20) 0.100 
Failed within 28 days 24.1% (33/137) 2.0% (2/98) <0.001 
* - Chi squared statistic with Yates' correction 
Mefloquine monotherapy (groups A & B) 
Patients who had cleared all their parasites within the first 48 hours had a higher AUCo-oo 
value compared to those patients with late parasite clearance, although this difference was 
only of borderline significance (geometric mean (95% CI, n): 50373 (46121-55017,43) vs 
45583 (42306-49125, 74) ng/ml*day, p=0.05). From the multiple logistic regression 
analysis with adjustment for age, type of dosage (split versus single), admission 
parasitaemia and temperature, a higher mefloquine AUCo_oo (p=O.038) was associated with 
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a significantly increased probability of parasite clearance within 48 hours (Figure 3.7). 
Patients still febrile after 24 hours had a significantly lower AUCo-oo value compared to 
patients whose fever had cleared within one day (geometric mean (95% CI, n): 43561 
(39003 - 48652, n=32) vs 50874 (46903 - 55170, n=61) nglml*day, p=0.026). Similar 
findings were observed for fever clearance at 48 hours, although the relationship between 
fever clearance in the first 24 or 48 hours and AUCo-oo values no longer remained after 
adjustment for the confounders mentioned above. There was no difference in AUCo-oo and 
V IF values between those patients whose infection recrudesced within 28 days and those 
who were cured. 
Probability of parasites clearing within 48 hours 
1.0 
0.8 
0.6 
0.4 
0.2 
IJ 
0.0 
20000 60000 80000 100000 200000 
AUC (nglml*day) 
Figure 3.7. Relationship of estimated probability of parasites clearing within 48 hours and 
whole blood mefloquine area under the concentration-time curve [AUC(O-oo)] values (nglml 
*day) derived from a multiple logistic regression model. 
Top. middle and bottom fitted curves correspond to admission parasite counts in the categories: 
<5000IJlI, 5000 to 10,000 IJlI, and> I 0,000 /Jll. 
Open circles - cleared parasites; Open squares - parasites not cleared by 48 hours. 
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3.4 Discussion 
Conventional PK studies of the antimalarial, mefloquine, have observed considerable inter-
individual variability in the PK parameters. The development of a population PK model for 
mefloquine provides estimates of the PK parameters, and an assessment of the different 
sources (e.g. clinical, demographic or laboratory factors) of inter-individual variance in 
these parameters. 
3.4.1 Summary of findings 
In this study of mefloquine blood concentrations obtained prospectively over a five year 
period from patients with multi-drug resistant falciparum malaria, the final population PK 
estimates were similar to those reported from previous studies (Karbwang and White, 
1990). Estimates were obtained for inter-individual variation in apparent clearance and 
volume of distribution. In these studies the fraction of drug absorbed (F) is not known, 
therefore an increase in estimated CLiF or V IF could result either from an increase in 
clearance or volume, or a reduction in F. As there is no reason to believe that the method 
of dosing should alter clearance or volume, differences in these parameters between dosage 
regimens were attributed to variation in the fraction of the drug absorbed. Splitting the 
25mg/kg dose of mefloquine monotherapy was associated with a 50% increase in oral 
bioavailability, and for the combination treatment, bioavailability increased by 20%. This 
finding provides further support for this method of administration since previous studies 
have shown that splitting the dose ofmefloquine into 15 and 10 mg/kg (at least 8 hrs apart) 
halves the rate of early vomiting (ter Kuile et al. 1995a), and vomiting has been shown to 
be a risk factor for treatment failure (ter Kuile et al. 1995b). There are two possible 
explanations for the increase in oral bioavailability for patients receiving the split dose 
regimen; a disease related reduction in oral bioavailability or that the absorption of 
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mefloquine in malaria is capacity limited. The observation that splitting the dose of 
mefloquine produces a much smaller increase in bioavailability when given in association 
with an artemisinin derivative argues in favour of a disease related reduction in oral 
bioavailability since artesunate accelerates recovery from malaria. This is further supported 
by the larger AUCo-«> found when the single dose of mefloquine in combined treatment was 
delayed until the second day of treatment. Acute falciparum malaria is associated with 
altered gastrointestinal motility, reduced visceral perfusion, and impaired absorption. 
Splitting the dose of mefloquine ensures that the second oral dose is given when the patient 
is in an improved clinical state. 
Mefloquine PK were influenced relatively little, or not at all, by factors such as age, 
weight, sex, or measures of acute malaria severity. It should be noted that only children 
aged 5 to 14 years were included in the studies where mefloquine was given in 
combination with artesunate, whereas patients treated with mefloquine monotherapy varied 
from 1 to 54 years of age. The lack of an association between age and the PK of 
mefloquine monotherapy suggests that no dosage adjustment is required for children. The 
original decision to adjust the dose of mefloquine according to body weight was an 
empirical decision that had not been tested formally. In this chapter the association 
between mefloquine PK and body weight for both actual dose (mg) and weight adjusted 
dose (mg/kg) was explored. For actual dose (mg), there were strong linear positive 
associations between the PK parameters (clearance and volume) and body weight. For 
weight adjusted dose (mg/kg), there were no associations between the PK parameters and 
body weight. The therapeutic implications of these data are that mefloquine dosage per kg 
body weight is a good approach and need not be further adjusted. Note the patients in the 
current dataset have body weights varying from 8 to 61 kgs. Therefore the observed 
findings may not hold for larger adults or small babies. 
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Whilst demographic factors could alter drug elimination, disease related factors are 
unlikely to have a major effect on the terminal phase of elimination once the patient has 
recovered from malaria (usually within 3 or 4 days). However in the acute phase of 
malaria, in addition to absorption alterations, there may be changes in volume of 
distribution related to altered tissue and blood drug binding, and changes in clearance 
related to impaired hepatic function and, for me flo quine, interruption in the entero-hepatic 
cycling of the drug. The shorter terminal half-life of mefloquine in patients with malaria 
compared to volunteers (Palmer et a1. 1993) has been attributed to interruption in entero-
hepatic recycling. Body temperature on admission was found to affect mefloquine blood 
concentrations in patients who received mefloquine monotherapy and split dosing, but this 
was not a significant covariate in the other patient groups. The relationship between body 
temperature on admission and V IF is complicated because some of the calculation of V IF 
is derived from data collected after fever clearance. If V IF changes than either V changes 
and/or F changes. From these data and since there was no association between temperature 
on admission and CLIF it is difficult to say whether body temperature on admission 
changes V or F. 
Despite considerable inter-patient variability in whole blood mefloquine concentration 
profiles, the derived PK parameters were not related significantly to the probability of cure. 
But as there were only 33 recrudescences in the 137 patients with mefloquine mono therapy 
(15 of the patients dropped out of the study before 28 days), this large PK study had 
limited power to detect such associations. These observations contrast with observations of 
halofantrine and lumefantrine (ter Kuile et a1. 1993b; White et a1. 1999a). Absorption of 
these two antimalarials is very variable. Plasma concentration profiles (particularly the 
AUCo-oo or the day 7 blood concentration) vary even more than for mefloquine, and are 
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major determinants of therapeutic outcome. The data with mefloquine suggest that, in this 
series, the variation in the infecting parasites' intrinsic drug sensitivity, and the immune 
responses of the patient which synergise with the antimalarial drug, were relatively more 
important than the variation in the patients' mefloquine blood concentration profiles in 
determining treatment response. However it is evident, from the considerably better cure 
rates with high dose (25 mg/kg), compared to low dose (IS mg/kg), that the profiles of 
blood mefloquine concentrations are an important determinant of the therapeutic response 
(ter Kuile et al. 1992). 
The improvements in oral bioavailability associated with splitting the mefloquine dose 
resulted in higher blood concentrations. This was associated with more rapid parasite 
clearance, and this has been shown to correlate with cure in mefloquine treated patients (ter 
Kuile et al. 1992; ter Kuile et al. 1995b). This suggests that cure rates would be improved 
by splitting the mefloquine dose. Nevertheless there was still considerable inter-individual 
variance in PK with split-dosing which suggests that the absorption ofthe drug was still far 
from complete. These data suggest that high dose mefloquine should always be given in a 
split dosage to optimise absorption and minimise treatment failures. 
3.4.2 Limitations of the data 
It was not possible to estimate the absorption rate constant (ka ) nor the inter-individual 
error of ka from the data available as no blood samples were collected within 24 hours 
following drug administration. The patients treated with mefloquine were suffering from 
uncomplicated P. falciparom malaria and not severe malaria. Therefore there was no 
clinical benefit to the patient to collect blood samples during the absorption phase of the 
drug. Since ka could not be estimated from the data for the above reasons, ka was fixed at a 
value of 7 Iday which was obtained from a different study of the same popUlation (Nosten 
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et al. 1991 a). The influence of fixing ka on subsequent parameter estimation has been 
comprehensively investigated by Wade et at. (1993). If no data are present in the 
absorption phase, as is the case with the mefloquine data, then misspecifying the rate of 
drug absorption and the model used to describe drug absorption (first-order absorption was 
chosen for the mefloquine data) has little consequence for estimation of the remaining 
population parameters. However if data contain even the slightest information about 
absorption, then a parameter to describe inter-subject variability in absorption should be 
included to protect against the inter-subject variability in ka being manifested into the inter-
subject variability of apparent volume of distribution. 
Other investigators have fitted two compartment models to characterise the PK of 
mefloquine (Looareesuwan et al. 1987; Boudreau et al. 1990). With two compartment 
models the drug has two decline phases, commonly a rapid phase followed by a slower 
phase. The data analysed in this chapter had blood samples only collected up to day 28 
while Looareesuwan et al. (1987) and Boudreau et al. (1990) collected blood samples up to 
days 63 and 67 respectively. In the paper by Looareesuwan et al. (1987) the terminal half-
life was observed to be 10 to 11 days, but no value was published for the first half-life. 
Boudreau et al. (1990) presented distributions of the elimination half-lives of four groups: 
cured (n=lO) and recrudescent patients (n=6) treated with 750 mg of me flo quine, and cured 
(n=9) and recrudescent patients (n=2) treated with 1500 mg of me flo quine. The mean half-
life of the first phase varied from two to five days and the mean half-life of the second 
phase varied from 19 to 45 days for the different groups of patients described above. 
Visual inspection of the PK profiles published by Boudreau et al. (1990) suggest a 
crossover between the fast and slow phases at around 10 to 12 days. The data presented in 
this chapter had only five to six main time points where samples were collected to form the 
population PK model. For the second phase, which occurs approximately 10 days after 
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drug administration, samples were collected before 1994 on days 14, 21 and 28 and after 
1994 on only days 14 and 28. Thus there is little spread in the sampling times for a second 
phase to be adequately characterised. In other words the failure in the present dataset to 
define a two compartment model could be due to the lack of a wide spread of sampling 
times. Kowalski and Hutmacher (2001) found from a simulation study that a one-
compartment model approximation to the plasma concentration-time curve for a drug 
known to exhibit two-compartment kinetics yielded accurate mean estimates of volume 
and clearance as well as sUbpopulation differences in clearance. 
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4. MEFLOQUINE PHARMACOKINETIC-PHARMACODYNAMIC 
MODELS 
4.1 Introduction 
In this chapter a mechanistic mathematical model was developed to describe the change in 
total parasite burden with time in vivo, in the presence of drug. The mathematical model 
was able to predict the total elimination of parasites, that is, radical cure. Population 
pharmacodynamic modelling of in vitro concentration-effect curves was performed to 
obtain estimates for some of the parameters of the mechanistic mathematical model. Total 
parasite burden versus time profiles in vivo were simulated for different scenarios to 
explore the influence of the pharmacokinetic (PK) and pharmacodynamic (PD) parameters 
on treatment cure. 
4.2 Methods 
4.2.1 Mathematical Model 
To find a mathematical equation that describes the change in total parasite burden over 
time in the presence of the drug, a slightly altered form of the mathematical model 
published by Hoshen et al. (1998), has been used. 
The number of parasites in a patient at any time (Pt) is a balance between their average 
multiplication rate and the proportion that are killed and cleared by the antimalarial and 
host defences. Thus the change in parasitaemia can be described as :-
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dP 
-=a.P- f(C).P- f(I)·P 
dt 
where 'a' is a parameter representing the growth rate constant ofthe parasite; 
j( C) is a function, dependent on the concentration of the drug (C), that represents the 
killing of the parasites; and f(I) is a function that represents the hosts' background 
immunity to malaria. 
The host contribution, which reflects "background immunity", contributes relatively little 
to drug effect at high concentrations, but becomes important at low drug concentrations. It 
will not be used further in this analysis, although in areas of high stable transmission where 
partially effective or ineffective drugs are used it is the main detenninant of therapeutic 
outcome. 
Thus 
dP 
-=a.P- f(C).P 
dt 
Killing is considered a first order process which continues unchanged throughout the 
process of parasite elimination (Day et al. 1996). It should be noted that malaria is 
exclusively an intravascular infection (extravascular fonns are not pathogenic) and that the 
antimalarial activity is related to plasma concentrations of free (unbound) antimalarial 
drug. 
68 
Parasite killing can then be described by an Emax type model. 
f(C) - k * cr 
- 1 cr C r 
+ 50 
where kJ - rate constant of parasite killing, 
r -slope of concentration effect curve, 
c - antimalarial drug concentration, 
& Cso - drug concentration which kills 50% of the parasites. 
The plasma antimalarial drug concentration in vivo is not constant; it rises as the drug is 
absorbed and then declines over time as the drug distributes throughout the body and the 
drug is eventually eliminated. In the case of mefloquine the elimination phase has been 
shown to be biexponential or triexponential (White, 1992c). Assuming that the 
intermediate concentrations which are selective occur only during the terminal phase (at 
least at low or intermediate levels of resistance), a mono exponential elimination phase 
corresponding to the slower second elimination phase of the drug was utilised. 
Therefore:-
where t - time (days), 
k - terminal elimination rate constant of mefloquine, 
& Co - maximum concentration of mefloquine (i.e. Cmax). 
. . dP ( A d' P, was determined by mtegratmg dt see ppen IX III). 
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The following solution results:-
where Po = total parasite burden at time 0 (i.e. before administration ofmefloquine). 
4.2.2 Parameter estimation and statistical analysis 
In non-immune subjects, the multiplication rate of the asexual stages of P. Jalciparum in 
the blood averages six-fold and can reach 20-fold per cycle (Kitchen, 1941; Kitchen, 
1949). For the model predictions presented in the results section (4.3) 'a' was calculated 
assuming that a single asexual malaria parasite multiplies 10 fold every two days. This 
gives a growth rate constant 'a' of 1.15 (lnlO 12). The terminal elimination rate constant (k) 
of the drug was assumed to be 0.036 (/day) (that is the value derived from population PK 
modelling of patients receiving a single dose of 25 mglkg of mefloquine monotherapy; 
Chapter 3, Table 3.2), following a treatment dose of mefloquine. The maximum parasite 
killing rate resulting from mefloquine was assumed to be 99% per cycle or 90% 1 day 
which corresponds to k,=3.45 Iday. This corresponds to a parasite reduction ratio (PRR) of 
100 fold, a relatively poor antimalarial effect, but one that has been documented, and is 
associated with mefloquine resistance (ter Kuile et at. 1992; White, 1999b). Killing rates 
up to 99.9% per cycle may occur with mefloquine. The artemisinin derivatives have been 
shown to have the highest PRRs of all the antimalarial drugs, greater than 10,000 or a 
reduction of99.99% parasites per two day asexual life cycle (White, 1997). 
As the mutational events which may confer resistance occur randomly, resistant mutants 
are more likely to occur in high biomass infections. Therefore a ''worst case scenario" has 
been chosen of a relatively high biomass P. Jalciparum infection corresponding to a total 
parasite burden at time zero of 1012 parasites in an adult (which corresponds to a parasite 
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count of approximately 100,000 Jill or 2% parasitaemia). The parameter estimates chosen 
above do not represent an "average patient", but instead a patient with a relatively high 
parasite burden from an area with existing mefloquine resistance. 
For the parameter Co the value of 1200 ng/ml was chosen which was derived from the 
population PK modelling of data from 24 patients treated with single dose of 25 mglkg of 
mefloquine monotherapy (Chapter 3). The parameter estimates and their respective 
variances from the derived population PK model (Table 4.1) were also used to simulate 
1000 PK profiles. The distribution of the inter-subject variability of the pharmacokinetic 
parameters was lognormal while the residual error was normally distributed (Table 4.1). 
The inter-subject variability values for the different PK parameters were assumed to be 
independent of each other. The 1000 simulations were performed using the computing 
package QBASIC. These simulated profiles were used to obtain estimates of the lowest 
and highest mefloquine concentrations that would be achieved in a population. 
Table 4.1:- Parameters used for simulation of pharmacokinetic profiles 
Parameter Estimate (SE) Estimate" 
CLIF (l/kg/day) 0.733 (0.051) 0.704 
VIF (l/kg) 20.37 (2.53) 20.56 
O)CUF 0.15 0.16 
O)VIF 0.56 0.55 
Residual additive error - 0'£ (nglml) 180.4 
CLIF - clearance divided by the fraction of drug absorbed; 
V IF - total apparent volume of distribution divided by the fraction of drug absorbed; 
0)- inter-subject variability in CLIF and V IF, modelled using multiplicative error models; 
" _ estimates obtained from non-linear mixed effects modelling of the 1000 simulated 
pharmacokinetic profiles. 
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Assuming one schizont releases 10 merozoites then the minimum inhibitory concentration 
(MIC) at which the net parasite multiplication rate (PMR) is unity corresponds 
approximately to the EC90 (i.e. the concentration which is 90% effective). 
Now ifthe MIC is the concentration at which the total parasite burden is not changing (i.e. 
a transient steady state) then: 
dP 
- = a.P- f(MIC).P = 0 
dt 
Substituting for j{MIC) :-
a -k * = 0 ( 
MICr ) 
I MIcr +C5/ 
Assuming MIC =::: EC90:-
[ ]
I/r 
C - kl -a EC 
50 - * 90 
a 
The EC90 in vivo is unknown but it must be related to the EC90 in vitro. However because 
in vitro susceptibility assessments are conducted in the absence of plasma (to which 
mefloquine is reported to bind avidly), platelets and white cells, the two are not equivalent. 
Unfortunately because mefloquine also binds to laboratory ware, notably plastic, precise 
estimates of plasma protein binding are not available. 
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Thus, 
EC90 (in vivo) = m * EC90 (in vitro) 
[where m is an unknown parameter] 
For the simulations presented in the results section of this chapter m was given the value of 
10. This value was chosen empirically. The EC90 (in vitro) was derived from modelling of 
in vitro concentration-effect curves where the effect measure is inhibition of parasite 
uptake of eH] hypoxanthine. It was assumed that the slope (y) of the concentration-effect 
curve in vivo is the same as that observed in vitro. For the parameters r and EC90, 
population estimates were derived from non-linear mixed effects modelling of in vitro 
concentration-effect curves of mefloquine (Lindstrom & Bates, 1990). Non-linear mixed 
effects models produce parameter estimates for the complete drug population and posterior 
estimates for each infecting isolate. The dataset contained a total of 415 in vitro 
concentration-effect curves from P. falciparum isolates collected by three different 
laboratories based in Thailand. 
In vitro susceptibility testing: 
All laboratories used a semi-automated dose response assay as described by Desjardins et 
al. (1979), and Webster et al. (1985), and used the same beta counter. Growth of 
synchronous parasite isolates or cultures was estimated using parasite uptake of a 
radioactive DNA precursor, eH] hypoxanthine, as a measure. Percentage growth at 
different mefloquine concentrations was calculated as the proportion of the counts in the 
drug free wells. Background counts (unparasitised, drug free wells) were subtracted from 
all counts. 
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The Anned Forces Research Institute of Medical Sciences (AFRIMS), Bangkok, Thailand 
measured 345 curves. The samples used in the dose response assays were collected in field 
trials conducted throughout Thailand between 1990 and 1994. 
The Wellcome Unit, Bangkok measured 44 dose response curves. The samples were 
collected during 1997 and 1998 from the Hospital for Tropical Diseases, Bangkok and on 
the western border of Thailand. 
The Shoklo Malaria Research Unit (SMRU) measured 26 dose response curves. These 
were collected from refugee camps situated along the western border of Thailand. The 415 
isolates comprise a wide range of mefloquine sensitivities from fully sensitive to highly 
resistant, which allow estimates of the best and worst possible scenarios for rand EC90• 
The PD model fitted was the following sigmoid inhibitory effect model:-
[ 
Cr ] E - E - E -E • 
- max (max 0) cr + (EC
9
/ /9) 
This is a reparameterised version of the standard sigmoid inhibitory effect model where 
ECso equals EC90 / 911r• E represents the proportion of uptake of eH] hypoxanthine in the 
nucleoprotein of the parasites in drug-free control wells corresponding to unrestrained 
growth in vitro. Maximum effect occurs when there is no uptake of eH] hypoxanthine (no 
growth). Eo represents minimum percent growth, Emax is the maximum percent growth, 
EC90 is the concentration of mefloquine required to inhibit 90 percent of the control 
parasites' hypoxanthine uptake and r is the slope of the curve. It should be noted that the 
exact relationship between inhibition of hypoxanthine uptake and growth inhibition has not 
been characterised. 
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Inter-strain variability in Emax, Eo, r and EC90 were modelled with mUltiplicative error 
models. Multiplicative error models ensure the individual strain parameters (e.g. Emax,i) 
must be greater than zero and that their distribution is skewed to the right. 
ii = r· exp(fJ/) 
The inter-strain variability (fJ) values for the above four parameters were assumed to be 
independent of each other. 
The residual intra-strain error was modelled using an additive error model since the error 
between the observed and predicted values was observed to be constant. 
Emax,j, Eo,j, ii and EC90 ,i are the PD parameters for the isolate and Emax, Eo, y and EC90 are 
. Th Emax EO r d EC90 d «. 'th the populatIon means. e fJi ,fJi' fJi an fJi are ran om euects WI zero mean 
• 2 2 2 d 2 t' I Th h" I and vanances 0' Emax, 0' EO, 0' r an 0' EC90, respec lve y. ey represent t e mter-lSO ate 
variability for each of the parameters. The magnitude of this variability is expressed as a 
coefficient of variation (CV). Eij is the jth measure of effect for the ith strain and Epij is the 
/h predicted measure of effect for the ith strain. Eij is the residual intra-subject error term 
and is assumed to be randomly and normally distributed with mean of zero and variance 
0'2. The NLME procedure (Lindstrom and Bates, 1990) of the SPLUS data programme 
(SPLUS 4.5 for Windows, Mathsoft, Inc.) was used to calculate estimates of the population 
PD parameters (Emax, Eo, Y, EC90) and their respective inter-strain variances (fJEmax, fJEO, r{, 
fJEC90). The programme also provides estimates of the residual random intra-strain error (E) 
and the variances of the inter-strain error terms (0'2 Emax, ci EO, ci r ' ci EC90). The goodness of 
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fit of each model (e.g. models having different numbers of random effects) was determined 
by the change in the objective function (minus twice the loglikelihood of the data). A 
significant drop in the objective function (with use of the X2 distribution) determined the 
model that best described the data. The goodness of fit of each model was also determined 
by the precision of the parameter estimates and examination of the scatter plot of residuals 
versus predicted measure of effect. 
4.3 Results 
4.3.1 In vitro concentration-effect curves 
Data collected from three different laboratories in Thailand were modelled to estimate 
parameters that describe the in vitro concentration-effect relationships for mefloquine. The 
model that gave the best fit to the three different sources of data was the inhibitory sigmoid 
Emu effect model with Emax, EC90 and r fitted as random effects. Fitting Eo as a random 
effect did not significantly reduce the objective function. The SPLUS programme used for 
fitting the sigmoid Emax model is given in Appendix N. The mean population PD 
parameters of the final model for the isolates from the three laboratories were similar 
(Table 4.2). These data were then combined and the sigmoid Emax model fitted to all 415 
isolates (Table 4.2). The population estimate of EC90 (population estimate = 50.4 nglml) 
had a 95% prediction interval from 213 nglml down to 12 nglml. The population estimate 
of the slope of the concentration-effect curve was 2.50 with the 95% prediction interval of 
1.22 to 5.13. The observed and population predicted effect measures (% uptake of eH] 
hypoxanthine) versus mefloquine concentrations for the three laboratories are shown in 
Figures 4.1 a, 4.1 b and 4.1 c. 
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Table 4.2:- Population pbarmacodynamic parameters derived from nonlinear mixed effects 
modelling of tbe in vitro data. 
Parameter AFRIMS Wellcome Unit SMRU All 415 strains 
EC90 (ng/ml) 51.08 (2.20) 49.00 (6.64) 53.88 (7.49) 50.43 (1.98) 
95% PI for EC90 12.55 - 207.84 8.89 - 270.15 13.93 - 208.34 11.96 - 212.56 
(ng/ml) 
y 2.44 (0.06) 2.47 (0.18) 3.19 (0.22) 2.50 (0.06) 
95% PI fory 1.21 - 4.92 1.03 - 5.93 1.85 - 5.49 1.22 - 5.13 
Emax (%) 102.30 (0.69) 97.85 (1.59) 103.96 (3.38) 101.89 (0.64) 
Eo(%) -1.56 (0.46) 0.36 (0.63) 2.24 (0.69) -0.76 (0.35) 
O)Emax 0.106 0.097 0.158 0.110 
O)EC90 0.716 0.871 0.690 0.734 
O)y 0.358 0.447 0.277 0.367 
crt (residual 10.85% 8.64% 6.76% 10.31% 
error, units-%) 
standard error given in parentheses; PI - Prediction Interval; 
Eo - minimum percent growth; Emax - maximum percent growth; 
EC90 - concentration of mefloquine required to inhibit 90% of the control parasites' hypoxanthine 
uptake; y - slope of the concentration effect curve; 
0)- inter-strain variability in Emax' EC90 and y, modelled using multiplicative error models. 
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Figures 4.la & 4.1b. Percent uptake of [3H]hypoxanthine compared to that in drug-
free control wells for various mefloquine concentrations. The solid line shows the fit 
of the data and represents the predicted concentration-time profile for the population 
mean. The dashed lines represent the 90% prediction intervals. 
Data (A) - U.S. Anned Forces Research Institute of Medical Sciences 
Data (B) - Wellcome Unit, Bangkok 
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Figure 4.1c. Percent uptake of eH]hypoxanthine compared to that in drug-
free control wells for various mefloquine concentrations. The solid line shows 
the fit of the data and represents the predicted concentration-time profile for 
the population mean. The dashed lines represent the 90% prediction intervals. 
Data (C) - Shoklo Malaria Research Unit 
4.3.2 Phannacokinetics ofmefloguine 
1000.0 
An important factor driving the selection of resistance is the number of parasites (P,) 
exposed to drug levels which give submaximal effects. The whole blood mefloquine 
concentration range giving intermediate levels of growth inhibition was chosen as 400 to 
600 ng/ml. As the precise relationship between in vivo and in vitro concentration-effect 
relations is not known this range cannot be defined precisely. This range was chosen 
because in 1990, when mefloquine resistance was detected first in Thailand, the mean 
(95% confidence interval) serum concentration at the time of first recrudescence was 638 
(546 to 730) ng/ml (Nosten et al. 1991b). This represented a concentration capable of 
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sustaining growth in the parasites infecting 29% of patients. A slightly lower concentration 
range was chosen to reflect an earlier stage of resistance. For mefloquine, the tenninal 
elimination rate constant is dose-independent, and so the time over which the infecting 
parasite population is exposed to intennediate inhibitory concentrations (i.e. 400 to 600 
nglml) is the same for different dosages of mefloquine (approximately 11 days, Figure 
4.2). 
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Figure 4.2 Simulated pharmacokinetic profiles for the two standard mefloquine 
doses, 15 mg/kg and 25 mg/kg obtained with the parameter estimates in Table 
4.1. 
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4.3.3 Predicting therapeutic outcomes 
Figure 4.3 shows the model simulations of the total parasite numbers versus time for the 
two commonly used mefloquine doses of 15 mg/kg and 25 mg/kg, based on the parameter 
estimates in Table 4.3. The estimate for Cso is derived from the population estimates of 
EC90 and y. Both EC90 and r are the population estimates from nonlinear mixed effects 
modelling of the in vitro data of isolates from Thailand. 
With the lower dose there are more parasites at all times (including during the period of 
intermediate or "selective" mefloquine concentrations) compared to the higher dose of 25 
mg/kg. If the parasite populations are all more drug sensitive than those given in the 
example then the differential advantage of the higher dose is smaller - thus as resistant 
mutants are selected the differential advantage increases, accelerating the apparent 
emergence of resistance. Furthermore it is apparent that with the starting parameters 
chosen for the model in this case (which represented a "worse case scenario" and were 
consistent with a significant level of resistance), the patient will not be cured with a dose of 
15 mglkg for any admission total parasite burden since a non-immune person is only cured 
of malaria if the total parasite burden falls below one parasite. The same patient would be 
cured with a dose of 25 mg/kg if the admission total burden did not exceed 109 parasites. 
Obviously at lower levels of mefloquine resistance (or greater background immunity) an 
increasing proportion of patients treated with 15 mg/kg would be cured. 
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Figure 4.3 Total malaria parasite burden versus time for the two standard mefloquine 
doses, 15 mg/kg and 25 mg/kg. The initial parasite burden corresponds to a parasite count 
of approximately 1 00,000 /~l, or 2% parasitaemia in an adult with falciparum malaria. 
Table 4.3:- Parameter estimates derived from population pharmacokinetic (Co & k) and 
pharmacodynamic (1 & Cso) modelling and published articles (a & k.) (White 1997). 
-
Parameter 
Po 
a 
k 
Co 
Cso 
Estimate 
l.IS/day 
0.036/day 
3.45/day 
1200 ngim1 (single dose of25 mglkg) 
717 ngiml (single dose of IS mglkg) 
2.S0 
66S.4 ngim1 [m*SO.43*(2)1/2.S] 
{where m=10 & EC90=S0.43 ngiml} 
Po _ total parasite burden at time zero; a growth rate constant of the parasite; 
k _ terminal elimination rate constant of mefloquine; 
kJ _ rate constant of parasite killing; Co - maximum concentration of mefloquine; 
I pe of the concentration effect curve; 'Y - SO 
drug concentration which kills SO% of the parasites. Cso-
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Other factors beside the dosage can affect the maximum concentration achieved. Acute 
malaria may affect absorption and the apparent volume of distribution of drugs because of 
reduced food intake, vomiting, reduced gastric motility and visceral blood flow. Figure 4.4 
depicts the parasite-time profiles for the population mean Cmax following 25 mglkg of 
mefloquine (defined Co in the model) and for the minimum and maximum Cmax values of 
the 1000 simulated PK profiles. With a dose of 25 mglkg the mean Cmax was 1200 nglml, 
with a range from 400 nglml to 7440 nglml. With the starting parameters of the model the 
absolute minimum Cmax required to cure an adult patient with an admission parasitaemia of 
2% is 1400 nglml. Non-linear mixed effects modelling of the 1000 simulated PK profiles 
produced similar parameter and variance estimates to those used in the original simulation 
of the 1000 profiles (see Table 4.1). 
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Figure 4.4 Relationship between parasite clearance over time and maximum 
mefloquine concentration (Co). In this example, Po is 1012, a is LIS/day, k is 0.036 
/day, k\ is 3.45 /day, y is 2.5, and Cso is 665.4 nglml. 
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The effects of varying values of the parameters y, EC90 and m on the parasite versus time 
profiles are shown in Figures 4.5, 4.6 and 4.7. The flatter the slope of the concentration-
effect curve the more likely the patient will suffer a subsequent recrudescence of the 
infection (Figure 4.5). For the lower limit (;=1.22) and the population mean estimate 
(;=2.50) the parasites never cleared and started to rise again around 3 weeks following 
treatment. Patients will start to fail after treatment for mefloquine if the slope of the 
concentration-effect curve drops below 3.5. Increases in the in vivo MIC will also increase 
the risk of treatment failure (Figure 4.6). For example if the in vivo MIC is 120 nglml, all 
the parasites are cleared from the body in less than 2 weeks. If the MIC in vivo increases to 
2126 nglml (the upper limit of the 95% prediction interval of the popUlation estimate), then 
the parasitaemia will continue to rise following treatment (R3 resistance). If the MIC in 
vivo is 5 fold the EC90 in vitro (i.e. m=5) then all the parasites are cleared from the body at 
2 weeks (Figure 4.7). However if the MIC in vivo is at least 20 times larger than the EC90 
in vitro (i.e. m=20), the parasitaemia keeps rising following treatment. For m=10 and 
m=15 the parasites never clear and start to rise again at around 3 weeks and 2 weeks 
respectively. 
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Figure 4.5 Relationship between parasite clearance over time and the slope of 
the concentration-effect curve (y). In this example, Po is 1012, a is LIS/day, k is 
0.036 /day, Co is 1200 ng/ml, kl is 3.45 /day, and Cso is 665.4 ng/ml. 
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Figure 4.6 Relationship between parasite clearance over time and the MIC in vivo. 
In this example, Po is 1012, a is LIS/day, k is 0.036 /day, Co is 1200 ng/mI, k\ is 
3.45 /day, and y is 2.5. 
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Figure 4.7 Relationship between parasite clearance over time and m (scalar value 
relating EC90 in vitro to MIC in vivo). In this example, Po is 1012, a is LIS/day, k 
is 0.036 /day, Co is 1200 nglml, kl is 3.45 /day, y is 2.5 and EC90 in vitro is 50.43 
nglml. 
4.3.4 Ratio ofCmn.to MIC in vivo 
The ratio of the maximum plasma concentration to the MIC, a widely used parameter in 
anti-infective drug PD modelling, is probably an important determinant of outcome in the 
case of antimalarial treatment with mefloquine. 
The function PI can be rewritten as:-
where 
(k, : al }R-' + (e-")' 
(k, :alJF + 1 
R = Cmax 
MIC 
kll(k.y> 
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R will obviously decrease with increasing resistance in areas where the treatment dose is 
fixed, and R will remain constant if the treatment is increased commensurate with the 
increase in resistance. 
Figure 4.8 shows the parasite-time profiles for R=l, 1.5,2 and 3. If the Cmax is three times 
greater than the MIC the patient will be cured of malaria (all the asexual parasites will be 
cleared from the body within three weeks). The infection will recrudesce if the Cmax 
achieved is only 2 fold the in vivo MIC. 
We can define Rc as the minimum value of R where the patient will still be cured of 
malaria. Rc occurs when the minimum value of PI is less than or equal to 1. To find the 
f h d · . dP. I minimum value 0 PI t e envatIve dt IS set equa to zero and solved for t. This gives the 
time when the minimum total parasite burden occurs:-
Substituting tmin into PI gives the following equation:-
kl/(k·Yl 
~l 
The above equation cannot be solved analytically, therefore Rc is derived numerically. 
Figure 4.9 plots Rc over the full range of possible parasite burdens. 
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Figure 4.8 Relationship between parasite clearance over time and the ratio of 
maximum mefloquine concentration (Co) to MIC (R). In this example, Po is 1012, a 
is 1.15 /day, k is 0.036 /day, k\ is 3.45 /day, and y is 2.5. 
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Figure 4.9 Relationship between the minimum value of Co to MIC ratio (Rc) 
required to clear all parasites and the total parasite burden on admission. In this 
example, a is LIS /day, k is 0.036 /day, k\ is 3.45 /day, and y is 2.S. 
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4.3.5 Benefit ofM25 over M15 
As stated earlier, Figure 4.3 shows clearly that at all times following drug administration to 
comparable infections the total parasite burden is greater for those patients receiving 15 
mg/kg compared with the larger dose of 25 mg/kg. 
If we assume that when the whole blood mefloquine concentration falls below 600 nglml 
the patient is exposed to drug levels which give sub maximal effects (i.e. 600 nglml 
represents the minimal parasiticidal concentration (MPC)) then blood mefloquine levels 
fall below the MPC on day 6 for those patients receiving 15 mg/kg, and on day 20 for 
those receiving 25 mg/kg. On these days the total parasite burden predicted for patients 
receiving 15 mg/kg of mefloquine in the earlier example was 4.87*1010 parasites and for 
those receiving 25 mg/kg was only 1152 parasites, this equates to a 4.23*107 fold 
difference. 
4.3.6 Time to recrudescence 
The WHO 28 day parasitological classification (World Health Organisation, 1973) has four 
classifications for therapeutic response; sensitive, RI resistance, RII resistance and RIll 
resistance. Patients classified as sensitive have cleared their asexual parasites by day 7 
without subsequent recrudescence between days 8 and 28. For RI (low grade) resistance 
the asexual parasites have cleared by day 7 but have reappeared by day 28. The day the 
parasites reappear microscopically is termed the time of recrudescence. For RII 
(intermediate grade) resistance the asexual total parasite count has reduced by at least 75% 
at 48 hours but has not cleared by day 7. For RIll (high grade) resistance the asexual total 
parasite burden either remains static or increases or reduces by < 75% of the admission 
parasite burden at 48 hours. 
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To determine the clinical efficacy of the drug it is important that patients are followed up 
long enough so that a patient that has actually failed (RI resistance) has not been classified 
as cured. The interval between administration of antimalarial treatment with mefloquine 
and recrudescence of the patient's infection depends on the killing rate of the drug and 
resistance of the parasites. Figure 4.10 is a 3 dimensional plot illustrating the relationship 
between three parameters; the time of recrudescence, kI, and the in vivo MIC. To create 
Figure 4.10 parasite versus time curves were simulated for patients receiving high dose 
mefloquine 25 mg/kg. The PK parameters used were the mean parameter estimates from 
the population PK modelling ofmefloquine monotherapy; Cmax=1200 nglml and k=0.036 
/day (Chapter 3). Those curves where the parasite burden fell below the level of detection 
(defined as 50 parasites /Ill or 2.5 * 1 08 parasites) before day 7 were selected. If k was ~1.2 
/day and the MIC ~ 360 nglml the parasitaemia does not clear by day 7 (RII or RIll 
resistance). If the MIC was < 360 nglml and k > l.2 /day the patient was cured (drug 
sensitive parasites). The time of recrudescence is the time at which the parasites can be 
detected again microscopically after falling below microscopic levels in the first week 
following treatment (defined as RI resistance). As kJ increases, that is the drug has a higher 
PRR or greater parasiticidal activity, cure rates will increase, but in those few failures 
which do occur, the interval from treatment to recrudescence occurs later. With higher 
levels of resistance (i.e. a high MIC) patients' infections will recrudesce earlier. T~e time to 
recrudescence was normally distributed with a mean (SD) of 42 (11) days ranging from 20 
up to 64 days. Table 4.4 presents the distribution of times to recrudescence for different 
levels of resistance (i.e. varying MICs in vivo). 
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Figure 4.10 Time to recrudescence following treatment with mefloquine at 25 mg/kg as 
a function of MIC in vivo and killing rates of the drug mefloquine (kt). The z-axis is the 
time to recrudescence (days), the y-axis is the killing rate (kt) ofmefloquine (/day), and 
the x-axis is the MIC in vivo (ng/ml). 
The pharmacokinetic parameters used in the simulation were Co = 1200 ng/ml and k = 
0.036/day. 
Nonraised rectangles represent two possible scenarios: the patient is cured or at day 7 
the parasites are still detectable. This illustrates that for relatively drug-sensitive 
parasites (MIC < 500 ng/ml) the infections are all cured with high killing rates and that 
with low killing rates recrudescences occur long after the conventional follow-up period 
of 28 days. Conversely, with highly resistant parasites, long follow-up (i.e., > 42 days) 
is not necessary. 
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Table 4.4:- Distribution of time to recrudescence for varying levels of resistance. 
MIC in vivo (nglml) 
500 
525 
550 
575 
600 
625 
650 
675 
700 
Time to recrudescence (days) 
Mean (SD) Range 
56.0 (6.2) 45-64 
52.0 (5.5) 42-59 
47.4 (4.9) 38 - 53 
44.0 (3.8) 37-49 
40.0 (3.2) 34-44 
36.4 (2.8) 31-40 
33.0 (2.3) 29-36 
30.0 (1.7) 27-32 
26.8 (1.3) 25-28 
MIC - minimum inhibitory concentration; SD - standard deviation. 
4.4 Discussion 
In this chapter a mechanistic model describing the change of total parasite burden over 
time (in the presence of drug) in vivo was derived. The model was dependent on seven 
different parameters; parasite burden before treatment, parasite multiplication rate, PK 
parameters (maximum concentration and terminal elimination rate constant of the drug) 
and PD parameters (rate constant of parasite killing, slope of the concentration-effect curve 
and drug concentration which kills 50% of the parasites). 
The model was developed for the treatment of malaria with mefloquine monotherapy. 
Parasite burden over time profiles were predicted for different dosages of mefloquine, for 
different levels of disease severity (defined by admission parasite burden), and for 
predicting the time when a patient will recrudesce for differing levels of mefloquine 
resistance. The model enables a clinician to investigate the in vivo consequences of 
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changes in a drugs PK profile, predict time to recrudescence, and predict relative risks for 
selecting resistant parasites (e.g. exposure to subtherapeutic drug concentrations). 
4.4.1 Different dosages of mefloquine 
The development of resistance to antimalarial drugs is a major threat to the health of 
people living in tropical countries. The speed at which resistance develops is affected 
considerably by the pattern of antimalarial drug use. Uncontrolled self medication with 
inadequate treatment courses provides a particularly potent selection pressure to the 
development of resistance as it exposes a large number of parasites to partially effective 
antimalarial drug concentrations. In this chapter the effects of two different systematic 
antimalarial treatment strategies (mefloquine monotherapy:- 25 mg/kg and 15 mg/kg) were 
examined. This is a particularly relevant example as resistance to mefloquine has 
developed rapidly on the Eastern and Western borders of Thailand, and the adjacent areas, 
and is now emerging separately in Vietnam. This could have been delayed or perhaps 
prevented. 
When new drugs are introduced, dose ranging studies are performed to determine the 
optimum dose and treatment schedule based on the therapeutic ratio (maximum efficacy / 
minimum toxicity). For most anti-infective drugs, with the notable exception of 
antituberculous and antiretroviral drugs, the prevention of resistance is usually not 
considered in this assessment. This conventional therapeutic appraisal usually leads to the 
conclusion that the smallest dose giving an "acceptable" cure rate should be deployed 
initially. For slowly eliminated antimalarial drugs, such as mefloquine, this will lead more 
rapidly to resistance than if a higher dose were deployed initially. There are two reasons 
for this. Firstly, the lower dose chosen initially, which for mefloquine was 15 mg base/kg, 
provides greater opportunity for the de-novo selection of genetic mutants, such as those 
containing increased copy numbers of the pfmdr 1 gene, with significantly reduced 
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susceptibility (Price et al. 1999b). This is because there is a greater probability of failing to 
achieve concentrations that would kill a mutant parasite and its progeny. Secondly, once 
these mutants have arisen and have been transmitted, then, provided they are highly 
mefloquine resistant, they will be more likely to survive low dose treatment in subsequent 
hosts. This increased survival probability results in an increase in the proportion of 
resistant mutant parasites. Thus resistance is selected more efficiently by the general use of 
a lower (15 mglkg) than higher (25 mglkg) dose. It should be noted that the simulated 
parasite burden-time profiles represent an area of low transmission where background 
immunity is low or absent (such as much of South East Asia and South America). In areas 
of high stable transmission host immunity may be sufficient to clear resistant infections. In 
addition a significant proportion of infections are transmitted from individuals who do not 
receive antimalarials. These two factors reduce the selection of resistant mutants and retard 
the evolution of drug resistance. 
Cost is a very important factor determining antimalarial drug use. If an antimalarial drug 
treatment costs 60% more (as would be the case for mefloquine high dose versus low 
dose), this could impose a significant financial burden on developing countries. However 
this must be balanced by the costs of resistance, both in terms of morbidity, and perhaps 
mortality, and also the need to fund newer and usually more expensive alternative drugs. 
The data and modelling predictions presented here provide a framework for such a 
pharmacoeconomic assessment. 
4.4.2 Disease Severity 
Patient cure and the development of drug resistance are both dependent on the initial total 
parasite burden of the patient (ter Kuile et al. 1995b). For a patient to be radically cured 
(i.e. all of the parasites in the body are eradicated) an effective antimalarial drug 
concentration needs to be present in the blood until either the last parasite has been 
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removed or immune defences are able to kill the remaining few parasites. Patients with a 
high parasite burden on admission will take longer to clear all their parasites because they 
have more parasites to remove. For drug resistance, if one malaria parasite in every lOx 
malaria parasites contains a mutation that confers a significant reduction in susceptibility to 
the drug being used then the probability of the patient harbouring such a resistant mutant is 
equal to _1_x PI (where PI is the number of parasites in a single patient at time t). Thus if 
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at time zero there are more parasites there is a greater probability that a resistant mutant 
will emerge. Increasing the dose of mefloquine ensures that concentrations remain above 
the minimum parasiticidal concentration longer and therefore gives a greater chance of 
eradicating all ofthe parasites from a hyperparasitaemic infection. 
4.4.3 Time to recrudescence 
Antimalarial drug resistance is commonly underestimated. When in vivo drug assessments 
are performed patients are followed usually for between one and four weeks. This is 
insufficient for mefloquine. The model presented here explains that recrudescences may 
occur well after one month following treatment. Furthermore early in the evolution of 
resistance (i.e. a low MIC), when there are few recrudescences, a greater proportion of 
recrudescences will occur after 28 days. Thus the degree to which mefloquine resistance is 
underestimated (failures ::s 28 days divided by total failure rate) is greater at low levels of 
drug resistance. As resistance worsens the mean time to recrudescence shortens. The 
simulations presented in Figure 4.10 provide estimates of the time to recrudescence for 
areas with different levels of mefloquine resistance. 
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4.4.4 Limitations of the model 
The parasitological response to an antimalarial drug is influenced by many factors. These 
are the parasites' drug susceptibility, host factors (e.g. natural immunity), PK factors (e.g. 
drug absorption), PD properties of the antimalarial drug (e.g. rate constant of parasite 
killing), and the intrinsic characteristics of the infection (e.g. parasite burden, and stage and 
synchronicity of parasite development at the time of drug administration). The model 
presented in this chapter includes parameters to represent the PK and PD properties of 
mefloquine, the parasites' susceptibility to mefloquine, and the initial parasite burden of 
the infection. However there are no parameters to represent the hosts' background 
immunity to malaria, and the initial stage and synchronicity of parasite development. 
Excluding a parameter to represent the level of the host's background immunity to malaria 
is probably acceptable for areas with low transmission and little host immunity, such as 
South East Asia. However for areas with high transmission, such as Africa, the model will 
predict a "worse scenario" in terms of parasite clearance compared with that actually 
observed. To include a function for background immunity is difficult since there is no 
direct measure of immunity. One possible solution to this problem is to change the parasite 
multiplication rate ('a') to a value called the 'adjusted parasite multiplication rate'. The 
'adjusted parasite multiplication rate' could be set at different values for immune, semi-
immune and partly immune patients. Again however it is not possible to estimate from data 
the 'adjusted parasite multiplication rate' for patients with different levels of natural 
immunity. Current estimates for the 'parasite mUltiplication rate' in the absence of drug are 
derived from patients with very little or no background immunity to malaria (Molineaux 
and Dietz, 1999). 
The stage and synchronicity of the P. [alciparum infection can complicate the 
characterisation of the PK-PD relationship. P. [alciparum has a 48 hour life cycle, during 
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which the parasite develops from tiny young ring forms, to pigmented trophozoites and 
then mature segmenting schizonts. Mefloquine is most active in vitro against the mature 
trophozoite and schizont forms (Geary et al. 1989). If a synchronous infection is treated at 
a time when the majority of the parasites are at the late schizont or tiny ring stages, the 
parasitaemia may rise after treatment as new rings are formed following merogony. The 
model presented in this chapter does not account for the stage-dependency of mefloquine 
and the synchronicity of the infection. Instead the model will predict for infections with 
varying distributions for the age of their parasites exactly the same parasite versus time 
profiles conditional that all other parameters are the same. For mefloquine, a slow-acting 
drug, the stage-dependence is probably less important because this dependence is 
smoothed by the long period during which mefloquine remains active in the body. 
However for artemisinin (a fast acting drug) it might be more important to relate the 
antiparasitic effect to stage-specificity and parasite synchronicity than to the PK for 
predicting clinical efficacy and determining dosage intervals (White, 1997; Hoshen et al. 
2000b). 
4.4.5 Limitations ofthe parameter estimates 
The PO parameters, slope of the concentration-effect curve and the concentration which 
kills 50% of parasites, are unknown in vivo. The parasite-time profiles simulated were 
based on extrapolating the PD parameters derived from in vitro data. Although careful 
analysis was performed to obtain the estimates of the slope and EC90 in vitro, two major 
assumptions were made to extrapolate these values to give estimates of the slope and EC90 
in vivo. Firstly it was assumed that the slope of the concentration-effect curve in vivo was 
the same as that observed in vitro. This assumption is very difficult to prove (or disprove). 
A different slope would imply a qualitatively different parasite transport system or enzyme 
kinetics for the supposed drug target in vivo and in vitro. In most other respects the malaria 
parasites behave the same in vivo and in vitro. In particular growth rates are comparable 
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and the popUlation dynamics are similar. Secondly it was assumed that the EC90 in vivo 
was ten times larger than the EC9Q in vitro. This number was chosen empirically and it can 
be seen in Figure 4.7 that changing the value from 5 up to 20 can have huge implications in 
terms of predicting patient cure. However it is difficult to determine what inflation factor 
should be applied to the EC9Q in vitro. Plasma or whole blood drug levels measured in vivo 
include free (unbound) drug and protein bound drug. Only the drug that is not bound in 
plasma is capable of crossing membranes and killing the malaria parasites. Thus in vivo the 
amount of free concentration that kills the parasite is much lower than the actual 
concentration measured due to plasma protein binding. In other words the in vivo 
concentration-effect curve is shifted to the right of the in vitro concentration-effect curve 
by an unknown amount. This shift in the curve results from protein binding. In vitro 
attempts to assess mefloquine plasma protein binding have been confounded by the 
tendency of mefloquine to stick to plastics and other laboratory ware. Protein binding is 
generally considered to be very high, approximately 98% (Karbwang and White, 1990). 
The in vitro parameters were derived from modelling of in vitro concentration-effect 
curves where the effect measure was inhibition of parasite uptake of eH] hypoxanthine. 
The inhibition of hypoxanthine uptake, is a measure that correlates with growth inhibition 
of parasite multiplication but it does not equate with it. 
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5. POPULATION DYNAMICS OF THE PLASMODIUM 
FALCIPARUMPARASITE WITIDN THE HUMAN HOST IN 
THE ABSENCE OF ANTIMALARIAL DRUGS. 
5.1 Introduction 
The discovery in 1917, by the Viennese psychiatrist Professor Julius Wagner Ritter von 
Jauregg, that a significant proportion of patients with neurosyphilis would improve 
following an attack of malaria led to a novel form of treatment for, what was then, an 
essentially incurable disease (Wagner-Jauregg, 1922). At that time approximately 10% of 
all inpatients in mental institutions in Britain had neurosyphilis. A four year cumulative 
mortality of 80% fell to less than 10% following the introduction of malaria therapy. 
Patients with neurosyphilis were treated by inducing a protracted attack of fa1ciparum or 
vivax malaria. Both mosquito borne and blood borne infections were induced. Laboratories 
were established in mental hospitals in Europe and the United States for such treatment 
(Collins and Jeffery, 1999). Relatively few isolates of the malaria parasites were used in 
the several major laboratories using this method. For example the Madagascar "strain" of 
Plasmodium vivax was used to infect over 10,000 patients during a 30 year period at the 
Horton Hospital in England. In most centres using malaria therapy, detailed records were 
routinely kept of symptoms, fever, parasite counts and the responses to treatment, in 
primary infections or in reinfections with both heterologous and homologous strains or 
species of parasites. These extensive records provide a unique source of information about 
the immunology and natural history of malaria in both the non-immune and previously 
infected adult human hosts. In addition, considerable experience was acquired in the 
modulation and elimination of infection, usually with chemotherapeutic agents. There was 
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no evidence that the presence of syphilis or the chemotherapy used for syphilis modified 
significantly the progression of the malaria infection (Winckel, 1941). 
Following the introduction of sporozoites, either by mosquito bite or injection, there is a 
phase of (pre-erythrocytic) development, which lasts approximately one week in 
hepatocytes (hepatic schizogony) before liberation of usually between ten thousand and a 
million motile parasites (merozoites) into the blood. These parasites then invade red cells 
and begin repetitive cycles of development and asexual reproduction in red cells. This 
leads to red cell destruction (haemolysis) and when the density of parasites in the blood is 
significant, the illness malaria. Plasmodium falciparum, P. vivax and P. ovale have an 
approximate two day intra-erythrocytic life span following invasion of a red cell. At the 
end of the parasite's life cycle the mature P.falciparum-schizont bursts releasing up to 32 
merozoites into the blood. The liberated merozoites invade red cells immediately. The 
microscopist can detect parasites only when the patient's parasitaemia exceeds 10 parasites 
If.d. This corresponds to greater than 100,000,000 parasites in the blood of an adult patient 
(White, 1998). This also corresponds approximately to the threshold for symptoms of 
illness. Thus after hepatic schizogony the first few asexual lifecycles are not detectable 
microscopically and the patient is well. Parasitaemias are detected, on average, 10-13 days 
following inoculation (Jeffery et al. 1959). 
A pictorial representation of P. falciparum parasitaemia over time from a patient with an 
induced infection is an oscillatory profile around an exponential rise in parasitaemia in the 
first week followed by a plateau and an eventual decline. The oscillation is present because 
approximately half way through the asexual cycle the P. falciparum-infected erythrocytes 
adhere to the capillary and venular walls (a process known as sequestration) and can no 
longer be seen microscopically (White et al. 1992a). 
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The usual progression of malaria, even in a naive host, is for the exponential increase in 
parasite numbers to stop (relatively abruptly). An equilibrium then occurs for days or 
weeks before parasite numbers begin to decline. After the acute illness low levels of 
parasites remain in the blood for several weeks or months before finally being eliminated. 
Only rarely does the multiplication of P. falciparum continue unchecked to result in life 
threatening parasite burdens. There are several reasons for this. One possible reason is the 
competition between parasites for host erythrocytes. In the past it has been assumed that P. 
falciparum invasion of erythrocytes is a random process. However, Simpson et al. (1999) 
found that the process is not random in the majority of patients. On average only 40% of 
circulating red cells were available for invasion for patients' with P. falciparum 
parasitaemia < 2%. Non-selective invasion was found in patients with severe malaria 
(Simpson et al. 1999) and was later shown to be a parasite property, and probable 
virulence determinant (Chotivanich et al. 2000a). Other factors that limit parasite 
multiplication are non-specific and eventually the development of specific immune 
defences from the human host. Schizonts reducing their multiplication potential may also 
be damaged by high fevers (Kwiatkowski, 1989; Kwiatkowski et al. 1990). 
The aim of this chapter was to estimate the parasite multiplication rate (PMR) and 
periodicity of the parasite cycle in the first week of patent parasitaemia in the absence of 
antimalarial treatment. Both PMR and periodicity of the parasite cycle are important 
parameters of mathematical models that predict the pharmacodynamics in vivo of 
antimalarial agents (White, 1997); the within-host dynamics of P. falciparum malaria 
(Molineaux and Dietz, 1999; Hoshen et al. 2000a); and the transition of asexual parasites 
to gametocytes (Diebner et al. 2000). Following antimalarial drug treatment the 
parasitaemia may fall as a result of sequestration or rise as a result of schizogony and 
merozoite release. These may erroneously be considered to represent success or failure 
respectively of treatment, yet they are the natural consequences of the infection. Such 
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changes need to be characterised before drug effects can be assessed. The period of initial 
growth represents the time when host defences have their least effects on the parasite 
population. The estimates of the two parameters, PMR and periodicity, were compared 
between different P. Jalciparom strains; and sporozoite and blood induced infections. 
5.2 Methods 
5.2.1 Patient data 
The basis for the present retrospective analysis consists of data extracted from 
parasitologic and fever records acquired between 1940 and 1963 at National Institutes of 
Health installations then located at the South Carolina State Hospital in Columbia, South 
Carolina and the Georgia State Hospital in Milledgeville, Georgia (Collins and Jeffery, 
1999), where malaria therapy was being routinely used in the treatment of neurosyphilis. 
An ethical analysis of the retrospective usage of these data for research revealed that there 
was no evidence that the patients were exploited (Weijier, 1999). The raw data were 
compiled by William E Collins and Geoffrey M Jeffery, who also provided the raw data 
and the data base to the Department of Medical Biometry, University of Tubingen, where 
the data have been computerised. 
Three species of Plasmodium (P. Jalciparom, P. malariae and P. ovale) were used in the 
malaria therapy of the African-American patients; P. vivax was ruled out because of 
genetic resistance to this species (Miller, 1976). Plasmodium Jalciparom was most 
frequently used because of the more desirable infection characteristics, availability, ease of 
transmission, and other factors; all of the infections considered in this analysis consisted of 
a number of strains of this species. Each patient was under close medical supervision. 
Consent for whatever treatments the hospital staff determined necessary was granted by the 
families or the courts when the patients were admitted to the hospitals. 
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Three hundred and twenty-eight of the patients infected with P. Jalciparum for the 
treatment of paresis and other mental disorders associated with tertiary syphilis were 
studied. All were primary infections. Patients were infected from one of the following 10 
different P. Jalciparum strains, where On' represents the number of patients infected with 
the corresponding strain:-
1) McLendon [n=141]: The McLendon strain was isolated in October 1940 from a 
patient who was admitted to the South Carolina State Hospital with malaria (Young 
et al. 1943; Young et al. 1948). 
2) EI Limon [n=91]: The EI Limon strain was isolated from a resident of EI Limon, 
Transisthmian Highway, Panama in 1948 (Jeffery et al. 1950). 
3) Santee Cooper [n=81]: The Santee Cooper strain was isolated during the summer of 
1946 from a patient living in the vicinity of the Santee Cooper impoundments in 
South Carolina (Eyles and Young, 1950). 
The seven other strains provided by various investigators were Colombia (n=6) , Costa 
(n=3), Thailand (n=2), So.Rhode (n=I), Strain_"7" (n=I), V-40G (n=l) and Walker (n=1). 
All patients remained in screened wards to prevent infection of local anophelines. Patients 
were infected either by the infection of parasitised blood or via sporozoite inoculation. 
With the latter, inoculation was either by the bites of infected anopheline mosquitoes or by 
the subcutaneous or intravenous inoculation of sporozoites dissected aseptically from 
mosquito salivary glands. For some patients treatment with non-curative doses of 
antimalarial drugs (primarily 325 or 650 mg of quinine sulphate) was given to modify and 
control the early stages of infection. Any history of recent malaria infection was also 
recorded. Thick and thin peripheral blood films were made daily, stained with Giemsa 
stain, and examined microscopically for the presence of parasites. Parasites were recorded 
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per J.11 of red blood cells as detennine by the method of Earle and Perez (1932). The 
detection threshold was approximately 10 parasitised red blood cells per J.11. Patients' 
temperature, pulse, and respiration were checked every four hours and hourly during 
episodes of fever by hospital personnel. 
5.2.2 Mathematical model 
To date no adequate mechanistic model has been found to describe the data from the 
neurosyphilis patients (Molineaux and Dietz, 1999). Therefore the mathematical model 
fitted to the data in this chapter was empirically derived. 
During the initial phase of the malaria infection the number of parasitised erythrocytes rise 
exponentially, giving 
dY =bY 
dt 
where 
Y - parasitaemia (I Ill) 
t - time (days) 
b - growth rate constant of the parasite (/day) 
This equates to:-
loglo Y = a +(bxt) 
where 
a - parasitaemia (loglO units) at time 0 
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The parasite multiplication rate (PMR) every two days is equal to 102b. Thus the following 
equation was fitted to the data to obtain the parameter of interest directly. 
loglo Y = a + (0.5 x loglo PMR x t) ...... (5.1) 
For a PMR of 10 and a parasitaemia of 10 IIlI at time 0 (i.e. a= I), equation 5.1 predicts the 
following parasitaemia versus time curve for the first 7 days of patent parasitaemia (Figure 
5.1). 
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Figure S.l. Predicted parasitaemia versus time profile for 
equation 5.1 where PMR = 1 0 and a= 1. 
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Unfortunately the parasitised cells that are seen microscopically do not represent all the 
parasites in the body. Erythrocytes containing mature parasites sequester in the 
microvasculature of vital organs (White and Ho, 1992b), and are therefore no longer 
microscopically visible. In other words on one day one may see parasitaemias reflecting 
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nearly all the parasites in the body, yet 24 hours later only a small proportion are visible 
(White et al. 1992a). Parasite sequestration causes the parasitaemia time profile to 
oscillate regularly about the simple loglinear relationship illustrated above (Figure 5.1), 
provided the parasite age distribution is unimodal and symmetrical. 
Therefore the following equation was fitted to the data, 
10g10 Y = a + (0.5 x loglo PMR x t) + ex sin( 2~ .t + k) 
perIOd 
where 
y - parasitaemia (//!I) 
t- time (days) 
a - parasitaemia (logJO units) minus c*sin(k) at day 0 
PMR - parasite multiplication rate every 2 days 
c - amplitude of sine wave 
period - periodicity of sine wave 
k - phase shift in sine wave 
...... (5.2) 
It was assumed that during the initial growth phase of the infection that parasite clearance 
was negligible. Data modelled by White et al. (1992a) indicated that there was little or no 
clearance of circulating rings in the first week of detectable parasites. 
Setting the five parameters of equation 5.2 at the following values: PMR=10, a=l, c=0.5, 
period=2, k=O. Figure 5.2 represents the predicted parasitaemia versus time curve. 
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Figure 5.2. Predicted parasitaemia versus time profile for equation 
5.2 where PMR=lO, a=l, c=O.5, period=2 and k=O. 
Since the data are fitted empirically the following equations (listed below) were also tried. 
All were less successful than equation 5.2. 
c x sin( 21r 1 + k) 
period 
loglo y = a + (b x t) + -----=-----
t 
log y=a*exp(bxt)+cxsin( 2~ l+k) 
10 perzod 
log y=a*[l-exp(bxt)]+cxsin( 2~ l+k) 
10 period 
The first seven days of microscopically visible parasitised erythrocytes were selected for 
statistical analysis. The first week of initial growth represents the time when host defences 
have little effect on the parasite population. If the age of the parasite is approximately 48 
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hours then over seven days 3 life cycles of the parasite will be observed. After seven days 
the majority of patients had parasitaemia-time profiles that had either reached a plateau or 
begun to decline. 
5.2.3 Statistical Analysis 
The data were analysed using three different statistical approaches; the standard two-stage 
method, the global two-stage method and nonlinear mixed effects modelling. 
5.2.3.1 Standard two-stage method (STS) 
The first stage is to estimate the parameters 'a', 'PMR', 'c', 'period' and 'k' through 
nonlinear regression (least squares method) using an individual's dense parasite-time data. 
Individual parameter estimates obtained in the first stage serve as input data for the second 
stage calculation of descriptive summary statistics, typically mean (or log-mean) parameter 
estimates and variance of the individual parameter estimates. The variability around the 
mean population parameter is calculated only from the individual parameter estimates, no 
adjustment is made to take account of the uncertainty in the estimation of the individual 
specific parameters. This approach therefore overestimates systematically the inter-
individual variability (Steimer et al. 1984). Each individual parameter is estimated from 
the original parasite-time data with some error. This error adds variability to the parameter 
estimates, thus increasing the estimate of the inter-individual variability. The STS method 
is only possible if there are sufficient data to estimate the model parameters for each 
individual, and if all data from each individual are described by the same structural model. 
The mathematical model in this paper has five parameters, and thus at least six data points 
per individual are required. 
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5.2.3.2 Global two-stage method (GTS) 
The GTS method is the same as the STS method for the first stage. As well as the 
individual parameter estimates, their covariance matrix is obtained. At the second stage the 
GTS method refines the estimation of the inter-individual variability through bias 
correction and differential 'weighting' of individual data according to its quality and 
quantity. GTS estimates for the mean population parameters and their corresponding inter-
individual variability are computed according to Prevost's recursive scheme (Prevost, 
1977). The required assumption for the GTS method is that the distributions of the 
parameters and their corresponding covariance matrix are all multivariate normal (Steimer 
et a1. 1984). 
5.2.3.3 Nonlinear mixed effects modelling 
The data for all individuals are analysed simultaneously, with mixed effects modelling 
taking into account both fixed and random effects. The fixed effects are the mean 
population parameters or a number of parameters that relate the parameters to other 
variables, such as strain, type of inducement, etc. The random effects are the inter-
individual variability and intra-individual variability. 
The nonlinear mixed effects modelling procedure (Lindstrom and Bates, 1990) of the 
SPLUS data programme (SPLUS 4.5 for Windows, Mathsoft, Inc., Cambridge, 
Massachusetts) was used to calculate estimates of the popUlation parameters ('a', 'PMR', 
'c', 'period' and 'k') and their respective inter-individual variances (118 , TlPMR, TIC, l1period 
and 11k). The programme also provides estimates of the residual random intra-individual 
error (8). Convergence was achieved when the objective value did not differ by more than 
some prespecified difference (e.g. 0.0001) and the programme returned the final estimates 
of the population parameters. The objective function (minus twice the log-likelihood of the 
data) was used to determine the model that best fitted the data. A significant drop in the 
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objective function from the general model to the restricted model was used to determine 
the final model. The change in the objective function was compared to a X2 statistic with 
degrees of freedom equal to the difference in number of parameters between the two 
models. The goodness of fit of each model was also determined by the precision of the 
parameter estimates and examination of the scatter plot of the residuals versus the 
predicted parasitaemia. The individual parameters were calculated with use of the posterior 
estimates. 
Patient covariates (e.g. inoculation vIa sporozoites (IVS», as a fixed effect, were 
incorporated into the model for PMR as shown below. 
PMRj = [PMR + 8(lVS)] x exp('lj,PMR) ' 
where e is the coefficient of the categorical variable 'IVS' and represents the change in 
PMR resulting from malaria infection via sporozoite inoculation compared with 
inoculation of parasitised blood. A statistically significant improvement in the objective 
function, improvement in the precision of the parameter estimate (SE), and reduction in 
inter-individual and residual variability were used to determine the importance of the 
covariates as predictors. 
5.2.3.4 Assessment of the information in the experimental design 
Parasite counts were recorded daily for all patients. To investigate the oscillating nature of 
the data using nonlinear mixed effects modelling the optimal experimental design would 
have parasite counts recorded at more frequent time points following the first observed 
parasite count. The accuracy of the parameter estimates produced from mixed effects 
modelling depends upon the number and timing of the samples (i.e. experimental design). 
Methods based on the Fisher information matrix have been developed and extended to 
population studies to evaluate experimental designs (Retout et a1. 2001). The popUlation 
Fisher information matrix was determined from the experimental design conditional on the 
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model and population parameter values. The standard error of each parameter was 
computed from the square root of the diagonal elements of the inverse of the Fisher 
infonnation matrix. 
S.3 Results 
Eighty-three of the patients were excluded from the overall analyses because they had 
received antimalarial treatment during the first seven days of the infection. The 
implications of excluding these patients are addressed later in this section. 
The remaining 245 patients had parasitaemia versus time modelled initially for each patient 
separately. By definition these patients had less severe infections than those who required 
rescue treatment. The model fitted the data adequately for 117 of the patients. The 
observed and fitted values for two of the patients are shown in Figures 5.3a and 5.3b. For 
35 of the patients the five parameter mathematical model could not fit the data because 
there were less than six data points (e.g. parasitaemia peaked early or there were missing 
data). Visual inspection of the data of the remaining patients suggested the following 
reasons for the poor fits:-
no oscillation (60) 
variable amplitude of the oscillation (16) 
shape very different from structural model (17) 
The patients' for which the model could not be fitted to their parasite count data were a 
mixture of infections and were similar to the 117 patients where the model adequately 
described the data (Table 5.1). 
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Table 5.1 gives the demographics of the 117 patients who were included in the statistical 
modelling. Table 5.2 presents the estimates of the population parameters and their 
respective inter-patient variability produced by the three analytical methods; STS, GTS and 
nonlinear mixed effects modelling. Figure 5.4 shows a plot of predicted parasitaemia, 
estimated from the STS, GTS and nonlinear mixed effects methods, and the observed 
parasitaemia against time. Appendix V contains the SPLUS programme used for the 
nonlinear mixed effects modelling. 
Table 5.1:- Characteristics of the infections of the patients 
N=117 N=35 N=93 
(good fit of the (not enough data (poor fit of the 
model) points) model) 
Strain 
EI Limon 29.9% 17.1% 16.0% 
McLendon 41.0% 48.6% 46.8% 
Santee 25.6% 28.6% 30.9% 
Other 3.4% 5.7% 6.4% 
Method of infection 
Sporozoite 37.6% 40.0% 20.4% 
Blood 62.4% 60.0% 79.6% 
Gametocyteless strain 
Yes 6.0% 5.7% 8.6% 
No 94.0% 94.3% 91.4% 
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Table S.2:- Comparison of methods for modelling ofthe 117 patients' data, comprising a total 
of 782 recorded parasite counts. 
Parameter 
a 
PMR 
c 
Period 
k 
co. 
COPMR· 
coc· 
COperiod 
COk 
Residual SD - CJ& 
Standard two-stage 
(STS) 
Estimate 
1.33 
8.11 
0.56 
2.20 
0.30# 
0.78 
0.61 
0.48 
0.38 
SD - standard deviation; SE - standard error; 
#- median; 
z - calculated using var(lo~p) = (I /p2) • var(p); 
Global two-stage Nonlinear mixed effects 
(GTS) modelling 
Estimate Estimate(SE) 
1.34 1.31 (0.06) 
8.26 8.20 (0.37) 
0.62 0.50 (0.04) 
2.17 2.36 (0.02) 
-0.14 0.38 (0.09) 
0.66 0.43 
0.21z 0.14 
O.44z 0.48 
0.34 
2.34 
0.485 
co - inter-patient standard deviation for the parameters a, PMR, c, period and k; 
• _ log-normal error model. 
Mathematical equation fitted to data:-
log Y = a + (O.5x loglO PMRxt) +cx sine 2~ J + k) 
10 perIOd 
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Figure S.4. Parasite counts (0) from 117 patients. Population predicted 
parasitaemia curves derived from STS (.), GTS (--) and nonlinear mixed 
effects modelling ( I.). 
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The three methods STS, GTS and nonlinear mixed effects modelling gave similar 
population mean estimates for all of the parameters except 'k', the phase shift in the sine 
wave. The parameter 'k' is not normally or even lognormally distributed. This is why the 
estimates from STS and GTS differ so much, because the estimate obtained from the STS 
method is the median value. The estimates for the inter-patient variability of the parameters 
differed between the three methods with the STS method producing the highest estimates. 
It was only possible to produce an estimate of the residual (intra-patient) variation using 
nonlinear mixed effects modelling. 
For nonlinear mixed effects modelling the inter-patient variability of the parameters 'PMR' 
and 'c' was assumed to be log-normally distributed. The parameter 'period' was observed 
to have negligible inter-patient variability in the mixed effects modelling and therefore the 
inter-patient variability of this parameter was not included in the final model. Surprisingly 
negligible inter-patient variability was observed for the parameter 'k'. Further investigation 
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showed that there was strong correlation between the inter-patient variability of parameters 
'c' and 'k'. Including both in the model would result in overparameterisation. Thus only 
the inter-patient variability of parameter 'c' was included in the final model. An additive 
residual error (intra-patient error) model was selected to estimate the residual variability in 
the mixed effects modelling. 
5.3.1 Patients' with parasitaemia that peaked earlier than seven days or with missing data 
Table 5.3 gives the results from nonlinear mixed effects modelling of 152 patients 
(including those 35 patients with missing data and early peaks). Nonlinear mixed effects 
modelling is capable of analysing sparse data as opposed to the other methods, STS and 
GTS. Comparing the estimates with those observed from the restricted dataset of 117 
patients it can be seen that the estimates are similar implying the selected patients do not 
represent a biased group. 
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Table 5.3:- Comparison of nonlinear mixed effects modelling for the two datasets:-
reduced dataset (only patients where individual fits were feasible) & inclusive dataset 
(reduced dataset plus the 35 patients with missing data or early peaks). 
Nonlinear mixed effects Nonlinear mixed effects 
modelling (n=152) modelling (n=117) 
Parameter Estimate (SE) 90% PI Estimate (SE) 90% PI 
a 1.32 (0.06) 0.46,2.18 1.31 (0.06) 0.60,2.02 
PMR 8.24 (0.39) 5.52,12.29 8.20 (0.37) 6.55,10.27 
c 0.44 (0.03) 0.19,1.01 0.50 (0.04) 0.23,1.10 
Period 2.35 (0.02) 2.36 (0.02) 
k 0.37 (0.10) 0.38 (0.09) 
0.520 0.432 
0.243 0.137 
0.503 0.484 
O>period 
O>k 
Residual SO - 0"£ 0.503 0.485 
SD - standard deviation; SE - standard error; PI - prediction interval; 
0> - inter-patient standard deviation for the parameters a, PMR, c, period and k; 
• -log-normal error model. 
Mathematical equation fitted to data:-
log Y = a + (0.5 x loglo PMR x t) + c x sin( 2~ .t + k) 
)0 perzod 
5.3.2 Non-oscillating data 
Sixty of the patients were observed to have parasite versus time profiles that did not 
oscillate (see Figures 5.5a-5.5d for four examples). These patients probably had 
asynchronous infections, that is, the age distribution of all the parasitised cells (circulating 
and sequestering) is almost uniformly distributed (White et a1. 1992a). Equation 5.1 was 
fitted to the data to obtain estimates of PMR using nonlinear mixed effects modelling. 
Table 5.4 presents the results. The patients' with non-oscillating parasitaemia versus time 
profiles were observed to have slightly higher PMRs compared to those patients' with 
oscillating profiles (8.84 (90% PI: 5.59,14.00) versus 8.24 (5.52,12.29)). 
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Figures 5.5a-b. Parasitaemia versus time profiles for patients 
with an asynchronous parasite population. 
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Figures S.Sc-d. Parasitaemia versus time profiles for patients with an 
asynchronous parasite population. 
8 
119 
Table 5.4:- Nonlinear mixed effects modelling results for the 60 patients 
with non-oscillatory parasitaemia-time profiles. 
Nonlinear mixed effects modelling 
Parameter Estimate (SE) 90% PI 
a 1.38 (0.07) 0.72, 2.04 
PMR 8.84 (0.58) 5.59, 14.00 
SE - standard error; PI - prediction interval. 
Mathematical equation fitted to data:-
10g,0 Y = a + (0.5 x loglo PMR x t) 
5.3.3 Amplitude of oscillation fluctuating 
Figures 5.6a and 5.6b represent two parasitaemia-time profiles for patients' with a 
fluctuating amplitude of the oscillation around the loglinear rise in parasitaemia. In Figure 
5.6a the rise and fall of the parasitaemia declines with time (i.e. the amplitude of the sine 
wave decreases with time). A high parasitaemia is reached rapidly reflecting a high PMR 
and thereafter the parasitaemia stabilises. For this patient the distribution of the age of 
parasites in their blood could be skewed towards younger parasites. In Figure 5.6b, the 
initial rise and fall in parasitaemia becomes more abrupt with time, suggesting the age 
distribution of the parasites infecting this patient is skewed towards older parasites. 
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Figures S.6a-b. Two examples of patients with parasitaemia versus time 
profiles that cannot be fitted with a rising sine wave. 
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5.3.4 Shape very different from structural model 
The seventeen parasitaemia-time profiles were a mixture of shapes. A few of them 
appeared to represent highly synchronous infections (i.e. the majority of parasites are the 
same age). The rise and fall in the parasitaemia was abrupt (see Figure 5.7 for two 
examples). The peaks of the oscillations below in Figures 5.7a and 5.7b may represent 
nearly all the parasites in the body at the corresponding time. Sequestration of the 
circulating parasitised red cells leads to a dramatic downward change in the parasitaemia. 
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Figures S.7a-b. Parasitaemia versus time profiles for two patients with a 
highly synchronous parasite population. 
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5.3.5 Covariates 
Fonnal hypothesis testing of the effect of each of the covariates on the parameters of 
interest (PMR and period) was performed using nonlinear mixed effects modelling of data 
from the 152 patients described previously (see Table 5.3). As the parameter 'period' had 
little inter-patient variability, only relationships between the covariates and the parameter 
'PMR' were investigated. Table 5.5 summarises the univariate effects of each covariate on 
the parameter 'PMR'. Those infections acquired via sporozoites had PMR values that were 
not significantly different to those following inoculation of parasitised blood. The El 
Limon and Santee Cooper strains both had higher PMR values compared with the 
McLendon strain (absolute mean increase in PMR related to El Limon: 2.06 (95% CI: 
0.63,3.49) and to Santee Cooper: 1.98 (95% CI: 0.53,3.43) when compared to McLendon 
strain (mean PMR=7.13». The final population parameter estimates, the inter-patient 
variability, and the residual variability including the effect of parasite strain are given in 
Table 5.6. Including the covariate, 'strain', in the model reduced the inter-patient 
variability of the parameter 'PMR' from 0.24 to 0.20. 
Table 5.5:-Summary of results with incorporation of covariates into the base model 
(0=152 patients). 
Effect of sporozoite 
induced infection on PMR 
Effect of strain on PMR 
(n=146*) 
Mc Lendon (n=65) 
El Limon (n=41) 
Santee Cooper on PMR 
(n=40) 
CI - confidence interval 
Parameter 
estimate 
-0.30 
Reference 
2.06 
1.98 
95% CI Change in objective p-value 
function 
-1.53,0.93 0.22 0.65 
10.89 <0.01 
0.63,3.49 
0.53,3.43 
* _ Six of the patients were infected with the following strains: Colombia (n=2), Costa (n=I), 
so.Rhode (n=I), Strain "7" (n=l) and Thailand (n=I). 
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Table 5.6:- Final estimates of parameters from the optimal model. 
Parameter 
a 
PMR (McLendon) 
Factor for El Limon 
Factor for Santee Cooper 
c 
Period (days) 
k 
O>PMR* 
O>period 
O>k 
Residual SD - crt 
Nonlinear mixed effects modelling (n=146) 
Estimate (SE) 90% Prediction Interval 
1.32 (0.06) 
7.13 (0.44) 
2.06 
1.98 
0.44 (0.03) 
2.36 (0.02) 
0.37 (0.10) 
0.53 
0.20 
0.50 
0.503 
0.45,2.19 
5.13,9.91 
0.19,1.00 
SE - standard error; SD - standard deviation; 
0> - inter-patient standard deviation for the parameters a, PMR, c, period and k; 
* _ log-normal error model. 
Mathematical equation fitted to data:-
log 0 Y = a + (0.5 x log,o PMR x t) + c x sin( 2~ .t + k) 
1 perIOd 
5.3.6 Association between PMR and both observed peak parasitaemia and amplitude of 
sine wave 
There was a significant strong positive correlation between PMR and the observed 
maximum parasitaemia in the first 7 days (Spearman rank correlation coefficient = 0.532, 
p<O.OOI). A significant negative association was observed between PMR and amplitude of 
the sine wave (Spearman rank correlation coefficient = -0.184, p=O.026). 
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5.3.7 Association between PMR and the different patients groups omitted from the 
analyses 
Of the 328 patients, 176 were not included in the above analyses. These patients comprise 
of four different groups: treated within the first 7 days (n=83), no oscillation in the 
peripheral parasite-time profile (n=60), variable amplitude in the peripheral parasite-time 
profile (n=16), and shape very different from the structural model (n=17). Each of these 
patient groups may influence the PMR and by excluding them may result in a biased 
estimate of the PMR. Therefore the simple loglinear equation (i.e. equation 5.1) was fitted 
to the parasite data of all 328 patients using nonlinear mixed effects modelling. For the 
patients treated within the first 7 days only the parasite counts recorded before treatment 
were included in the modelling. Table 5.7 presents the results. The popUlation mean 
estimate for PMR is 7.7 slightly less than the estimate observed when fitting equation 5.2 
to the subset of 152 patients. When investigating the effect of the different patient groups 
on the estimate of the PMR, those patients treated during the first 7 days and those with 
non-oscillating parasite-time profiles had significantly higher PMRs whereas the patients 
with a parasite-time profile that was very different from the structural model had 
significantly lower PMRs (Table 5.8). 
Table 5.7:- Nonlinear mixed effects modelling results for all 328 patients. 
Parameter Estimate 90% Prediction Interval 
a 
PMR 
COa 
COPMR* 
Residual SD - O't 
(SE) 
1.46 (0.04) 
7.70 (0.29) 
0.47 
0.30 
0.633 
0.69,2.23 
4.70, 12.61 
SE - standard error; SO - standard deviation; 
co _ inter-patient standard deviation for the parameters a and PMR; 
* _log-normal error model; 
Mathematical equation fitted to data:-
10g
IO 
Y = a + (0.5 x 10glO PMR x t) 
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Table 5.8:- Summary of covariate analysis of all 328 patients. 
Group PMR estimate 95% confidence interval 
Inclusive (n=152) Reference 
Treat (n=83) 5.93 4.05,7.81 
No_osc (n=60) 1.60 0.50,2.70 
Var_amp (n=16) 0.52 -1.22,2.26 
Shape_diff(n=17) -2.96 -3.96, -1.96 
'Inclusive' - the patient data modelled successfully by equation 5.2 using nonlinear mixed effects 
modelling; 
'Treat' - treated in the first seven days; 
'No_osc' - no oscillation in the parasitaemia-time profile; 
'Var_amp' - variable amplitude of the oscillation in the parasitaemia-time profile; 
'Shape_diff - shape very different from the structural model (i.e. an oscillatory profile around an 
exponential rise). 
5.3.8 Assessment of information in the experimental design 
To calculate the Fisher information matrix for the above model and experimental design, 
the final estimates of the population parameters, inter-patient variability and intra-patient 
variability from mixed effects modelling plus the sampling times (day 1, 2, 3, 4, 5, 6, and 
7) and number of samples for each patient (approximately 7) were investigated using a 
programme written for the software application MATLAB (Retout et a1. 2001). The 
coefficient of variation for the population parameter estimates and estimates of inter-
patient variability were reasonable (ranges of 0.6 % - 12.7% for population parameter 
estimates and 16 - 44% for inter-patient variability estimates) except for the inter-patient 
variability of ok' (CV=301%). The parameter Ok' is included in the model to account for 
patients having their first detectable count parasite at different stages of the parasite cycle. 
It is not a parameter of primary importance. The results indicate that the other four 
parameters and their respective inter-patient variability are estimated reasonably from the 
sampling times (parasite counts recorded daily) of these data. 
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5.4 Discussion 
The majority of intra-host malaria models have no strong similarity to the natural infection 
observed in an individual (Molineaux and Dietz, 1999). Most of the intra-host malaria 
models (Gravenor et al. 1995; Hetzel and Anderson, 1996; Austin et al. 1998) are based 
on the model by Anderson et al. (1989) which is a set of four coupled differential equations 
representing the rate of change in un infected erythrocytes, parasitised erythrocytes, 
merozoites and immune effectors over time. The data that were simulated from the above 
models were never formally compared to observed data. Furthermore the Anderson model 
cannot yield simultaneously a realistic value for the number of parasitised erythrocytes 
produced per schizont and the number of merozoites produced per schizont. Consequently 
an empirical model was chosen to fit the data from non-immune or partially immune adults 
receiving P. Ja/ciparum for the treatment of neurosyphilis. The advantage of the model 
chosen was that two of the parameters represented important biological measures, parasite 
multiplication rate every 48 hours (PMR) and length of parasite life cycle (period). 
5.4.1 Summary of findings 
The patient parasitaemia versus time profiles demonstrated huge variability across patients. 
Fitting the data separately for each individual or by using nonlinear mixed effects 
modelling gave similar mean popUlation parameter estimates but varying estimates for 
inter-patient variability of some of the parameters. As expected the inter-patient variability 
for the parameters 'a' and 'PMR' were over-estimated by the STS method compared to 
GTS and nonlinear mixed effects modelling. Analysis of pharmacokinetic experimental 
data has also shown the STS approach to overestimate systematically the inter-individual 
variability of the parameters (Sheiner and Beal, 1981). Nonlinear mixed effects modelling 
estimates are not contaminated with the error involved in the estimation of individual 
parameters. 
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The mean population estimate of 'PMR' was approximately 8 and varied across patients. 
This differs from the Figure of 12.3, reported by Gravenor et a1. (1995) which was 
obtained from simple loglinear regression of the initial growth phase (defined as that 
period until the maximum parasitaemia during the first week of detection in the blood). In 
this chapter eighty-three of the patients were excluded from the analysis because they 
received antimalarial treatment during the first seven days of the infection whereas 
Gravenor et a1. (1995) analysed all patient data and only excluded the parasite counts 
recorded after the administration of quinine. This implies that the estimate of the PMR 
could be biased downwards. However when fitting equation 5.1 to the data of all 328 
patients (i.e. including the pre-treatment parasite count data from the 83 patients treated 
within the first 7 days and the parasite count data from the 93 patients where equation 5.2 
could not fit the data) the population mean estimate ofPMR remained approximately 8. 
PMR was observed to be highly dependent on the P. falciparum strain. The strains given to 
the patient are nested under institution (El Limon and Santee Cooper strains in Georgia, 
McLendon strain in South Carolina). Consequently the differences in PMR could also be 
confounded by institutional differences in treatment practices. For example, at the South 
Carolina institution, there might have been a more conservative criterion for determining 
the patients requiring treatment to control the infection which would explain the lower 
pMRs. However at the Georgia location there was a significantly higher percentage of 
patients treated compared to South Carolina (31 % versus 20% respectively, p-
value=O.042). This finding favours the explanation that the observed differences in PMR 
result from intrinsic multiplication differences between the different P. falciparum strains 
as opposed to the different institutions. Figure 5.8 illustrates the change in predicted 
parasitaemia for different PMR values. 
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The mean population estimate of the length of the parasite life cycle was approximately 55 
hours (2.3 days) which is greater than the generally quoted 48 hours. The periodicity of the 
sine wave is highly dependent on the exact timings of the recording of parasite counts. 
Parasite counts were detennined daily and for this analysis they were assumed to be 
exactly 24 hours apart. However blood films were made each morning usually between 8 
and lOam. On any given day, the timing of the blood film could vary by several hours 
from the day before to the day after. 
Given that considerable variation was observed across patients and parasites for PMR, 
future intra-host models and phannacokinetic-phannacodynamic models that include 
parasite multiplication must incorporate both variation among parasites and individual 
hosts. In these induced P. falciparum infection studies the population estimate for PMR 
was approximately eightfold per two day life cycle with a 90% prediction interval from 5.5 
to 12.3. These values therefore represent the maximum values for zero drug effect in any 
study of antimalarial phannacodynamics in non-immune patients. 
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5.4.2 Limitations of the model 
The parasitaemia versus time profile does not continue to rise indefinitely. It is usually 
contained by the host. The control mechanism intervenes abruptly reducing the PMR from 
approximately 8 fold per cycle to a value of one or less. The model used for this paper will 
predict the parasitaemia continues to rise after seven days not reflecting the true pattern of 
the infection. Thus the predictive values of this model are confined to the unrestrained 
expansion phase ofthe infection and cannot be extrapolated past seven days. 
5.4.3 Limitations of the data 
The sampling interval for the parasite count data was one day. For a time series with a one-
day sampling interval the highest frequency, termed 'Nyquist frequency', that can be 
restored is 0.5. In other words the minimum period (i.e. parasite life cycle) that can be 
determined from the data is two days. With the current data, nonlinear mixed effects 
modelling did not produce a parameter to represent the inter-individual variability in the 
parameter 'period of parasite life cycle'. Therefore it is not possible to determine the 
probability of the period being less than 48 hours. Figure 5.9 presents predicted 
parasitaemia versus time profiles for varying periods of the sine wave. Vertical lines are 
drawn at daily intervals to highlight the limited data available for predicting the periodicity 
of the sine wave. 
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Fluctuations in parasitaemia are caused by sequestration and ring form clearance (fall in 
parasite count), and later schizont rupture and meront reinvasion of erythrocytes (rise in 
parasite count). The inability of the model to fit adequately 93 of the individuals is not 
necessarily a result of model misspecification. It may be explained by discrepancies 
between the peripheral blood parasite count (detected microscopically) and the total 
parasite burden in falciparum malaria. The ratio of circulating to sequestering cells at any 
time is largely dependent on the synchronicity of the infection (White et al. 1992a). If the 
parasite age distribution is synchronous and from a single or dominant "brood", then the 
observed parasitaemia increases with a rising sine wave pattern (Figures S.3a & S.3b). In 
highly synchronous infections the peripheral parasitaemia rises and falls dramatically 
(Figures 5.7a & S.7b) whereas a completely asynchronous infection gives a rising straight 
line on a semi-log plot (Figures S.5a-d). Parasites with an age distribution that is not 
nonnally distributed will have very different parasitaemia versus time profiles. Some 
infections consist of two or more discrete "broods" with different characteristics, giving 
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rise to an infinite range of possible profiles. White et al. (1992a) presented a model that 
contained just two parameters; the standard deviation of parasite age since merogony 
(schizogony) as a measure of synchronicity, and a multiplication factor for each 48 hour 
asexual life cycle. Svensson (2000) adjusted for synchronicity by including a parameter 
that represented the time for one life cycle in the average parasite, that is parasite mean 
residence time. Although parasite mean residence time does not measure synchronicity of 
an infection it does present a way of taking account of the variation across patients 
resulting from synchronicity. In this chapter the amplitude of the sine wave of equation 5.2 
represents empirically the synchronicity of the infection. Patients with very large 
amplitudes have highly synchronous infections whereas moderately synchronous infections 
have amplitudes close to zero. Aysnchronous infections could not be fitted by equation 5.2 
because there was no oscillation in the profiles. The amplitude did not differ between 
patients infected with different P. Jalciparum strains. In vivo it is not possible to measure 
the synchronicity of an infection as not all parasite stages are present in the peripheral 
blood. Therefore to calculate the total parasite burden and the number of parasites within 
each stage one needs to extrapolate from data collected describing the distribution of 
parasite stages in the peripheral blood. Even with these proxy distributions of parasite age 
it is still difficult to mechanistically quantify synchronicity. 
The mathematical model presented in this chapter can only be validated in the relatively 
narrow range of detectable parasitaemias (i.e. parasitaemias above 10 /~l or a total parasite 
burden of> 5* 1 07 parasites). Additionally the parasitaemias recorded may be inaccurate 
due to small counting errors; this error increases with decreasing numbers of parasites per 
slide. 
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6. SEQUENTIAL PHARMACOKINETIC/PHARMACODYNAMIC 
MODELLING FOR MEFLOQUINE 
6.1. Introduction 
Information regarding the pharmacokinetics (PK) and phannacodynamics (PD) of a drug 
helps provide the clinician with optimal dosing strategies. Recent statistical methodology 
enables concurrent mathematical modelling of the kinetics and dynamics. There are two 
approaches to this type of modelling, sequential PK-PD modelling (see section 1.2.3.1) or 
simultaneous PK-PD modelling (see section 1.2.3.2). In brief, for the sequential approach 
population PK modelling of the concentration-time data is performed initially and from 
this modelling concentrations are predicted which correspond to the times at which the PD 
measurements were taken. Population PD modelling is then performed using the PD-time 
data and the predicted concentrations. Whereas for simultaneous modelling both the PK 
and PD models are fitted together to all observed PK and PD measurements. 
population PK-PD modelling has already been applied successfully to a number of 
different medical conditions. Four examples, from Phase III trials, are given by Machado et 
al. (1999) where the results of the popUlation PK-PD modelling assisted regulatory 
decision-making. Population modelling has also been applied to data from preclinical PK 
and toxicokinetic studies, dose titration studies, and the integration of PK-PD into disease 
progression models. 
For the antimalarial drug, mefloquine, little work has been done using the population 
approach to investigate how the drug concentrations relate to the therapeutic effect. 
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Svensson (2000) applied population PK-PD modelling to patients with falciparum malaria 
receiving one of three different treatments: oral artemisinin for 3 days followed by 
mefloquine on day 4; oral artemisinin for 3 days plus mefloquine on day 1; or a single dose 
of mefloquine. The mechanism-based PD model successfully described the antimalarial 
efficacy of artemisinin, mefloquine and a combination of the two drugs. 
In this chapter sequential PK-PD modelling was performed on PK and PD data collected 
from patients receiving mefloquine monotherapy for the treatment of uncomplicated P. 
falciparum malaria during 1990-1992. Individual specific PK parameter estimates obtained 
from the population PK modelling performed in Chapter 3 were used to predict 
concentrations corresponding to the times at which the PD measurements, that is parasite 
counts, were taken. The mechanistic PD model derived in Chapter 4 was the mathematical 
model chosen to represent the change in parasite count over time for the sequential PK-PD 
modelling. 
6.2 Methods 
6.2.1 Study population 
PK and PD data were collected prospectively from patients receIvmg mefloquine 
monotherapy as part of trials conducted between 1990 and 1992. The patients were from 
the Karen ethnic minority and lived in camps for displaced persons situated along the 
western border of Thailand in an area of low and seasonal malaria transmission 
(Luxemburger et al. 1996). Health care in these camps is provided by Medecins Sans 
Frontieres (MSF). 
Patients who came to the clinics were enrolled into prospective studies of antimalarial 
treatment if they had symptoms and a microscopically confirmed infection with asexual 
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stages of P. Jalciparum in the peripheral blood. The exclusion criteria for these studies 
were the following; weight less than 8 kg, quinine administration within the previous 7 
days, or mefloquine or sulfadoxine-pyrimethamine within the previous 14 days, pregnancy, 
signs of severe or concomitant disease requiring hospital administration (World Health 
Organisation, 1990). 
All patients received one of the two following mefloquine (Lariam, 250 mg base tablets, 
Roche Pharmaceuticals) dosing regimens: 25 mglkg (single dose) or 25 mglkg (split dose: 
15 mglkg on day 0 followed by 10 mglkg 24 hours later). 
Informed consent was obtained from the patients or their parents or guardians. All studies 
were approved by the Ethical Committee of the Faculty of Tropical Medicine, Mahidol 
University, Bangkok, Thailand, and by the Karen Refugee Committee, Mae Sod, Thailand. 
6.2.2 Pharmacodynamic model 
The variable chosen to represent therapeutic response was the number of parasites recorded 
in a malaria smear. Malaria parasite counts were determined on Giemsa-stained thick films 
as the number of parasites per 500 white blood cells, and converted to parasitaemia by 
assuming a white blood cell count of 8000 /Jll. Patients were examined daily thereafter 
until they became aparasitaemic, and they were then seen once a week for at least 4 weeks. 
If the blood smear was positive on day 7, and the patient was asymptomatic, smears were 
taken again on days 8 and 9. If still positive, the case was considered a failure and 
retreated. Symptomatic patients with a positive blood smear on day 7 were considered 
failures and retreated immediately. Patients whose blood smears became positive between 
days 9 and 28 were also considered failures and retreated irrespective of symptoms. 
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Parasitaemia was converted to 'Total parasite burden' by multiplying the parasitaemia (l1l1) 
by (5*106)/70 (blood volume Ill/kg) and the body weight (kg) of the patient. 
The mathematical model chosen to represent 'Total parasite burden' over time was the 
following mechanism-based differential equation (see section 4.2.1 for more detail):-
-------- (6.1) 
where 
. d c: ·th b· ·th . Pij - total parasite bur en lor I su ~ect at J time, 
Cij - mefloquine level for ith subject at /h time, 
t - time (days), 
Po - total parasite burden at admission, 
k\ - rate constant of parasite killing, 
Cso - drug concentration that kills 50% of the parasite, 
a - growth rate constant of the parasite, 
y _ slope of concentration effect curve. 
Following treatment with mefloquine, the average parasitaemia-time profile is that of a lag 
phase, during which the population mean parasitaemia remains unchanged (White, 1997). 
The explanation for this is the stage-specific killing action of mefloquine. Mefloquine 
mainly kills trophozoites, that is, the older parasites that are not visible to the microscopist 
(Geary et al. 1989). Thus, a time lag of one day was introduced into the model. 
Another alteration to the model was introduced. When the predicted total parasite burden 
dropped below 10 parasites the programme was set so that the predicted parasite burden 
137 
remained <10 parasites and the patient was predicted as cured. This was implemented to 
avoid equation 6.1 predicting that a patient had recrudesced even though their minimum 
predicted total parasite burden was less than 10 parasites (i.e. radical cure). 
The mefloquine levels for each subject at each time point where parasitaemia was recorded 
were simulated using the individual specific PK parameter estimates obtained from the 
population PK modelling executed in Chapter 3. The use of the predicted, rather than 
observed, concentrations may reduce attenuation bias in estimating the population PD 
parameters, as observed concentrations are measured with error. 
The equations used for the simulations are given below:-
The subject's given a split dose - 15 mglkg on day 0, 10 mglkg on day 1. 
eL, 
[ 7 x 15000 (-v·
1 
-7.1)] C. = x e ' -e 
I (7x VJ-CLi 
10000 -eL, (1-1) [ 7x ( v' -7(1-1»] + x e' -e' (7x Vi)-CLi 
------------ (6.2) 
The subject's given a single dose - 25 mglkg on day 0 
eL, 
7 x 25000 (-v·1 -7.1)] C -[ x e ' -e 
i - (7 x V) - CLi ------------- (6.3) 
The mechanism-based differential equation (equation 6.1) cannot be integrated analytically 
and instead was integrated numerically using a FORTRAN NAG (Numerical Algorithms 
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Group, Oxford, UK) routine, 'D02EAF', that employs a Runge Kutta method (Farlow, 
1994) to numerically integrate the differential equation. 
6.2.3 Statistical model 
A lognormal error model was used to characterise the residual intra-individual error: 
JdP" JdP .. loge ( d:) = loge ( d;1J ) + eij 
In which Pij is the jth observed parasite count for the ith individual and Ppij is the predicted 
parasite count for the ith individual. Eij is the residual intra-individual error term and is 
assumed to be randomly Normally distributed with zero mean and variance (J2. 
The inter-individual variability in the PD parameters was modelled according to an 
exponential variance model; that is, it was assumed that the PD parameters are log-
normally distributed: 
kt 
e.g. k. i = k. x exp(17i ) 
where kJi is the kl parameter of the ith individual, kl is the popUlation mean parameter, and 
llikl expresses the random difference between kli and k l . The values for llikl are normally 
distributed with zero mean and variance (JkI 2. 
6.2.4 Data analysis 
The PD model was fitted to the data with the nonlinear mixed effects modelling 
programme NONMEM (version IV) using a popUlation approach (Beal and Sheiner, 
1979). The programme applies the first-order conditional estimation method (Beal and 
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Sheiner, 1992) to obtain the population PD parameters, the inter-individual variability in 
these parameters and the residual intra-individual variability. The best PD model was 
assessed using the NONMEM objective function and inspection of scatterplots of the 
residuals versus the predicted values. A difference in the objective function of greater than 
3.84 (X2 value for 1 degree of freedom) for an additional parameter in the model was 
interpreted as a significant change in the fit (p-value<0.05). 
6.3 Results 
One hundred and fifty-two patients with acute falciparum malaria between 1990 and 1992 
were available for analysis. Of these 104 were cured (patient did not recrudesce during 28 
days of follow-up) and 33 failed. The remaining 15 patients were last seen with a negative 
malaria smear on the following days: day 7 (1 patient), day 8 (1), day 14 (6) and day 21 
(7). The demographic characteristics of the patients are given in Table 6.1. 
The limit of detection of parasites microscopically is 50 parasites per JlI or a 'Total parasite 
burden' of 2.5*108. Parasite counts that were recorded as zero were therefore excluded 
since the parasitaemia could be anywhere between 0 and 50 parasites per JlI (i.e. a parasite 
burden between 0 and 2.5*108 parasites). 
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Table 6.1:- Demographics and admission characteristics of patients receiving mefloquine 
monotherapy (n=152). 
Cured (n=104) Failed (n=33) Unknown (n=15) 
Year of Study 1990 - N=44 1990 - N=9 1990 - N=10 
1991 - N=60 1991- N=24 1991 - N=5 
Males N (%) 56 (54) 25 (76) 8 (53) 
Age (years)3 16 (13.6-18.3) 13 (9.3-16.7) 15.6 (8.2-23.0) 
[1.5-54] [0.8-51 ] [2.7-54] 
<5 N(%) 10 (10) 6 (18) 2 (13) 
5-14 N(%) 52 (50) 15 (46) 7 (47) 
>14 N(%) 42 (40) 12 (36) 6 (40) 
Weight (kgt 32.6 (29.7-35.6) 29.2(23.3-35.1) 31.5(22.2-40.9) 
[8-61 ] [8-59] [10-55] 
Primary Infection 85 (82) 19 (58) 9 (60) 
N(%) 
Fever on admission 75 (72) 22 (67) 10 (67) 
N(%) 
Prolonged history of 65 (73) 21 (70) 12 (92) 
fever N (%)* 
Pure P. falciparum 85 (86) 32 (100) 13 (93) 
infection N (%)* 
Haematocrit (%) 3.* 35.6(34.2-36.9) 33.3(30.2-36.4) 30.6(26.2-35.0) 
<30% N(%) [20-55] [21-44] [15-35] 
8 (11) 4 (25) 3 (30) 
Parasite count per ~1 3014 (2096-4334) 5119 (2799,9360) 3968 (1326,11877) 
blood b [50-101274] [249-114660] [243-146080] 
>10,00011l1 N(%) 28 (27) 15 (46) 4 (27) 
a - mean (95% CI) [range] 
b - geometric mean (95% CI) [range] 
• _ missing data for some patients (for haernatocrit: cured n=72, failed n=16, unknown n=10). 
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6.3.1 Patients defined as 'cured' 
For the 119 patients that were cured (including the 15 patients who did not return for a 
blood smear on day 28) only 246 detectable parasite counts were recorded (median number 
per patient = 2, range = 1 - 4, see Table 6.2). These patients add little information for the 
modelling especially since a time lag of one day for the PD response to the drug was 
included in the model. 
Table 6.2 Number of detectable parasite counts recorded for patients defined as 'cured'. 
Day Frequency 
0 119 
1 73 
2 42 
3 12 
Total 246 
6.3.2 Patients defined as 'failure' 
The 33 patients who failed within 28 days had a total of 136 parasite counts (detected 
microscopically) recorded (median number per patient = 4, range = 2-7, see Table 6.3). 
Twenty ofthe patients received mefloquine as a split dose and 13 received mefloquine as a 
single dose. 
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Table 6.3 Number of detectable parasite counts recorded for patients defined as 'failure'. 
Day Frequency 
0 33 
1 25 
2 22 
3 15 
4 4 
5 2 
6 3 
7 2 
9 1 
14 2 
19 2 
21 10 
22 
23 2 
28 12 
Total 136 
6.3.2.1 Population phannacokinetic-phannacodynamic modelling 
Two of the parameters were entered into the model as fixed values:-
a = 1.04 /day, growth rate constant of the parasite. 
This corresponds to the parasite multiplying and successfully re-invading 8 red cells every 
2 days (48 hours). The value of8 is the population mean parameter estimate of the parasite 
multiplication rate (PM~8) derived in Chapter 5. 
y = 2.5, slope of concentration effect curve. 
The value of 2.5 corresponds to the population mean parameter estimate derived from 
population modelling of the in vitro data in Chapter 4. It has been assumed that the slope of 
the concentration-effect curve in vitro is the same as in vivo. 
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The above two parameters were fixed because there is insufficient data to estimate all five 
parameters. 
The parameters estimated from the data were the following:-
Po - total parasite burden at admission 
k\ - rate constant of parasite killing 
c50 - drug concentration that kills 50% of the parasites 
Using the posterior individual specific PK parameter estimates obtained from the 
population PK modelling performed in Chapter 3, whole blood mefloquine concentrations 
were simulated for the same times at which the individual's parasite counts were recorded. 
The mefloquine concentrations were simulated using equations 6.2 or 6.3 depending on 
whether the patient received a split or single dose respectively of mefloquine monotherapy. 
This gave 136 paired observations of parasite count and mefloquine concentration data. 
Figure 6.1 a is a scatterplot of the observed total parasite burden versus time for all 33 
patients. Figure 6.1 b is a plot of the predicted mefloquine concentrations versus time. At 
day 1 the simulated mefloquine concentrations are zero because it has been assumed that 
there is a time lag of one day before a reduction is observed in the peripheral parasite 
count. Estimates of the population parameters and their variability obtained from the 
sequential PK-PD modelling are given in Table 6.4. The data did not permit estimation of 
the inter-individual variability of all three PD parameters, especially for the parameter C50• 
The model that best fitted the data included inter-individual variability for both k\ and Po. 
The population mean parameter estimate for k\ was observed to be 3.25 which equates to 
mefloquine reducing the number of parasites approximately 80 fold every 48 hours. The 
posterior individual estimates of k\ varied from 1.12 up to 4.53 (i.e. reducing parasites 
from 1.17 up to 1,111 fold every 48 hours). The population mean parameter estimate for 
the total parasite burden on admission (Po) was 5.9* 109 and the posterior individual 
estimates varied from 1.5*109 up to 2.1 *1010. The drug concentration which kills 50% of 
the parasites, C50, was estimated to be 760 ng/m!. Therefore the average MIC in vivo for 
mefloquine against P. falciparum prevalent at the time of the study which caused 
recrudescent infections was 562 ng/ml (since MIC = C50*((kl-a)/arl/y, see section 4.2.2 of 
Chapter 4). 
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Figure 6.1a. The observed parasite counts (log transformed) over time 
for the 33 patients' who failed treatment during 28 days of follow-up. 
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Figure 6.1b. The simulated whole blood mefloquine levels (ng/ml) at 
the time points where the parasite counts were recorded for the 33 
patients' who failed treatment during 28 days of follow-up. 
8 
~ 
30 
Table 6.4:- Population pharmacodynamic parameters derived from sequential nonlinear 
mixed effects modelling of the parasite count and mefloquine concentration data. 
Parameter 
a (lday) 
y 
Lo~(Po) 
Po 
kl (lday) 
Cso (ng/ml) 
MIC in vivo (ng/ml) 
(J)eso 
(residual error, units -lo~P) 
Estimate (SE) 
Fixed at the value of 1.04 
(i.e. a PMRts of 8 fold) 
Fixed at the value of2.5 
22.5 
5.9*109 
3.25 
760 
562 
0.87 
0.34 
not estimated 
1.46 
* - normal distribution; 1\ - lognormal distribution 
95% Prediction Interval 
1.07*109 - 3.25*1010 
1.67 - 6.33 
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Figure 6.2 shows the observed parasite counts, population predicted values and individual 
predicted values versus time for the 33 patients who failed within 28 days. The population 
predicted profile has at the same time point different predicted values of the total parasite 
burden. This is because the model (equation 6.1) does not just include parameters (e.g. k l ) 
but also a variable that represents the mefloquine concentration (Ci) for the ith patient. For 
some patients (n=22) the model predicts that the patient should have been cured but instead 
they actually failed. Figures 6.3a and 6.3b are examples of two patients. Figure 6.3a is of a 
patient that the population predicted values predicted the patient should have been cured 
while the individual predicted values predicted the patient failed. Figure 6.3b represents a 
patient that both the population and individual predicted values predict the patient is cured. 
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Figure 6.2. Observed parasite counts (0), population predicted values ( .. ) 
and individual predicted values (e) versus time for the 33 patients' who 
failed treatment during 28 days of follow-up. 
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Figures 6.3a & 6.3b. Observed parasite counts (0), population predicted 
values (.) and individual predicted values (.) versus time for two of the 
patients' who failed treatment during 28 days of follow-up. 
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6.3.2.2 Relationship between pharmacodynamic parameters and covariates 
The parameter estimates given in section 6.3.2.1 predict that 22 of the observed failures 
should have been cured. These 22 subjects include all 20 subjects that received a split dose 
and two subjects that received a single dose of mefloquine. These patients that the model 
incorrectly predicted were not different from the remaining 11 patients in age or admission 
parasite count but did have a significantly lower temperature on admission (see Table 6.5). 
The patients included in these studies had no evidence of receiving quinine within the 
previous 7 days, nor mefloquine or sulfadoxine-pyrimethamine within the previous 14 
days. After 1994, on the basis of completed studies, these inclusion criteria were modified. 
Patients were only included in future studies and classified as a primary infection if no 
antimalarial medication had been given in the preceding 63 days. Historical data of the 
treatment of the 33 patients was looked over by a medical physician. Patients were then 
classified as either a primary or secondary infection according to the new definition of a 
primary attack. Only 19 of the 33 patients were observed to be a primary infection 
according to the new definition. Of the patients incorrectly classified by the model only 
41 % (9/22) were primary infections while 90% (10/11) of those patients correctly 
classified by the model were primary infections (Table 6.5). An individual's therapeutic 
response is determined by several factors including baseline parasite burden, degree of 
immunity, drug levels and drug responsiveness of the infecting parasites. It is likely 
therefore that these patients were infected by relatively resistant parasites. 
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Table 6.5:- Association between model predictions and demographic and disease related 
factors. 
Demographic or disease 
factor 
Age of patiene 
<5 years 
5-14 
>14 
Temperature on 
admissionb 
Parasite count on 
admissiona 
Primary infection 
Model predicted failure 
(correct, n= 11) 
14(0.8,51) 
2 (18%) 
4 (36%) 
5 (46%) 
38.4 (0.97) 
1.1*1010 
(7.9*108,4.2*10 11 ) 
10 (90.9%) 
a - median (range); b - mean (SO) 
6.3.2.3 Sensitivity analyses 
Model predicted cure 
(incorrect, n=22) 
10 (1.2, 28) 
4 (18%) 
11 (50%) 
7 (32%) 
37.5 (1.02) 
1.5*1010 
(6.7*108,8.6*1010) 
9 (40.9%) 
p-value 
0.418 
0.019 
0.749 
0.009 
Varying the values of the fixed parameters 'a' and 'y' did not improve the fit of the model 
to the data. For example, if the parameter 'a' is increased to 1.15 (i.e. a PM~8 of 10 fold) 
then the model compensates by reducing k\ to a very small (unrealistic) number in order to 
fit the data. The computer programme displays a warning stating that the estimate of k\ is 
very close to the lower boundary of the parameter and is probably not interpretable. Figure 
6.4 is a scatterplot of the observed and population predicted parasite counts versus time for 
the model with 'a' fixed at 1.15 and 'y' fixed at 2.5. The model predicts that in the first 
week of infection the total parasite burden hardly changes (estimates k\, the rate constant 
of parasite killing, to be 1.38, that is reducing the parasites approximately 1.6 fold every 48 
hours). However the observed parasite counts decrease and drop below the level of 
detection before reappearing a week or more later. 
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Figure 6.4. Observed parasite counts (0) and population predicted values 
( ... ) versus time for the 33 patients' who failed treatment during 28 days 
of follow-up (fixed parameters: 'a' = 1.15 and 'y'=2.5). 
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6.4 Discussion 
The mechanistic PD model described in this chapter represents the change in total parasite 
burden over time and could be used to predict the response of different dosing regimes or 
for differing areas of resistance. Sequential PK-PD modelling of paired parasite count and 
mefloquine concentration data has been performed to investigate if the mechanistic PD 
model fits the observed parasite count data. 
6.4.1 Summary of findings 
The mechanistic PD model did not successfully predict the parasite count data for 22 of the 
patients. This means that the current model with the five parameters (k), C50, Po, a and y) 
and mefloquine levels is too simple to predict correctly the response for all patients. Some 
of the patients were not primary infections, and perhaps were significantly more resistant 
than the other infections in this series. Thus no model based on PK data and quantifiable 
PD parameters could ever predict those patients to fail. 
Recrudescence could not be distinguished reliably from re-infection because the study took 
place in an area of malaria transmission. Using data collected from the health clinics in the 
camps, ter Kuile et al. (1993b) estimated that during the study the mean risk of new 
symptomatic P. Jalciparum infections was 4.8% (95% confidence interval: 4.4 - 5.2%) per 
28 days. If it is assumed that patients are protected for 14 days by prophylactic drug 
concentrations after treatment with mefloquine then 2.4% (95% confidence interval: 2.1 -
2.7%) of the study patients would have a new symptomatic infection during the 28-day 
followup period. In other words it is possible that 4 of the 33 patients classified as a 
recrudescence were actually harbouring a new infection. 
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The results from the sequential PK-PD modelling did give realistic population mean 
estimates for the parameters, k\, Cso and Po. White et al. (1997) proposed that the killing 
action ofmefloquine was between 10 & 1000 fold every 48 hours and Price et al. (1999a) 
proposed that the MIC in vivo of mefloquine was approximately 500 ng/ml. From the 
modelling of the current data k\ was estimated to be 80 fold every 48 hours and the MIC in 
vivo to be 562 ng/ml. 
6.4.2 Limitations of sequential pharmacokinetic-pharmacodynamic modelling 
Sequential population PK-PD modelling is relatively new and there are problems 
associated with the method. To model successfully the response, a reasonable range of 
concentrations across subjects is required. It is also important to choose the appropriate 
response for the PO model. In other words the clinical relevance, ease of measurement, 
variability in the response and overall sensitivity to changes in drug concentration need to 
be considered. 
Instead of using sequential PK-PD modelling, simultaneous PK and PD modelling (see 
section 1.2.3.2 for more details) could have been applied to the data. General opinion is 
divided between whether it is more informative to perform a simultaneous or sequential 
analysis. Despite this debate, it is well established that the presence ofPK data (even small 
amounts of suboptimally sampled PK data) improves the precision of the estimates of the 
PD parameter values (Hashimoto and Sheiner, 1991). 
6.4.3. Limitations of the model 
The PD model presented in this chapter does not include any parameters to represent the 
stage-specific killing action of mefloquine. However a lag phase of one day was included 
to account for the stage-specificity of mefloquine. The antimalarial mefloquine has a long 
half-life and therefore it may not be so important to include in the model the stage-
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specificity of the drug. Conversely for a drug with a short half-life such as artesunate the 
stage dependency of the drug is important. Svensson (2000) used the life cycle of the P. 
falciparum parasite as the basis for a mechanistic model to address the PD effect of 
artemisinin, mefloquine and the combination. The model consisted of four parasite 
compartments representing different asexual parasite stages (ring stages, early 
trophozoites, late trophozoites and schizonts). Models in which mefloquine acted on a 
different number of parasite compartments did not describe the data better than a model in 
which mefloquine acted on all four parasite compartments. 
The model also does not include a parameter to represent immunity. However the 22 
patients incorrectly predicted by the model had a similar age distribution to the eleven 
patients correctly predicted (see Table 6.5). 
6.4.4 Limitations of the data 
The observed data is limited to the relatively narrow range of detectable parasites (i.e. > 
2.5 * 108 parasites). This means there is little information for estimating the concentration 
where 50% of the parasites are killed because at these concentrations the number of 
parasites in the blood cannot be detected. Any parasite counts recorded as zero (i.e. below 
the level of detection) were excluded from the analyses. Whether to exclude these values 
or set them to the limit of determination is much debated in the field of pharmacokinetics. 
Rahman et a1. (1999) examined the effect of deleting time points at which the drug 
concentration was recorded as below the limit of quantification, as opposed to including 
these points as censored observations. They observed that including the censored data 
results in greater precision of the PK parameters. Additionally the parameter representing 
the final slope of the curve becomes steeper when the censored data are included giving 
rise to smaller half-lives of the drug. The model fitted to the data was a 3-compartment 
model, which is an exponentially decreasing function. The model presented in this chapter 
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is a parabola and the parasite counts below the level of detection occur around the 
minimum of the parabola. Thus exclusion of these data points may have an even greater 
impact on the parameter estimates besides the reduced precision identified by Rahman et 
al. (1999). 
Another problem regarding the observed parasite count data is that the observed data only 
represents the parasitised red blood cells in the peripheral blood (not the sequestering 
parasites). Depending on the distribution of the age of the parasites, the number of 
parasites in the peripheral blood may represent only a fraction of the total parasite burden. 
More severe infections have been thought to be related more to the sequestering parasites 
than to the younger stages circulating in the blood (White, 1998). 
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7. SUMMARY AND IMPLICATIONS FOR FUTURE RESEARCH. 
Despite the high rates of mortality and morbidity associated with malaria very few new 
antimalarial drugs are being developed (Trouiller and Olliaro, 1999). Hence there is much 
to be gained by optimising currently available antimalarials. Mefloquine is the most widely 
used drug for the treatment of multi drug-resistant falciparum malaria. Using 
pharmacokinetic (PK) and pharmacodynamic (PD) data from field trials, where mefloquine 
was administered either alone or in combination with artesunate, important information 
regarding dosing for the clinician has been obtained. Moreover a mechanistic PO model 
has been derived which can be used as a prediction tool for therapeutic efficacy of 
mefloquine for differing dosages and differing areas of resistance. PK, PD (in vivo and in 
vitro) and malaria therapy data have been modelled to obtain estimates of the parameters in 
the mechanistic PO model. 
7.1 Population pharmacokinetics of mefloquine. 
In Chapter 3 a retrospective population PK analysis of mefloquine data from patients 
receiving mefloquine as part of trials conducted between 1990 and 1995 was performed. 
The population PK analysis was performed to provide information that would help to 
optimise the dosage of mefloquine, both when used alone and in combination with an 
artemisinin derivative. 
The study population consisted of 257 patients treated for uncomplicated P. Jalciparum in 
malaria clinics situated on the western border of Thailand. There were four different 
treatment groups; mefloquine monotherapy (25 mglkg (single dose) or 25 mg/kg (split 
dose: 15 mglkg on day 0 followed by 10 mglkg 24 hours later)} and combined therapy of 
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mefloquine and artesunate (mefloquine given as either a single dose or a split dose). In 
total 432 whole blood mefloquine concentrations were available for data analysis from the 
patients receiving mefloquine monotherapy, ranging between I and 7 per individual 
(median 3). This data set was generally "sparse" as 50% of the patients had 3 or less blood 
samples recorded. For the patients receiving combined therapy 588 whole blood 
mefloquine concentrations were available, ranging between 3 and 7 per individual (median 
6). 
The mefloquine PK were influenced relatively little, or not at all, by factors such as age, 
sex, or measures of acute malaria severity. Splitting the 25 mg/kg dose of mefloquine 
monotherapy was associated with a 50% increase in oral bioavailability, and bioavailability 
increased by 20% for the split dose on the combination treatment. Oral bioavailability was 
also observed to be associated with more rapid parasite clearance, a surrogate outcome 
measure for cure. The apparent volume of distribution (V IF) was significantly lower in 
patients' receiving split doses of mefloquine monotherapy (mean 8.14 l/kg; 95% CI: 7.49 
to 8.86 l/kg) compared with a single dose (mean 20.37 l/kg; 95% CI: 16.26 to 25.51 l/kg). 
If it is assumed that apparent clearance and volume of distribution are unaffected by dose 
regimen, then splitting the 25 mg/kg mefloquine dose improves oral bioavailability and the 
therapeutic response in the treatment of acute falciparum malaria. 
7.2 Mefloquine pharmacokinetic-pharmacodynamic model. 
In Chapter 4 a mechanistic mathematical model was developed that describes the change in 
total parasite burden with time in vivo, in the presence of mefloquine. The model consists 
of seven parameters: two of which represent the PK of mefloquine, and another two PO 
parameters that represent the mefloquine concentration effect curve. Estimates for these 
PK and PD parameters were obtained from population modelling of PK and in vitro PO 
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data from the same region (i.e. western border of Thailand) respectively. The other three 
parameters: parasite multiplication rate, total parasite burden on admission, and mefloquine 
parasite killing rate, were estimated using values from the literature. 
Model simulations confirmed that, early in the evolution of resistance, conventional 
assessments of the therapeutic response 28 days after treatment underestimate considerably 
the level of resistance. Longer follow-up is required. The model also indicates that initial 
deployment of a lower (IS-mg/kg) dose of mefloquine provides a greater opportunity for 
the selection of resistant mutants and would be expected to lead more rapidly to resistance 
than de novo use of the higher (25-mg/kg) dose. 
7.3 Population dynamics in vivo ofthe natural infection of falciparum malaria. 
In Chapter 5 estimates were obtained for the parasite multiplication rate every 48 hours and 
periodicity of the parasite cycle from modelling of a unique dataset. In the early part of the 
20th century, before the introduction of penicillin, patients suffering from neurosyphilis in 
Europe and the United States were treated by inducing a protracted attack of falciparum or 
vivax malaria. The number of parasites within a patient was recorded daily, and these 
records provide a unique source of information regarding the natural history of malaria in 
the non-immune adult host. The statistical modelling of the data was restricted to the first 
week of patent parasitaemia, the period of growth when host defences have minimal effect. 
The patient parasitaemia versus time profiles varied greatly between patients. Parasite 
multiplication rate every 48 hours was estimated to be approximately 8 fold with a 95% 
prediction interval of 5.5 up to 12.3 fold. The parasite life cycle was estimated to be 55 
hours, however this estimate is highly dependent on the sampling interval of one day. 
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7.4 Sequential pharmacokinetic-pharmacodynamic modelling for mefloquine 
Sequential PK-PO modelling was performed in Chapter 6 on paired parasite count and 
mefloquine concentration data collected from 33 patients whom recrudesced (RI 
resistance) following treatment with mefloquine monotherapy. A patient suffering from P. 
falciparum can recruduesce due to a number of factors including the killing rate, 
absorption and plasma half-life of the drug, and the drug susceptibility of the parasite. The 
mechanism based PO model used for the sequential PK-PD modelling included parameters 
for the killing rate and PK of the drug and successfully fitted 11 of the patients. The 
remaining 22 patients were predicted by the model to be radically cured. Thirteen of these 
patients did not have primary infections and therefore could contain parasites that are 
highly resistant to mefloquine, a difficult confounder to measure and include in the model. 
Approximately four of these patients could have new infections as opposed to 
recrudescences. Techniques now exist to differentiate between treatment failures and new 
infections but these were not available during 1990 and 1991, the years when the parasite 
count and mefloquine concentration data were collected. 
Although the current mechanistic PD model did not successfully fit 66% of the patients it 
is one of the few attempts where a mechanistic PD model for mefloquine has been 
sequentially fitted to parasite count and mefloquine concentration data. Reasons for the 
poor fitting could be: recrudescences actually being new infections, secondary infections 
(i.e. retreated infection), major sequestering of the parasites in the first week of patent 
parasitaemia, sparseness of the observed parasite count data, model misspecification and 
finally logistic reasons, that is microscopic level of detection. 
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7.5 Further issues and future research 
The development of population PK-PD models provides a framework for optimisation of 
antimalarial dosing regimens. The modelling presented in this thesis provides a good start 
for future PK-PO models. However there are two main areas that need to be discussed and 
researched further. 
1) Does the mechanistic PO model developed in this thesis need to be extended to include 
more parameters describing the intra-host malaria dynamics before it can inform 
clinicians regarding optimal dosing and the development of drug resistance? (section 
7.5.1) 
2) Can the approach to PK-PD model development for mcfloquine in this thesis be 
utilised for development of PK-PD models of other antimalarial treatments? (section 
7.5.2) 
The PK and PD parameters of mechanistic PD models need to be estimated from PK and 
PD data. Besides retrospective modelling of datasets currently available, new data need to 
be collected with the aim of using the data for popUlation PK-PD modelling. With the 
collection of more detailed parasitaemia data, the mechanistic PD model presented in this 
thesis could be expanded to analyse parasite age structure more accurately. Guidelines 
regarding the design of population PK and PD studies are presented in section 7.5.3. 
7.5.1 Current mechanistic pharmacodynamic model requires more parameters? 
The mechanistic PD model described in this thesis did not adequately describe all 33 
patients who recrudesced within 28 days. Many reasons for this lack of fit have been 
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discussed in Chapter 6. For example, the model needs more parameters to describe the in 
vivo parasite versus time relationship. Currently the model has only one parameter that 
describes the change in parasite burden over time in the absence of drug, that is the parasite 
multiplication rate. Other factors that change the parasite burden with time include host-
immunity (both non-specific and specific), synchronicity of the parasite distribution, and 
sequestration of the parasites. 
7.5.1.1 Host immunity 
The natural immunity of a patient can affect the dynamics of the P. falciparum infection. 
The mechanistic model (equation 6.1, Chapter 6) could be extended to include a function 
that represented the immunity of a patient (see below). 
where f(l) is a function representing host immunity. 
Three possible measures to represent immunity that are easily obtainable from patient data 
are the age of the patient, the temperature of the patient at each parasite recording and the 
size of the patient's spleen. Another measure to represent host immunity is the host's 
previous exposure to malaria, also obviously a function of age, however this is highly 
unreliable due to recall bias. Bruce et al. (2000) observed that infections often last for 
several weeks in young children but generally for only a few days in adults. This variation 
is widely held to be a result of acquired immunity, resulting from multiple infections. 
Consequently the age of the patient could be used as a surrogate measure for natural 
immunity. Note the level and variation of immunity across different age groups will differ 
for areas of high and low transmission of P. falciparum. 
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Another measure investigated to represent non-specific host immune defences was the 
presence of fever (Kwiatkowski and Nowak, 1991; Gravenor and Kwiatkowski, 1998a). 
Fever was found to be the main regulatory factor of parasite burden (in the absence of 
drug) for the early part of the infection. The models investigated the early control of P. 
Jalciparum density through a toxic feedback system. Once the parasite rose above a value 
called the "pyrogenic threshold", fever would develop and suppress parasite growth. 
However it is difficult to assign a single level to represent the pyrogenic threshold of all 
patients. Jeffery et al. (1959) demonstrated that malaria therapy patients vary by orders of 
magnitude in the density at which they control their parasitaemia and in the parasite 
density associated with first fever. The pyrogenic threshold of the patient may be a better 
measure of immunity. The patient data modelled in this thesis consisted of symptomatic 
patients. Thus their pyrogenic threshold is equal to or below the parasitaemia recorded on 
admission; a parameter already included in the mechanistic PD model. 
Spleen size is sometimes used as a marker of endemicity (Gilles, 1993) and therefore is 
linked to immunity. It usually reflects previous contact with malaria and non-specific 
immunity. During a P. Jalciparum infection the spleen within a patient rapidly enlarges to 
clear the parasites from the circulating red cells (Angus et al. 1997; Chotivanich et al. 
2000b). 
All of the measures mentioned above represent non-specific measures of host immunity. 
Specific measures of host immunity such as antibodies and cell mediated responses are 
very difficult to quantify and measure especially when the patient has a new active 
infection. 
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7.5.1.2 Synchronicity 
The age of the P. falciparum parasites range from 0 to 48 hours. The tenn 'synchronicity' 
represents the spread of the age of the parasites in a single infection. A highly synchronous 
infection means the age of the parasites within the patient are very similar whereas an 
asynchronous infection represents a patient harbouring parasites of all ages. Infections that 
are synchronous will have periodic peripheral parasite versus time profiles. However 
asynchronous infections will have non-fluctuating parasite-time profiles. White et al. 
(1992a) suggested a simple mathematical model to describe the changes in circulating and 
sequestered parasite numbers with time. The model uses two parameters only; the standard 
deviation of parasite age as a measure of synchronicity, and a multiplication factor each 48 
hour asexual life cycle. Hoshen et al. (2000a) combined the two methods of White et al. 
(1992a) and Anderson et al. (1989) to fonn a single model that explains the periodicity of 
malaria and includes immunity and chemotherapy. In both of the above studies parasite-
time profiles were simulated and compared visually to observed patient data. No attempt 
was made to estimate the parameters from the data using statistical modelling techniques. 
Svensson (2000) included in their model a parameter that represented the time for one life 
cycle in the average parasite, that is parasite mean residence time. They stated that by 
varying this parameter the parasites are allowed to distribute over the four compartments 
(ring stages, early trophozoites, late trophozoites and schizonts) during the two life cycles 
before the introduction of drug into the system. Individuals with parasites that have similar 
residence times are highly synchronised. This will account for the possibility of infections 
being more synchronised in some patients compared to others. Although the parameter 
does not measure the synchronicity of an infection it does present a way of taking account 
of the variation across patients resulting from synchronicity. Unfortunately the data did not 
support estimation of parasite mean residence time and the corresponding inter-parasite 
variability. Instead parasite mean residence time was fixed at 48 hours. 
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The synchronicity of an infection varies markedly across patients. In Chapter 5 some of the 
malaria therapy patients had periodic parasitaemia-time profiles whereas some had profiles 
that did not osciIlate. For the empirical model fitted to the malaria therapy patients the 
amplitude of the sine wave of equation 5.2 could be considered to empirically represent the 
synchronicity of an infection. Patients with very large amplitudes have highly synchronous 
infections whereas moderately synchronous infections have amplitudes close to zero. Non 
fluctuating patient parasite profiles could not be fitted by equation 5.2 because there was 
no periodicity in the profiles. 
In vivo it is not possible to measure the synchronicity of an infection as not all parasite 
stages are present in the peripheral blood. Therefore to calculate the total parasite burden 
and the number of parasites within each stage one needs to extrapolate from data collected 
which describes the distribution of parasite stages in the peripheral blood. Retrospective 
investigation of blood films from severe and non-severe infections confirmed that a 
predominance of mature parasites in the peripheral blood reflects a greater sequestered 
biomass, and thus more severe disease (Silamut and White, 1993). Staging of intra-dermal 
smears has also been performed (Nakazawa et al. 1995). In the intra-dermal smears later 
stages of the parasite have been observed and this smear may therefore be a better 
represcntation of the distribution of all parasites. However staging of both peripheral blood 
and intra-dermal smears still only represents proxy distributions of the parasite age. Even 
with these proxy distributions of parasite age it is still difficult to mechanistically quantify 
synchronicity. The proposed model presented by Svensson (2000) did not give a measure 
of synchronicity but did take into account the synchronicity of an infection using a measure 
of parasite mean residence time. Further research involving data that includes some 
knowledge of the parasite distribution (i.e. peripheral parasite count data where staging has 
been performed) is required to fully quantify the models based on the parasite's life cycle. 
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7.5.1.3 Sequestration 
One of the major problems associated with modelling of fa\Ciparum malaria is that the P. 
falciparum parasite disappears from the blood after about 24 - 26 hours. This process is 
known as sequestration and accounts for the discrepancy between peripheral blood 
parasitaemia (microscopically visible) and total parasite burden. Clearly it is difficult to 
fonn a reliable picture of the response to antimalarial therapy without knowing the 
behaviour of the sequestered parasite population. Unfortunately there is no direct method 
of measuring the sequestered parasites. Gravenor et al. (1 998b ) developed an age-
structured mathematical model with two compartments (circulating and sequestering 
parasites) that allows the number of sequestered parasites to be estimated from sequential 
observations of parasitaemia on peripheral blood smears. Their results suggest that 
peripheral parasitaemia can predict clinical outcome (e.g. recrudescence), but only insofar 
as it reflects the number of sequestered parasites. This is not the case in highly 
synchronous infections or during treatment with an antimalarial drug that acts on a specific 
stage of parasite development. Note the patient data used in the modelling was from severe 
malaria patients treated with the short acting drugs, artesunate and quinine. The model 
developed in this thesis was for mefloquine, a drug with a long-half life used for treating 
patients with uncomplicated malaria. 
Often mechanistic models are criticised for not having parameters describing every feature 
of the disease. However a model cannot encompass every feature, but hopefully the 
missing features are not crucial (McKenzie, 2000). The value of a mathematical model is 
its ability to identify what factors are important and need to be considered when deciding 
on drug policies. The model suggests that the evolution of resistance can be substantially 
delayed by the appropriate choice of drug treatment regimen (Hastings and D'Alessandro, 
2000). 
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7.5.2 Application of population pharmacokinetic-pharmacodynamic modelling to other 
antimalarials 
Population PK modelling has been applied to lumefantrine (Ezzet et a1. 2000), artemisinin 
(Sidhu et al. 1998), proguanil (Hussein et al. 1996), atovaquone (Hussein et al. 1997), 
and both mefloquine and artemisinin (Svensson 2000). For lumefantrine the prospective 
population PK-PO study found the area under the concentration-time curve (AUe) to be 
the principle determinant of antimalarial activity. For artemisinin, Sidhu et al. (1998) 
failed to identify any associations between the PK and PD parameters. For proguanil and 
atovaquone, retrospective population PK analyses of data from Phase WIll clinical trials 
were perfomled to examine the effect of patient covariates and dose. Svensson (2000) 
performed population PK modelling to investigate whether artemisinin influences the PK 
of RS- and SR- enantiomer of mefloquine. Further, a PD parasite model was developed, 
based on the parasite's life cycle describing the efficacy of artemisinin, mefloquine and a 
combination of the two drugs. 
Mechanistic PO models have been developed for chloroquine (Hoshen et a1. 1998), 
artesunate (Hoshen et al. 2000b), and both mefloquine and artemisinin (Svensson 2000). 
For both chloroquine and artesunate, simulations for different dosages, etc. were presented 
but no formal fitting of the model to PK-PD data was performed. The mefloquine PD 
model presented in this thesis was an extension of the chloroquine PD model including a 
parameter for the slope of the concentration-effect curve. The model for artesunate 
included stage specificity of the drug action since artesunate has a very short half-life. It 
was observed that standard PK-PD modelling failed to explain the clinical results and lead 
to the postulation that a small fraction of the parasites, as a result of chemotherapeutic 
pressure, become cytostatic or 'dormant'. Svensson (2000) developed a mechanistic PO 
parasite model that was based on the parasite's life cycle (defined as 4 stages: ring stages, 
early trophozoites. late trophozoites and schizonts), and the PK of the antimalarial drugs. 
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The PO parameters were estimated using population sequential PK-PD modelling of the 
patient parasite density-time profiles. The mechanism-based PD model successfully 
predicted the antimalarial effect of artemisinin, mefloquine and a combination of the two 
drugs. 
The mechanistic PO model developed in this thesis could be adapted for application to 
other antimalarial treatments. It is a simple model where the essential parameters can be 
estimated from clinical and laboratory data. Two major factors need to be considered when 
adapting the model for other antimalarial drugs: the plasma half-life and stage specific 
action of the antimalarial. Antimalarial drugs vary greatly in both stage-specificity (ter 
Kuile et al. 1993a; Geary et al. 1989) and plasma half-life (White, 1992c) and both of 
these factors can have major effects on the parasite clearance (White, 1997). Once the 
model has been formulated, formal testing (i.e. sequential PK-PD modelling) and 
validation are required (Machado et al. 1999). The mechanistic PD model could then be 
used to simulate important clinical scenarios to inform the clinician on the optimal dosage 
required for their patients with P. Jalciparum. 
Population PK-PO modelling has been performed successfully for drugs that treat other 
medical conditions. Some examples are the drugs: ivabradine (Duffull and Aarons, 2000), 
ketorolac analgesia (Mandema and Stanski, 1996), theophylline (Holford et al. 1993) and 
levodopa (Triggs et al. 1996). For the drug ivabradine, a novel bradycardic agent that has 
been developed for the prevention of angina, a sequential linked PK and PO simulation 
model was developed. It is intended to use this model as the basis for designing clinical 
trials where exercise tests are the intervention for measurement of the outcomes. For 
ketorolac analgesia, the treatment of moderate to severe postoperative pain, the derived 
population PK-PO model simulated the relationship between dose, time, and the 
percentage of patients with adequate pain relief. The simulations suggested that 30 mg 
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intramuscular ketorolac was the optimal initial dose for postoperative pain relief. For 
theophylline, a treatment for episodes of severe airways obstruction, the PK-PD modelling 
observed that the action of theophylline was most marked at the start of treatment, 
theophylline may no longer have important beneficial effects after 72 hours, and the 
incidence of adverse effects increased at theophylline concentrations >20 mg/I. For 
levodopa, the principle treatment for symptomatic control of Parkinson's disease, the PK-
PD model was observed to have satisfactory predictive performance and may in the future 
prove valuable as a means for optimising individual patient dosage schedules. 
7.5.3 Study design for popUlation pharmacokinetic-pharmacodynamic studies of 
antimalarials 
For new antimalarial drugs it is vital that within the design of the Phase III trial data are 
collected for population PK-PD modelling either from a sub-group of patients or from each 
patient. For current antimalarial drugs, field trials investigating the efficacy of the drug 
need to allow for collection of PK-PD data. Moreover in vitro data should be collected to 
provide information about drug resistance. 
Prospective population PK-PD studies have been performed for the antimalarial drugs, 
lumefantrine (Ezzet et a1. 2000) and artemisinin (Sidhu et a1. 1998). For lumefantrine, 
data were combined from a conventional inpatient PK study of adults and a population 
based community study of patients of all ages. The objective of the study was to identify 
the factors that affect the PK of lumefantrine and thus the therapeutic response. The study 
population consisted of 51 adult patients treated at a hospital in Bangkok, Thailand, and 
215 patients aged more than two years treated at a malaria clinic in Mae La on the western 
border of Thailand. A total of 655 venous samples were available from the 51 patients in 
Bangkok, approximately 14 samples per patient. For the 215 patients from Mae La 793 
capillary samples were available, averaging four samples per patient. All patients were 
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seen daily for the first 5 days and then weekly from day 7 to day 63 for recording of 
parasite count, temperature, subjective adverse effects and a neurological examination. 
Sidhu et al. (1998) performed a prospective study of artemisinin where patients were 
allocated randomly to two blood sampling occasions on day 1 of treatment and where a 
subgroup of patients had a single blood sample taken on day 5. The sampling schemes 
were assessed before the study by using data obtained from a previous study of the PK of 
oral artemisinin in adult patients where many blood samples per patient were collected (12 
samples from each of 15 subjects). The motivation to perform a prospective population PK 
study of artemisinin was the lack of PK knowledge in the paediatric population because of 
the problems associated with performing intensive blood sampling and limitations in 
sensitive analytical methodologies. The study population consisted of 23 children (aged 2 
to 12 years) and 31 adults (aged 16 to 45 years) living in Song Be Province, Vietnam. A 
total of 140 concentrations (107 concentrations on day 1 of treatment, 33 concentrations on 
day 5) were available from 54 patients with acute, uncomplicated P. Jalciparum malaria. 
Blood samples were collected on day 5 to investigate the inter-occasion variability in the 
PK parameters since constancy over time in the PK of artemisinin was unlikely to be a 
valid assumption. The parasitaemia measurements were timed to coincide with blood 
sampling for the PK determinants to investigate the association between the PK of 
artemisinin and the PD outcome measures. 
Population PK-PD studies can form part of large clinical trials where a few blood samples 
are taken from each patient or from a randomly selected sub-group of patients. The 
methods for the popUlation PK-PD study must be part of the protocol. Recommendations 
regarding the design of popUlation PK-PD studies are listed below:-
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1) To determine the timing of blood samples and the number of subjects, computer 
simulation and optimal design methods (D'Argenio, 1981; Mentre et al. 1997; 
Retout et al. 200 I) can be used. These methods ensure that data are collected at 
informative times for estimation of the PK-PO profiles. Note designs involving 
more individuals, even if many are sparsely sampled, dominate designs calling for 
many samples on fewer persons (Hashimoto and Sheiner, 1991). 
2) Patients should be sampled throughout the duration of the study to allow for 
changes over time in the PK parameters (known as inter-occasion variability). 
3) The study investigator should be given a sampling window (that is, a range of times 
rather than a particular time) when a blood sample must be collected. It is important 
that the investigator understands the importance of accurately recording dosing and 
sampling times. 
4) The times of blood sampling should be convenient both to patients and to clinical 
staff. 
7.6 Conclusion 
The development of resistance to antimalarial drugs is a major threat to the health of 
people living in tropical countries. The speed at which resistance develops is affected 
considerably by the pattern of antimalarial drug use. When new antimalarial drugs are 
introduced, dose-ranging studies are performed to determine the optimum dose and 
treatment schedule on the basis of the therapeutic ratio. The prevention of resistance is 
usually not considered in this assessment. With a mechanistic PO mathematical model a 
more effective method exists to inform clinicians regarding drug usage and the 
170 
development of drug resistance. Accurate predictions from the model depend on precise 
estimates of the PK, PD and parasite growth parameters. In this thesis estimates of these 
parameters have been obtained for mefloquine from population modelling of PK, PD in 
vivo, PD in vitro and historical malaria therapy datasets. 
Modem malaria research reqUIres mathematicians and statisticians working alongside 
clinicians and economists. With this multidisciplinary group the costs of resistance in 
terms of both morbidity and perhaps mortality need to be balanced against the cost of an 
antimalarial drug to ensure that the small financial budgets of developing countries are 
used effectively for the current and future burden of malaria. 
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APPENDIX I 
SPLUS programme for fitting a one compartment model. 
Dosing regime - 15 mg/kg at time 0 followed by 10 mglkg 24 hours later. 
# fitting mefloquine with a 1 compartment model (oral dosage) 
compl.oral<-
function(cl,v,DOSE,TIME) 
{ 
((7*DOSE)/((v*7) -cll )*(exp(-(cl/v)*TIME)-exp(-(7*TIME))) 
} 
all.nlme<-
function () 
{nlme(CONC -
(Ql*compl.oral(cl*exp(eta.cl) ,v*exp(eta.v) ,lOOO*DOSE1,Tl)+ 
Q2*compl.oral(cl*exp(eta.cl) ,v*exp(eta.v) ,lOOO*DOSE2,T2) 
) , 
data = pkvensp.comb, 
fixed = list(cl-.,v-.), 
random = list(eta.cl-.,eta.v-.), 
start = list (fixed = c(O.6,20)), 
cluster = -ID, 
re.structure 
var.function 
verbose=T 
) 
} 
lid" , 
II identity" , 
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APPENDIX II 
SPLUS programme for fitting a one compartment model. 
Dosing regime - 25 mg/kg at time 0 
# fitting mefloquine with a 1 compartment model (oral dosage) 
compl.oral<-
function(cl,v,DOSE,TIME) 
{ 
((7*DOSE*1000)/((v*7)-cl))*(exp(-(cl/v)*TIME) -exp(-(7*TIME))) 
} 
all.nlme<-
function () 
{nlme(CONC -
compl.oral(cl*exp(eta.cl) ,v*exp(eta.v) ,DOSE,TIME), 
data = pkvensi.comb, 
fixed = list(cl-.,v-.), 
random = list(eta.cl-.,eta.v-.), 
start = list (fixed = c(O.6,20)), 
cluster = -ID, 
re.structure 
var.function 
verbose=T 
) 
} 
"d", 
II identi ty" , 
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APPENDIX III 
dP To find PI integrate 
dt 
dP 
- = a.P- f(C).P 
dt 
substitute C
Y 
f(C) = k * Y 
I CY + c
so 
thus 
-= a-k * *P dP [ (C
Y
)] 
dt I C Y +cs/ 
dP 
- =f(t)*P 
dt 
[since C is a function of time and a, k" y& C50 are constants] 
Using the separation of variables method to integrate:-
C Y ff(t)dt = a.t - k, * f dt CY +C Y 50 
where 
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APPENDIX IV 
SPLUS programme for fitting an inhibitory sigmoid Emax effect model. 
# fitting concentration-effect curve to mefloquine 
compl.invitro<-
function(a,b,ic,g,M.CONC) 
{ 
(b -(b-a)*((M.CONCAg)/((M.CONCAg) + ((ic Ag)/9)))) 
} 
all.nlme<-
function () 
{nlme(EFF.PERE -
compl.invitro(a,b*exp(eta.b) ,ic*exp(eta.ic) ,g*exp(eta.g),M 
. CONe) , 
data = merge. thai, 
fixed = list(a-.,b-.,ic-.,g-.), 
random = list(eta.b-.,eta.ic-.,eta.g-.), 
start = list (fixed = c(l,lOO,50,3)), 
cluster = -ID, 
re.structure 
var.function 
verbose=T 
) 
} 
IId ll , 
lIidentityll, 
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APPENDIX V 
SPLUS programme for fitting the empirical model to the patient data from studies 
conducted between 1931 and 1963 where malaria was used for the treatment of 
ncurosyphi lis. 
# Fitting a function to the patient data 
model.vol<-
function(a,b,c,d,k,DAY) 
{ 
a + (O.5*loglO(b)*DAY) + (c*sin((6.28/d)*DAY + k)) 
all.nlme<-
function () 
{nlme(LG10PARA -
model.vol(a+(eta.a) ,b*exp(eta.b) ,c*exp(eta.c) ,d,k,DAY), 
data = nlme.146, 
fixed = list(a-.,b-EL.LIMON+SANTEE.C,c_.,d_.,k_.), 
random = list(eta.a-.,eta.b-.,eta.c-.), 
start = list(fixed=c(1.3,8.2,O,O,O.5,2.4,O.4)), 
cluster = -PATIENT, 
re. structure = "d", 
var.function = "identity", 
na.action na.omit, 
verbose = T 
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